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Abstract 
 
Cardiovascular disease is the number one cause of death worldwide. In the treatment 
of such disease, vascular surgery commonly utilises grafts to replace or bypass 
damaged regions of the circulatory system. Currently, autograft vessels represent the 
gold standard for vascular bypass; however, these are of limited availability and quality. 
Synthetic conduits are also available, but these are of little use as small diameter 
vessels (<5 mm) due to high incidence of failure through infection or thrombosis. A 
need exists for a better vascular graft with tissue engineering offering an attractive 
solution.  
Although the development of tissue engineered vascular grafts (TEVGs) is being 
explored by a number of research groups using a wide range of methods, to date, a 
TEVG has not yet been produced that closely matches the mechanical performance of 
the autograft vessels currently favoured in vascular surgery.  
 
This research aimed to develop a method of manufacturing TEVGs with mechanical 
properties more similar to the current gold standard vessels. These TEVGs would be 
biocompatible, non-immunogenic and able to grow and remodel in vivo. Additionally, 
the TEVG manufacturing process would also be readily adaptable to producing more 
complex geometric shapes than simple tubes. It was hypothesised that this may result 
in an improvement in the performance of the TEVGs and may also expand the possible 
clinical applications.  
 
Following a review of the literature, presented in Chapter 1, a synthetic polymer 
scaffold based tissue engineering approach was selected as the method for producing 
the TEVGs. This approach has been widely adopted in the field of vascular graft tissue 
engineering. Synthetic polymer scaffold based methods are compatible with a range of 
manufacturing processes; have shown success in a variety of in vivo studies of TEVGs, 
including human trials; and had the potential to be adapted to produce a TEVG in a 
variety of predefined geometries.  
A synthetic polymer scaffold would be developed with properties, such as elasticity, 
degradation rate and porosity, specifically optimised towards the development of a 
TEVG with mechanical properties similar to the current gold standard autografts. 
TEVGs would be produced in vitro by seeding cells onto the synthetic polymer scaffold 
and then culturing them in a bioreactor under physiologically relevant flow to 
encourage cell proliferation and appropriate ECM deposition.  
 
A novel photocurable form of poly(glycerol sebacate), poly(glycerol sebacate) 
methacrylate (PGS-M) was proposed as the material for the synthetic polymer scaffold. 
This material had the potential to provide the mechanical performance and 
degradation properties identified as requirements for the scaffold, along with being 
biocompatible and easy to process into various scaffold geometries.   
In Chapter 2, different variants of PGS-M were produced which varied in molecular 
weight and degree of methacrylation (DM). These were characterised using various 
analytical chemistry techniques. It was determined that both the molecular weight and 
DM could be controlled by altering the reaction conditions used in the synthesis of the 
polymer. The degradation of the different variants of PGS-M was examined and this 
revealed that the polymer was susceptible to enzymatic degradation. Increasing the 
DM appeared to have an inverse effect on the degradation rate. The mechanical 
properties of PGS-M were also assessed and found to largely depend on the DM of the 
polymer and not the molecular weight.  
 
A 30% DM, low molecular weight (30% Low Mw) PGS-M was selected as the most 
suitable variant of PGS-M for producing a scaffold for use in culturing a TEVG. In 
Chapter 3, the biocompatibility of 30% Low Mw PGS-M is presented. Flat surfaces of 
the polymer were able to support the growth and proliferation of human dermal 
fibroblasts, human adipose derived stem cells and human coronary artery smooth 
muscle cells (SMCs) for several days in culture. Additionally, growth on the PGS-M 
surfaces does not appear to alter the phenotype of the SMCs. It was determined that 
culture on PGS-M surfaces may have effects on the metabolic activities of the three 
cell types investigated and that these effects may be subtle and cell specific.  
 
In Chapter 4, porous scaffold structures, suitable for use in tissue engineering, were 
produced from 30% Low Mw PGS-M using a porogen leaching method with sucrose 
particles. Combining PGS-M with sucrose particles of different sizes, at different ratios, 
allowed variation of the scaffolds’ handling properties, pore sizes, porosities and 
wettability. SMCs seeded onto the porous PGS-M scaffolds remained viable for 7 days 
in static culture and partially infiltrated the scaffold interiors.    
A method was then developed to produce the porous scaffolds as tubes of suitable 
geometry and porosity for use in the generation of TEVGs. Additionally, a method for 
producing porous PGS-M scaffolds in a variety of geometries was also demonstrated as 
a proof-of-concept. This method used a novel hybrid additive manufacturing and 
porogen leaching approach.  
 
A bioreactor was required for the culture of the tubular PGS-M scaffolds, once seeded 
with cells, to produce TEVGs. In Chapter 5, a design brief was proposed for a bioreactor 
capable of culturing the TEVGs under dynamic conditions and applying mechanical 
stimulation. This had been identified as advantageous in previous studies in TEVGs.  
A design process was implemented, with a number of initial ideas evaluated to 
determine an integrated final solution. The final bioreactor design utilised a pulsatile 
flow to provide mechanical stimulation to the developing TEVGs. The bioreactor was 
manufactured and assessed for sterility and its ability to provide mechanical 
stimulation to developing TEVGs. The pulsatile flow could be modulated to produce 
pressures and flow rates within the range of physiological blood flow which were 
appropriate for the culture of TEVGs. Modifications to the design were implemented, 
as required, to improve performance. 
 
The knowledge gained from the previous chapters was combined in Chapter 6. Porous 
tubular scaffolds, produced from 30% Low Mw PGS-M were seeded with human 
coronary artery SMCs and cultured in the bioreactor as TEVGs. The TEVGs were 
cultured for 7 days under dynamic and static conditions. TEVGs cultured under 
dynamic conditions, with mechanical stimulation produced by the pulsatile flow in the 
bioreactor, displayed highly variable results, but demonstrated the partial formation of 
blood vessel-like tissue in a small instance. TEVGs cultured under static conditions 
produced repeatable results, although with reduced vascular tissue formation 
compared to the grafts cultured under dynamic conditions. Both culture regimes 
produced TEVGs containing collagen and elastin and both also appeared to cause a 
change in the phenotype of the attached SMCs, from contractile to proliferative.  
 
Finally, Chapter 7 suggests the possible further work that may be conducted to explore 
the PGS-M scaffold based TEVGs, as the original aims of the research were not fully 
realised. Suggestions of how the bioreactor culture may be modulated and optimised 
are made along with ideas for generating TEVGs of varied geometries.  
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Chapter 1 - Literature Review, Research 
Aims and Objectives 
 Introduction 1.1
Cardiovascular disease is the number one cause of death globally.1 Disorders are often 
associated with the narrowing or blockage of blood vessels leading to reduced blood 
flow and tissue damage due to inadequate nutrient supply. Common presentations are 
coronary heart disease, cerebrovascular disease, peripheral arterial disease and deep 
vein thrombosis. It is predicted that the annual incidence of cardiovascular disease 
related mortalities will rise to 23.3 million worldwide by 2030.2 
Treatments for cardiovascular disease range from dietary and lifestyle modification to 
pharmaceutical and surgical intervention.3 When required, vascular surgery may 
involve endovascular procedures such as angioplasty, stent insertion or atherectomy 
to widen a stenosed vessel or remove the obstruction. Alternatively, a vascular graft 
may be used to replace or bypass a damaged or occluded vessel. Despite the advances 
in endovascular surgery and its increased popularity over recent decades, vascular 
bypass grafting remains commonplace and is believed to be the optimal choice for 
patients requiring long-term revascularisation solutions (life expectancy >2 years).4–8  
Around 400,000 coronary artery bypass grafting (CABG) procedures are performed 
each year in the USA alone.9 
Currently, the favoured conduits for vascular grafting are autologous arteries or veins. 
The structures of these are shown in Figure 1. Although the use of arteries, such as the 
internal thoracic artery (ITA) or radial artery, is associated with superior patency,10–13 it 
is the saphenous vein (SV) that is the most commonly used autograft vessel.14 This is 
due to the limited availability of arteries and the more severe complications associated 
with their removal compared to veins. Despite representing the gold standard, patency 
rates for SV grafting remain limited with both CABG and femoropopliteal (fem-pop) 
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bypass grafts showing failure rates of around 50% at 10 years.14,15 Additionally, 
autologous vessels have limited availability, may be of poor quality and their extraction 
causes donor site morbidity.5,15–17  
 
 
Figure 1. Cellular structure of arteries and veins. Both types of blood vessel are 
composed of layers of cells. Endothelial cells line the luminal surface. These are 
supported by a basement membrane which is surrounded by a layer of smooth muscle 
cells and elastic fibres and then a layer of fibroblasts and connective tissue. The vessel 
wall is thicker in arteries compared to veins due to the presence of a thicker layer of 
smooth muscle cells. This is required to resist the high pressure blood flow carried by 
the arteries.18    
 
Synthetic vascular grafts are also available as an alternative to autologous vessels. 
These grafts have demonstrated satisfactory long-term results when used in large 
diameter arteries (>8 mm), such as in aorto-iliac substitutes where patency is around 
90%,19 and in medium diameter arteries (6-8 mm), such as carotid or common femoral 
artery replacements.20 In small diameter vessels (<6 mm) however, synthetic grafts are 
of limited use due to poor patency rates. These vessels include the coronary arteries, 
infrainguinal arteries (below the inguinal ligament) and infrageniculate arteries (below 
the knee). Autologous vessels have proved superior to synthetic grafts for these 
installations (Figure 2). In CABG, the use of polytetrafluoroethylene (PTFE) conduits 
resulted in 1 year patency rates of ~60% compared to over 95% when using the SV. 
After 2 years, the patency of PTFE conduits declined to just 32% whereas SV grafts 
remained above 90%.21–24 In above the knee fem-pop bypass, results have shown PTFE 
graft patency rates of ~59% at 5 years compared to ~78% when using the SV.15,25–29 A 
3 
 
synthetic conduit is only suggested as a choice if no other suitable autologous vessel is 
available.24 Improvements in patency have been achieved by seeding autologous 
endothelial cells (ECs) onto the luminal surface of synthetic grafts, however, these 
grafts have been unable to exceed the performance of autologous vessels.30 
Vascular graft failures are most commonly associated with thrombosis, intimal 
hyperplasia, atherosclerosis or infection. Thrombosis occurs as a result of damage to, 
or the absence of, ECs lining the graft lumen leading to the adherence of blood 
proteins and the activation of clotting mechanisms.31,32 Intimal hyperplasia is caused 
by the migration of vascular smooth muscle cells (SMCs) from the vessel media to the 
intima and their proliferation and extracellular matrix (ECM) deposition. Intimal 
hyperplasia may occur in the graft vessel or in the native vessel around the 
anastomosis. There are multiple causes including (i) compliance mismatch between 
the graft and native vessel; (ii) vessel diameter mismatch; (iii) damage to, or a lack of, 
ECs; (iv) suture line stress concentrations; (v) trauma during surgery and (vi) 
haemodynamic factors causing blood flow disturbances.33–39 Atherosclerosis appears 
to be the main cause of graft failure after one year.40 Atheroma formation is associated 
with the same factors as in the native arteries and occurs by a similar process. 
Monocytes invade the vessel neointima forming macrophages and, eventually, foam 
cells resulting in the development of atherosclerotic plaque.39,41,42 Graft infection is 
more common in synthetic conduits due to their susceptibility to bacterial colonisation. 
Infections cause chronic inflammation and release toxins which complicate graft 
healing and can lead to sepsis and anastomotic failure or rupture.43–47  
Given the limitations of current vascular bypass conduits, a tissue engineered vascular 
graft (TEVG) presents an attractive potential solution for the future of vascular surgery. 
A tissue engineered vessel with the ability to grow, remodel and repair in vivo, but 
without the need for autograft surgery has clear advantages and would be of great 
benefit. This chapter will review the current state of the art in vascular graft tissue 
engineering including an examination of the design requirements for a TEVG, an 
overview of the methods being used to produce such constructs, discussion of the 
various animal and limited human trials that have taken place and some considerations 
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for the future developments of TEVGs. This review will then be used to justify the 
research conducted and define the aims and objectives.   
 
 
Figure 2. Patency rates for small diameter vascular bypass procedures using the SV and 
PTFE conduits (data for CABG using PTFE conduits was only available up to 45 
months).14,15,21–29,33,48  
 
 Design requirements for a TEVG 1.2
As an integrated part of the vascular network, a TEVG must satisfy a number of design 
criteria to be fit for purpose.20,49 Fundamentally, the construct is a conduit for 
supporting the flow of blood, therefore it must withstand the pressures exerted by this 
flow without bursting or experiencing permanent deformation through aneurysm. The 
pressure drop experienced within the flow over the graft length must also be 
sufficiently small and the luminal surface properties must be such that thrombus 
formation mechanisms are not triggered. The graft should possess suitable compliance 
to prevent the formation of high stresses around the anastomosis and be of a 
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geometry that does not induce certain, undesirable, flow characteristics, as both of 
these factors have been associated with failures in current bypass solutions.33,34,38,50–52 
The graft should also be non-cytotoxic and should not trigger a negative immunogenic 
response, such as chronic inflammation, complement cascade initiation or activation of 
the adaptive immune system. Additionally, from a clinical product perspective, a TEVG 
should be suitable for implantation; with kink resistance and the ability to be handled, 
manipulated and sutured; and be able to be mass produced in a range of lengths, 
quality controlled, stored and shipped at an economically viable cost. Ultimately, the 
graft should be able to grow, remodel and self-repair in vivo. 
 
 Techniques for manufacturing a TEVG 1.3
The first tissue engineered blood vessel construct was actually produced in the mid-
1980s by Weinberg and Bell.53 Bovine ECs, fibroblasts and SMCs were co-cultured in a 
collagen matrix and then shaped into tubes. Although tissue architectures analogous 
to natural blood vessels were achieved, the constructs required the support of a 
Dacron mesh and their mechanical properties were poor.  
Since then, a number of different approaches have been taken to produce a clinically 
viable TEVG. Although these vary widely in terms of materials, manufacturing methods, 
cell source and culture protocol, they can be broadly categorised into scaffold based 
methods, using synthetic or natural materials; decellularised natural matrix techniques 
and self-assembly processes.   
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 Scaffold based methods 1.3.1
Most cell types are unable to organise themselves into complex three-dimensional 
structures during culture, therefore the use of a scaffold, to provide a template of the 
required construct, is a popular approach in tissue engineering (Figure 3). Vascular 
tissue engineering has seen the use of scaffolds made from a range of synthetic and 
natural materials and manufactured using a number of different techniques.   
 
 
 
  
 
Figure 3. Scaffold based TEVG manufacture. Cells are harvested from the patient and the 
required types isolated and expanded in vitro. The cells are then mixed with a scaffold 
forming material, such as collagen or fibrin, and shaped in a tubular mould or seeded 
onto a porous polymer scaffold. The construct is then cultured in a bioreactor and may 
be conditioned to develop suitable mechanical properties for use as a TEVG. 
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 Synthetic polymers 1.3.1.1
To date, the most extensive clinical trial of a TEVG has involved a construct produced 
using a synthetic polymer scaffold. The group of Shin’oka has developed a vascular 
graft for use in the treatment of cardiovascular disorders in children. Such disorders 
are particularly challenging, from a clinical perspective, often requiring multiple 
interventions as the child matures.54 A tissue engineered graft solution with the 
potential to grow, remodel and repair in vivo is therefore particularly suited to use in 
children. Using a porous scaffold produced from a degradable co-polymer mesh of 
poly-L-lactide (PLLA) and poly-ε-caprolactone (PCL), reinforced with polyglycolide 
(PGA), vascular grafts for use as extracardiac cavopulmonary conduits to correct single 
ventricular physiology have been examined in 25 patients for up to 7 years.55 These 
grafts were produced by culturing autologous bone marrow-derived mononuclear cells 
(BM-MNCs), extracted from the anterior superior iliac spine, on the scaffolds in vitro, 
prior to implantation. All grafts remained patent with no rupture, aneurysm formation, 
infection or ectopic calcification reported, although angioplasty was required in a small 
number of cases to retain patency.56 Four patients died from non-graft related issues 
during the trial. Explant examination showed complete degradation of the scaffold 
material and the formation of recognisable vascular tissue with a wall of SMCs and a 
lumenal EC layer. It was noted, at late-term follow-up, that 40% of patients did not 
require daily medication. This is considerably lower than patients receiving similar 
procedures using synthetic vascular grafts which often require long-term 
anticoagulation or anti-platelet therapy.57,58 Although the success of this trial is 
encouraging, it must be recognised that the TEVGs constructed were of a large internal 
diameter (12-24 mm) and were implanted in a high flow, low pressure system. 
Therefore, the success cannot be expected to easily translate into small-diameter 
constructs under high pressure, arterial, flow. Shin’oka and colleagues are attempting 
to adapt their approach to produce a TEVG suitable for such use, although with the 
focus remaining on potential utilisation in paediatrics.59  
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With the clear aim of developing small-diameter TEVGs for use in arterial flow, 
Niklason and colleagues have shown considerable success using a synthetic polymer 
scaffold based approach. This research group pioneered the development of 
bioreactor systems for generating TEVGs, in vitro, using biomimetic mechanical 
stimulation.60 It has been well established that mechanical stimulation is important in 
tissue engineering, having a direct impact on cell function and fate. Niklason’s 
bioreactor design utilises a distensible silicone tube which carries a pulsatile flow of 
culture medium. When a synthetic polymer scaffold seeded with cells is placed around 
this tube, it is subjected to physiologically relevant strains. In vitro work using PGA or 
PGA and poly(lactide-co-glycolide) (PLGA) scaffolds seeded with bovine SMCs and ECs 
showed that ECM formation and vessel strength were increased by the application of 
mechanical stimulation, compared to statically cultured controls.60,61 Pulsatile flow was 
applied for 8 weeks at 2.75 Hz (165 beats per minute), imparting a 5% radial distension, 
in an effort to mimic foetal development in large animals. Vessel burst pressures of 
2150 ± 709 mmHg were achieved, similar to those reported for the human SV (SV 
average burst pressure is 2134 ± 284 mmHg62–66), and vessel architectures and 
compliance were also comparable to natural vasculature.67 A subsequent in vivo 
investigation, using autologous SMCs and ECs, showed one of these engineered vessels 
remained patent for up to 4 weeks when implanted in a Yacatan mini pig as a SV graft 
with no evidence of stenosis or dilation.  
As an interesting progression, Niklason and colleagues then integrated a 
decellularisation step into their TEVG production process. Using decellularisation 
allows non-autologous cells to be employed in producing the vessel structure during 
bioreactor culture on the polymer scaffold. These cells are then removed using a 
treatment of enzymes and detergents, leaving behind only their ECM onto which 
autologous ECs can then be seeded, shortly before implantation. This strategy largely 
decouples the TEVG manufacturing process from the recipient, potentially providing an 
off-the-shelf graft solution. A number of in vivo studies, in small and large animals, 
have been conducted to explore the efficacy of using an in vitro-derived and then 
decellularised graft. In nude mice, decellularised vessels derived from human SMCs 
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were implanted as aortic interposition grafts for 6 weeks and showed 83% patency 
with no deterioration of the ECM as a result of the decellularisation process.68 In 
porcine and canine models, decellularised grafts derived from allogeneic SMCs and 
then seeded with autologous ECs exhibited 100% patency at 30 days and 1 year, 
respectively, when implanted in carotid artery positions.69,70 Additional work in canines 
also showed 100% patency for these grafts as coronary artery bypass conduits for 30 
days.70 In Baboons, similar constructs showed 88% patency over 6 months as 
arteriovenous fistulas (AVFs).70 In all cases, grafts showed significant remodelling after 
implantation and the formation of tissue comparable to the adjacent native vessels. 
Very little intimal hyperplasia was reported, which was particularly interesting in the 
porcine carotid artery bypass study, as this animal model is usually considered to 
demonstrate accelerated intimal hyperplasia formation.71 These findings resulted in 
the undertaking of pilot studies in humans with the TEVG employed as an AVF for 
vascular access in patients with end stage renal disease.72 TEVGs were implanted into 
60 patients with an average follow-up of 16 months. At 12 months, primary and 
secondary patency rates were 28% and 89%, respectively. The major cause of loss of 
primary patency was thrombosis. No aneurysms were detected throughout the cohort 
and this was considered impressive, given the TEVGs were regularly punctured for 
haemodialysis access. The grafts demonstrated invasion and remodelling by the host, 
becoming populated with SMCs, and did not appear to generate a significant immune 
response, suggesting the decellularisation process was sufficient. Notably, the 
performance of the TEVGs exceeded that of PTFE grafts, in multicentre studies, in 
terms of patency and infection rate.73,74 Studies into this type of TEVG are ongoing 
with a transition towards a commercial product expected.    
Results for a number of TEVGs based on synthetic polymer scaffolds have been 
reported by many other researchers around the world, including successes in animal 
models. These studies have shown great variation in relation to the polymers 
employed; scaffold manufacturing methods; seeded cells and culture protocols (Table 
1). In Ovine models, non-woven PGA scaffolds seeded with autologous myofibroblasts 
and ECs have shown long term patency, of up to 100 weeks, as pulmonary artery 
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replacements.75,76 These grafts had internal diameters of 10-18 mm and integrated 
well with the native vasculature, developing comparable tissue structures and showing 
complete scaffold degradation during the study period. In Lewis Rats, poly(ester 
urethane)urea (PEUU) scaffolds produced using electrospinning and thermally induced 
phase separation showed success as aortic interposition grafts for 8 weeks when 
seeded with rat muscle-derived stem cells or human pericytes.77,78   
 
The use of completely acellular synthetic polymer scaffolds as TEVGs is also being 
explored. Using acellular scaffolds eliminates the need for in vitro cell culture and 
instead focuses on encouraging rapid host cell invasion and scaffold remodelling, after 
implantation, through scaffold architecture and surface chemistry. In canine models, a 
scaffold produced from a composite of non-woven PGA, poly(lactide/caprolactone) 
(P(LA/CL)) and poly(glycolide/caprolactone) (P(GA/CL)) exhibited patency for up to 12 
months, as a pulmonary artery replacement.79 Explants showed scaffold degradation 
and the formation of SMC and EC layers with ECM contents similar to the native tissue. 
Similar works showed patency for up to 12 months for non-woven PLLA and PGA 
scaffolds and 8 weeks for electrospun PCL and polyurethane (PU) scaffolds when 
implanted as canine carotid artery and femoral artery interposition grafts, 
respectively.80,81 Additionally, studies in murine models have shown noteworthy 
results with grafts produced from electrospun PCL or poly(glycerol sebacate) (PGS) and 
PCL exhibiting host remodelling, ECM deposition and native tissue structures when 
implanted in arterial positions.82,83  
 
The use of synthetic polymer scaffolds is the most widely investigated method for 
producing a TEVG and has yielded significant successes. The relatively low expense of 
producing synthetic polymer scaffolds coupled with the ability to tune various 
properties associated with them has been key to their extensive use and offers great 
potential for the future. The mechanical properties of these scaffolds, along with their 
degradation rate and topography have all been shown to influence the development of 
TEVGs.78,82,84–91 Long production times, including extended in vitro culture steps, 
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present a large potential barrier to the clinical application of TEVGs based on synthetic 
polymer scaffolds. However, the recent use of decellularisation protocols, following in 
vitro culture, to largely move TEVG production offline and the potential of acellular 
“scaffold only” grafts both offer hope for the future.70,79–83 
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Table 1. Studies towards the development of a synthetic polymer scaffold based TEVG. 
Scaffold material and 
manufacturing method 
Development 
level 
Cell source Comments Group 
P(LA/CL) and PGA or PLLA.  
PGA mesh coated in 
additional polymers in a 
mould. 
In vivo 
(human trial) 
Autologous 
BM-MNCs 
First human trial of a TEVG.  
Grafts patent for up to 7 years. 
Explants showed complete 
degradation of the scaffold. 
Large diameter vessel in high flow, 
low pressure system.  
Shin’oka et 
al.55,56 
PGA.  
Mesh sewn into a tube. 
In vivo 
(human trial) 
 
Porcine SMCs and 
ECs or human 
SMCs  
Early work pioneered pulsatile flow 
bioreactor culture for TEVGs. 
Human trials employed TEVGs 
cultured in vitro and then 
decellularised as AVFs.  
Across 60 patients, TEVG 
performance was superior to PTFE 
grafts.  
Niklason et 
al.61,70,72,92 
PEUU. 
Thermally induced phase 
separation and 
electrospinning. 
In vivo 
(murine model) 
Murine 
muscle-derived 
stem cells or 
human pericytes 
Grafts showed patency for up to 8 
weeks.  
Host cell invasion and good 
integration observed.  
Burst pressures estimated at ~4000 
mmHg.   
Vorp et al.77,78,91 
PGA and poly-4-
hydroxybutyrate (P4HB). 
Non-woven PGA coated in 
P4HB. 
In vivo 
(ovine model) 
Autologous ovine 
ECs and 
fibroblasts 
Graft patent up to 100 weeks as a 
pulmonary artery replacement (large 
diameter vessel).  
Complete scaffold degradation 
observed.  
Graft collagen content exceeded the 
native vessel.   
Hoerstrup et 
al.75,76 
PGS and PCL.  
Porogen leaching and 
electrospinning. 
In vivo 
(murine model) 
acellular Patent up to 90 days in the rat aorta.  
Graft stress-strain response similar to 
the native vessel.  
Cell infiltration and organised elastin 
deposition observed.  
Wang et al.82,93 
PGA, P(LA/CL) and P(GA/CL).  
Non-woven PGA coated in 
P(LA/CL) and reinforced with 
P(GA/CL) 
In vivo 
(canine model) 
acellular Patent for 1 year in the pulmonary 
artery (large diameter vessel). 
Scaffold fully degraded by 6 months 
in vivo.  
SMC and EC layers formed.  
Elastin and collagen content equalled 
the native vessel. 
Yamazaki et 
al.79 
PGA and PLLA.  
Woven PGA and PLLA. 
In vivo 
(canine model) 
acellular Graft patent for up to 1 year in the 
carotid artery.  
Formation of SMC and EC layers 
observed.  
Graft collagen and elastin content 
increased in vivo. 
Sawa et al.81 
PU. 
Porogen leaching. 
In vitro Human SMCs Cyclic strain increased cell 
proliferation, collagen content, 
strength and stiffness in cultured 
grafts. 
Santerre et al.94 
PGA and PCL.  
Polymer sheets seeded with 
cells concentrically 
wrapped. 
In vitro Bovine 
fibroblasts, SMCs 
and ECs 
Significant elastin deposition 
observed.  
In vitro-remodelled graft showed a 
stress-strain response similar to 
native bovine arteries.  
Vacanti C et 
al.95 
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 Natural polymers 1.3.1.2
A number of different naturally derived polymers have been employed to generate 
scaffolds for use in TEVG production (Table 2). Significant successes have been seen 
using fibrin as a scaffold material. This material can be produced from polymerised 
fibrinogen isolated from a patient’s own blood plasma.96 The group of Tranquillo used 
fibrin gel to entrap human dermal fibroblasts and produce tubes using a mould.97 A 
TEVG was then assembled by concentrically layering these tubes and allowing them to 
fuse together, however, after 3 weeks in culture, burst pressure values were just 543 ± 
77 mmHg, well below those for natural vessels. Similar to synthetic polymer scaffolds, 
the application of mechanical stimulation improved the vessels mechanical strength.98 
In vitro culture in a perfusion bioreactor; applying cyclic strain and lumenal, ablumenal 
and transmural flow; generated a TEVG with a burst pressure of 1542 ± 188 mmHg and 
comparable compliance to natural vasculature. In a similar approach to Niklason’s 
group, Tranquillo and colleagues have also recently reported on the use of 
decellularisation in their production of TEVGs.99 Fibrin based grafts were cultured in 
vitro using ovine dermal fibroblasts and then decellularised. These acellular grafts 
exhibited comparable compliance to human vasculature and burst pressures exceeding 
those of the human SV. When implanted in the femoral artery of an ovine model these 
grafts remained patent for up to 24 weeks with no occlusion, dilation or mineralisation 
reported, representing the first long-term function of a natural polymer scaffold based 
TEVG in the artery of a large animal model. Explants demonstrated considerable 
remodelling with complete graft cellularisation and increased collagen and elastin 
content. These TEVGs also demonstrated somatic growth, over 44 weeks, when 
implanted into the pulmonary arteries of lambs.100  
Additionally, Andreadis and colleagues have also examined a fibrin based TEVG in an 
ovine model. Here, fibrin tubes with entrapped vascular SMCs were implanted as vein 
interposition grafts in lambs.101 The lumenal surface of these TEVGs was seeded with 
ECs prior to implantation and they showed patency for up to 15 weeks. Examination of 
explants showed that in vivo remodelling increased graft mechanical strength; 
14 
 
however, this reached only 25% that of the native aorta. Altering fibrinogen 
concentrations and using bone marrow-derived smooth muscle progenitor cells was 
demonstrated to produce stronger vessels, although this design of TEVG still remains 
to be tested under atrial flow.102,103 Recently, hypoxia coupled with insulin 
supplementation was also shown to improve the strength of fibrin based TEVGs by 
enhancing collagen deposition in the entrapped cells.104  
 
Silk-derived fibroin also has potential as a scaffold material for TEVGs. It offers 
tailorable mechanical properties, slow degradation in vivo and is compatible with a 
number of manufacturing processes.105 In vitro work, using woven and electrospun 
fibroin scaffolds, has shown acceptable biocompatibility and adherence using a range 
of vascular cell types.105–107 In subsequent studies in rats, as abdominal aorta 
replacements, acellular fibroin scaffolds showed cell invasion by SMCs and ECs and 
vascular tissue formation. Patency rates of 85% at 12 months were achieved, with no 
thrombosis or aneurysm observed. It was also suggested that the mechanical 
properties of these scaffolds could be improved to better emulate those of the native 
vasculature by using fibre alignment techniques during the manufacturing process.105 
Additionally, Mantovani and colleagues have constructed a scaffold composed of silk 
fibroin and collagen using electrospinning. Although this was shown to have superior 
strength compared to fibroin alone, it remained weaker than natural vessels. 
Viscoelasticity and good cell adherence were also shown, although there are as yet no 
reports of in vivo results.108 
 
Building on the early work of Weinberg and Bell,53 the use of collagen in TEVG scaffolds 
has continued. The integrity of collagen based scaffolds has been improved by 
modifying fibre density and orientation, adding crosslinks and using specific shape 
forming techniques.109–113 Mechanical stimulation during in vitro culture has also been 
used. Using a bioreactor to apply mechanical conditioning through cyclic strain was 
shown to improve tissue organisation and significantly increase the strength of 
collagen gel based TEVGs.114,115 The addition of elastin fibres to form a hybrid scaffold 
15 
 
was also shown to alter the mechanical properties of engineered vessels to more 
closely resemble those of natural tissue, with a non-linear, J-shaped, stress-strain 
response.116 In all cases however, the ultimate tensile strengths and burst pressures of 
these constructs remained well below those of native vessels.   
 
The linear polysaccharide chitosan has also been considered for the production of 
TEVG scaffolds. Chitosan is a derivative of chitin and is similar in structure to 
glycosaminoglycans which are a common ECM element.117 Porous structures can easily 
be fabricated from chitosan using freezing or lyophilisation techniques and, in vivo, the 
material is slowly degraded by lysozyme with little foreign body reaction. Using a mesh 
of knitted chitosan fibres, coated in a chitosan and gelatine solution and then freeze-
dehydrated, a porous scaffold was produced with a burst pressure of 4000 mmHg and 
a suture retention strength of 4.4 N.118 Both of these values exceed those of the native 
vessel they were compared to (ovine carotid artery). The scaffold also showed 
acceptable cell adhesion and proliferation over 2 days using rabbit vascular SMCs. 
Although this report is promising in terms of mechanical performance, continued work 
using this scaffold is lacking. An alternative, constructed from cross-linked and freeze-
dried chitosan and collagen, has also been shown to support vascular cell adhesion and 
proliferation and, additionally, exhibited suitable biocompatibility in vivo when 
implanted in rabbit livers.119 However, the scaffold mechanical properties reported in 
this case were inferior to native blood vessels, with an ultimate tensile strength of just 
310 ± 16 kPa. A question mark clearly remains over the mechanical properties of a 
chitosan scaffold and also how these may change over longer periods of in vitro cell 
culture or in vivo.   
 
Although advantageous in terms of cell adhesion and biocompatibility, natural polymer 
based TEVGs have largely remained limited by their poor mechanical strength. 
Additionally, a high degree of compaction occurs in a number of natural polymer 
scaffolds, which produces a very dense matrix that vascular cells may have difficulty 
breaking down to remodel.120 The use of dynamic bioreactor culture to improve vessel 
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mechanical properties has now been demonstrated.98,101,103 Although the use of 
bioreactors increases production complexity, the recent successes seen in 
decellularised fibrin based TEVGs show the possibility of an off-the-shelf graft solution 
even if lengthy in vitro culture is required. This graft design has great potential for 
clinical utility, but is yet to be evaluated in the human circulatory system.   
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Table 2. Studies towards the development of a natural polymer scaffold based TEVG. 
Scaffold material and 
manufacturing method 
Development 
level 
Cell source Comments Group 
Fibrin.  
Gelled with encapsulated 
cells. 
In vivo 
(ovine model) 
Ovine dermal 
fibroblasts 
Fibrin based TEVG cultured in vitro 
then decellularised.  
Decellularised constructs possessed 
burst pressures of ~4200 mmHg and 
compliance similar to natural vessels. 
Grafts remained patent for up to 24 
weeks in the femoral artery and 
completely recellularised. 
In lambs, TEVGs demonstrated 
somatic growth in the pulmonary 
artery. 
Tranquillo et 
al.97–100 
Fibrin.  
Gelled with encapsulated 
cells. 
In vivo 
(ovine model) 
Ovine vascular 
SMCs, bone 
marrow smooth 
muscle progenitor 
cells and ECs 
Patent for up to 15 weeks in the 
jugular vein.  
Grafts integrated well with the native 
vessel and remodelled to 25% the 
strength of the ovine aorta.  
Progenitor cell based TEVGs were 
stronger than those derived from 
vascular SMCs and produced greater 
elastin in vivo. 
Andreadis et 
al.101,103 
Silk fibroin.  
Gel spun into a tube. 
In vivo 
(murine model) 
Acellular Patent for up to 4 weeks in the rat 
aorta.  
Graft invasion by host SMCs and ECs 
observed. 
Kaplan et al.105 
Silk fibroin.  
Woven into a tube. 
In vivo 
(murine model) 
Acellular Patent for up to 1 year in the rat 
aorta.  
SMC and EC invasion observed at 12 
weeks.  
Fibroin content reduced by 48 weeks, 
while collagen content increased.  
Masataka et 
al.106 
Silk fibroin.  
Electrospun and then coated 
with collagen. 
In vitro NIH/3T3 
fibroblasts 
Cells adhered and proliferated on the 
scaffold.  
Construct strength was below that of 
natural vessels (~900 mmHg). 
Mantovani et 
al.108 
Collagen.  
Gelled with encapsulated 
cells. 
In vitro Porcine SMCs and 
ECs 
Cell proliferation and collagen 
remodelling observed over 7 days.  
Very low burst pressures achieved 
(~18 mmHg).  
Mantovani et 
al.121 
Collagen.  
Gelled with encapsulated 
cells. 
In vitro Murine aortic 
SMCs 
Construct strength improved by 
increased collagen deposition as a 
result of mechanical stimulation. 
Burst pressures remained well below 
those of natural blood vessels. 
Nerem et al.114 
Collagen and elastin. 
Freeze dried then 
crosslinked. 
In vitro Human umbilical 
vein SMCs 
Construct strength improved by 
mechanical stimulation.  
Stress-strain curve partially matched 
native vessels.   
Feijen et 
al.116,122 
Chitosan and gelatin. 
Knitted chitosan tube 
dipped in gelatine and 
freeze dried 
In vitro Murine vascular 
SMCs 
Burst pressures of 4000 mmHg 
achieved.  
Suture retention strengths also 
exceeded the ovine carotid artery.  
Zhang X et al.118 
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 Hybrid polymer scaffolds – synthetic and natural polymers  1.3.1.3
Not all scaffold based approaches to producing a TEVG have been based exclusively on 
natural or synthetic polymers. A number of researchers have developed scaffold 
systems that utilise a combination of both (Table 3).  
Coating of synthetic polymer scaffolds with natural polymers, in an effort to improve 
biocompatibility and cell adhesion, has been used extensively with collagen, 
fibronectin and gelatine all employed.81,86,123,124 Synthetic polymers have also been 
used to provide reinforcement to weaker natural polymer scaffolds. Fibrin gels, with 
encapsulated ovine SMCs and fibroblasts, reinforced with a mesh of poly(L/D)lactide 
(P(L/D)LA) have been studied in an ovine model.125 Following 21 day culture in a 
perfusion bioreactor, these engineered vessels were implanted as carotid artery 
interposition grafts and showed patency for up to 6 months with dense, although not 
cohesive, collagen and elastin deposition observed. In other work, a bilayered scaffold 
with an inner layer of recombinant human tropoelastin and an outer layer of PCL has 
demonstrated success in a rabbit model.62 These grafts possessed mechanical 
properties not significantly different from the human ITA in terms of compliance and 
burst pressure. The elastin appeared to aid cell attachment and also conferred reduced 
platelet adhesion. When implanted as acellular grafts in the carotid artery position 
they showed 100% patency over 1 month with no dilation or thrombosis and little 
change in mechanical properties. Additionally, good results have been reported for 
acellular hybrid vessels of PCL, with PU and collagen or spiders silk and chitosan, in 
arterial positions in canines and rats, respectively.80,126,127   
These hybrid scaffolds may be considered as new “smart” biomaterials that 
incorporate the strength, tunability and manufacturing control of synthetic materials 
with the improved biocompatibility and biochemical cues that come from natural 
polymer components. Therefore, the use of hybrid scaffolds has the potential to 
exploit the best of both synthetic and natural polymer scaffold systems to produce 
TEVGs. However, some of the limitations associated with using polymer scaffolds to 
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generate a TEVG are likely to remain a factor, particularly the requirement for long 
periods of in vitro culture to generate robust constructs.  
 
 
 
Table 3. Studies towards the development of a hybrid polymer scaffold based TEVG. 
Scaffold material and 
manufacturing method 
Development 
level 
Cell source Comments Group 
P(L/D)LA and fibrin gel. 
Extruded polymer 
surrounded by fibrin gel 
with encapsulated cells. 
In vivo 
(ovine model) 
Ovine SMCs, 
fibroblasts and 
ECs 
Patent up to 6 months in the ovine 
carotid artery.  
Graft integrated well with the native 
vessel.  
Collagen and elastin deposition 
observed.  
Jockenhoevel et 
al.125 
PCL and Chitosan. 
Electrospun. 
In vivo 
(ovine model) 
Acellular Patent up to 6 months in the ovine 
carotid artery. 
Graft ECM and mechanical properties 
became similar to the native artery. 
Only ~9% of the original scaffold 
material remained after 6 months. 
Breuer et at.126 
PCL and collagen. 
Electrospun. 
In vivo 
(lapine model) 
Acellular Patent for up to 1 month as rabbit 
aortoiliac bypass grafts.  
Little cell invasion or thrombosis 
observed.  
Atala et al.128 
PCL, spider silk and chitosan.  
Electrospun. 
In vivo 
(murine model) 
Acellular Patent up to 8 weeks in the rat aorta.  
Host cell invasion shown. 
Zhang D et al.127 
PCL and synthetic elastin. 
Electrospun 
In vivo 
(lapine model) 
Acellular Similar mechanical properties to the 
ITA demonstrated.  
Grafts remained patent for 1 month 
in the rabbit carotid artery. 
Weiss et al.62 
PCL and PU-collagen 
composite.  
Electrospun. 
In vivo 
(canine model) 
Acellular Patent for up to 8 weeks in the canine 
femoral artery. 
A thin layer of ECs formed in vivo. 
Zhang J et al.80 
Gelatine-vinyl acetate 
copolymer.  
Electrospun. 
In vitro Murine SMCs Dynamic culture conditions increased 
ECM deposition. Collagen and elastin 
content reached 70-80% that of the 
native rat aorta in 5 days.  
Nair et al.84 
PU and polyethylene glycol 
(PEG)-fibrin. 
Electrospun PU with seeded 
cells rolled up and coated in 
PEG-fibrin hydrogel.  
In vitro Murine smooth 
muscle 
progenitors 
Graft stress-strain response after 
dynamic culture was very similar to 
the human coronary artery, although 
with lower ultimate tensile strength. 
Hahn et al.87 
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 Decellularised natural matrices 1.3.2
The use of decellularised natural matrices in tissue engineering takes advantage of the 
structure and mechanical performance of natural tissue ECM while avoiding any 
adverse immunological reactions due to its origin. The decellularisation process refers 
to the removal of antigenic cellular material from the tissue (Figure 4). 
Decellularisation may involve a variety of chemical agents, such as acids and bases, 
hypo/hypertonic solutions, detergents and solvents; biological agents, such as 
enzymes and chelating agents; and physical methods, such as agitation, pressure and 
abrasion.129 Preservation of the ECM is intended, in order to maintain the tissue’s 
mechanical properties.130,131 A number of clinical products based on decellularised 
tissues, both human and animal in origin, are available for a wide range of applications 
including dermal, soft tissue, cardiac, ophthalmic and dentistry.129 
Decellularised vascular grafts were first developed in the 1960’s using animal tissue.132 
In the years since then, a range of these grafts have been made commercially available. 
These include Artegraft®, Solcograft® and ProCol® which were based on decellularised 
bovine blood vessels and SynerGraft® model 100 which was derived from 
decellularised bovine ureter.133–140 Although these grafts have been utilised in vascular 
bypass surgery and as vascular access conduits, largescale adoption of them has not 
been seen. A number of studies, including prospective, randomised trials, concluded 
these decellularised xenogeneic grafts offered no clear advantage compared to 
alternative synthetic conduits.141–144 Patency rates were comparable, at best, and the 
probability of graft salvage in the event of complications, such as infection or 
pseudoaneurysm, was lower. Decellularised xenogeneic grafts also cost considerably 
more than synthetic grafts.  
A product based on decellularised human donor veins has also been developed and 
commercialised for use as an AVF (SynerGraft® processed human cadaver vein 
allograft). However, just as with decellularised xenogeneic grafts, this has not been 
widely adopted. Studies suggested this graft offered no improvement in patency 
compared to established solutions. The decellularised human vessels appeared more 
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resistant to infection, compared to synthetic alternatives, but were more susceptible 
to aneurysm.145 Additionally, the availability of the human donor vessels required to 
produce this product is unpredictable and there are complex ethical and regulatory 
issues associated with the commercialisation of such tissue.  
 
 
 
Figure 4. TEVG manufacture using decellularised matrices. Tissue is harvested from an 
animal source and decellularised using various chemical and/or mechanical processes. 
Where vascular tissue is decellularised, the result is a tube composed of only ECM. 
Decellularised non-vascular tissue, such as small intestinal submucosa (SIS) or amniotic 
membrane, may be shaped into a tubular construct. Cells extracted from the patient 
are then seeded onto the decellularised scaffold forming a TEVG after maturation. 
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The limited performance of commercially available decellularised vascular grafts has 
been suggested to be due to their lack of cellularity on implant.133,139 The major failure 
modes observed are graft related thrombosis, infection and aneurysm. These may be 
combated by adding cells to the grafts, particularly luminal endothelial cells, prior to 
implantation. TEVG developers have taken to exploring this strategy (Table 4). In a 
“first in man” study, a decellularised human iliac vein seeded with autologous cells has 
shown success when used to produce a conduit for extrahepatic portal vein 
obstruction bypass (meso Rex bypass) in a paediatric case.146 The vein was 
decellularised with detergents and enzymes and then seeded with autologous bone 
marrow-derived ECs and SMCs in vitro. After 6 days of bioreactor culture, the vessel 
was successfully implanted in a 10 year old girl. Patency was reported up to 2 years, 
although narrowing of the graft, at 9 months, required the insertion of a second 
section. This procedure offers potential, although only a single human implant has 
been reported and this was in low pressure flow.     
A variety of decellularised vessels seeded with cells have been evaluated in animal 
studies also. In ovine models, positive results have been reported for decellularised 
porcine carotid arteries as carotid artery bypass grafts and AVFs. Following seeding 
with endothelial progenitor cells (EPCs), these grafts showed patency up to 4.3 and 5.6 
months, respectively.147,148 Additionally, in canines, decellularised carotid arteries 
(porcine and allogeneic) have shown patency up to 2 months in the carotid artery 
position.130,131  
Non-vascular tissues, such as the small intestinal submucosa (SIS) and amniotic 
membrane, have also been decellularised and used to produce TEVGs. The SIS is a 
natural ECM sheet that has seen clinical application in many areas including skin, 
bladder, tendon and intestine.149 Early work used porcine SIS, decellularised by 
abrasion and sutured into tubes, to produce TEVGs. When implanted in an acellular 
state, these grafts showed superior patency compared to PTFE conduits over 180 days 
in the canine carotid artery.150 Host cell invasion and remodelling altered their 
compliance and burst pressures to similar to the native vessel.151 Implantation in the 
canine aorta also showed good patency and remodelling, although the change in graft 
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compliance was smaller.152 Ovine SIS has also been examined in vitro for its potential 
as a TEVG. When cultured as sheets under uniaxial strain, this tissue supported SMCs, 
differentiated from a hair follicle, which deposited collagen and elastin. The tissue also 
showed compliance properties similar to the native ovine carotid artery, although with 
lower tensile strength.153 Most recently, acellular SIS tubes implanted as carotid artery 
interposition grafts in an ovine model demonstrated ~92% patency over 3 months.154 
These grafts were quickly populated by host cells, with a confluent endothelium 
formed after 1 month and significant collagen and elastin deposited. The grafts also 
demonstrated mechanical properties similar to the native artery.  
The amniotic membrane is another natural ECM sheet, forming the inner layer of the 
placental membrane. It is covered by epithelium and contains collagen, fibronectin and 
laminins and has been shown to be biocompatible and non-immunogenic in ocular 
surface transplantation.155 TEVGs produced in vitro using human amniotic membrane 
supported the growth and proliferation of ECs and SMCs. These constructs utilised 
decellularised amnion, either shaped around a mandrel and chemically cross-linked 
with glutaraldehyde or as a base for the culture of a cell sheet before being rolled into 
a tube.156,157 In the latter, mechanical testing of the cultured vessels after 40 days 
under pulsatile flow showed a J-shaped stress-strain response, indicative of soft tissue, 
and a rupture strength 71% that of the human carotid artery, although the elastic 
modulus and compliance properties differed somewhat from this vessel. In a further 
step, TEVGs constructed from human amniotic membrane sutured into tubes were 
examined in a lamb model as interposition grafts in the jugular vein.158 These grafts 
showed 100% patency over 48 weeks with no dilation, thrombosis or stenosis. Despite 
being implanted with their epithelium intact, little immune response was observed 
highlighting the low immunogenicity of the amniotic membrane. It remains to be seen 
how grafts produced using the amniotic membrane perform under arterial flow and 
pressure.  
The natural architecture of decellularised tissues coupled with their diverse structural 
and functional biomolecular compositions makes them potentially advantageous for 
use in TEVGs.159,160 Their inherent mechanical strength reduces the need for in vitro 
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culture or may remove this altogether. Suitably decellularised blood vessels possess 
mechanical properties ideal for use as vascular grafts and decellularised non-vascular 
tissue may be conditioned for vascular applications.153,161 Additionally, as 
decellularised matrices are remodelled they may release chemoattractants with 
mitogenic or chemotactic activities that stimulate further host cell invasion and assist 
TEVG integration and remodelling.162 However, there are also a number of limitations 
associated with using decellularised natural matrices. The decellularisation process is a 
compromise between removing antigenic cellular material and maintaining the ECM. 
Variation between protocols with respect to this balance is large.163,164 Inadequate 
decellularisation has been associated with adverse immune reactions and sudden 
failures in implants, while aggressive treatments may remove important ECM 
components, such as elastin, leading to altered mechanical properties that may render 
the tissue no longer fit for purpose.165–168 It has also been suggested that in vivo 
recellularisation of decellularised tissues may be inhibited by their dense ECM 
networks restricting cellular invasion or by chemical alterations to the matrix caused 
by the cell removal processes.131,169–171 Indeed, a lack of graft cellularity has been 
associated with the limited success of the decellularised vascular grafts that have 
achieved commercial availability. Control over the geometry of decellularised TEVGs is 
another issue, as the size and shape of the tissue available is restricted. Composite 
grafts may be constructed, but this adds complexity and expense to the graft 
manufacturing process and may affect mechanical performance and 
biocompatibility.158,159 Additionally, a number of graft properties; including geometry, 
mechanical properties and chemistry; may vary based on the age and health of the 
donor, making control of graft quality a challenge. 
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Table 4. Studies towards the development of a decellularised natural matrix based TEVG. 
Scaffold material and 
manufacturing method 
Development 
level 
Cell source Comments Group 
Bovine carotid artery. 
Decellularised 
In vivo 
(clinical experience) 
Acellular First commercialised decellularised 
vascular grafts.  
Comparing performance with PTFE 
conduits showed no significant 
improvement in patency as AVFs.  
Salvage of decellularised grafts was 
more challenging after complications 
compared to PTFE grafts. 
Sterling et al.138 
Johnson et al.172  
 
Bovine mesenteric vein. 
Decellularised. 
In vivo 
(clinical experience) 
Acellular Poor results when used in peripheral 
bypass procedures. 
Failures associated with thrombosis 
and aneurysm. 
Lawson et al.134 
Davies et al.136 
 
Bovine ureter. 
Decellularised. 
In vivo 
(clinical experience) 
Acellular Prospective, randomised trial 
comparing decellularised bovine 
ureter with PTFE conduits when used 
as AVFs. 
No significant difference found. 
Morsy et al.133 
Human vein.  
Decellularised 
In vivo 
(clinical experience) 
Acellular Compared results for decellularised 
human veins, cryopreserved human 
veins and PTFE conduits as AVFs. 
Decellularised grafts showed no 
improvements in patency.  
Kurbanov et 
al.145 
Human iliac vein. 
Decellularised. 
In vivo 
(human trial) 
Autologous SMCs 
and ECs 
First human trial of a decellularised 
vessel seeded with stem cells. 
Extrahepatic portal vein bypass.  
Patent for up to 2 years, although 
partial narrowing at 9 months 
required the addition of a second 
graft section.  
Sumitran-
Holgersson et 
al.146 
Porcine artery. 
Decellularised. 
In vivo 
(ovine model) 
Autologous ovine 
ECs 
Grafts showed an average patency of 
4.4 months as AVFs.  
ECs covered 50% of the graft lumen 
after 6 months.  
Atala et al.147 
Canine carotid artery. 
Decellularised. 
In vivo 
(canine model) 
Canine bone 
marrow-derived 
SMCs and ECs 
Patent for up to 8 weeks in the 
carotid artery.  
Cell seeded grafts performed better 
than acellular controls. 
Explants showed a layered vascular 
wall structure with collagen and 
elastin deposition. 
Kim et al.130 
Human umbilical vein. 
Frozen, machined to a 
uniform diameter and then 
decellularised.  
In vitro Human umbilical 
cord vein ECs or 
fibroblasts 
Bioreactor culture shown to increase 
vessel burst pressures. Burst 
pressures remained below that of 
human arteries at ~1200 mmHg. 
McFetridge 
et al.169 
Human SIS. 
Decellularised and shaped 
into a tube. 
In vivo 
(ovine model) 
Acellular Patent up to 3 months in the carotid 
artery. 
Host cells invaded the graft with a 
confluent endothelium after 1 month. 
Andreadis 
et al.154 
Porcine SIS.  
Decellularised and shaped 
into a tube. 
In vivo 
(canine model) 
Acellular Patent for up to 60 days in the carotid 
artery.  
Explants showed graft remodelling.  
Burst pressures exceeded human 
vessels (~5600 mmHg).  
Lantz et al.150,151 
Human amniotic membrane.  
Membrane seeded with cells 
and then rolled up. 
In vitro Human SMCs and 
umbilical vein ECs 
Graft stress-strain response was 
similar to human vasculature. 
Rupture strengths were 71% that of 
the human carotid artery. 
McFetridge 
et al.156 
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 Tissue engineering by self-assembly 1.3.3
In a departure from the classic paradigm, tissue engineering by self-assembly (TESA) 
does not utilise a scaffold or supporting matrix in the creation of a TEVG (Figure 5). 
This approach was pioneered in the form of sheet-based tissue engineering, but now 
includes other methods, such as microtissue aggregation and cell printing.  
 
L’Heureux and colleagues were the first to use sheet-based tissue engineering to 
produce a TEVG. The process involves the production of sheets of cells which are then 
layered and shaped around a mandrel, forming the tubular structure of a vascular graft. 
Media supplementation is used to encourage the cultured cells to produce large 
amounts of ECM, thus generating strong and robust sheets for TEVG fabrication.173   
Early work attempted to produce a TEVG with a structure that mimicked natural 
arteries.66 Sheets of human SMCs were wrapped around a mandrel and followed by 
sheets of fibroblasts. Culture in a flow bioreactor allowed the layers to fuse together 
before ECs were seeded onto the vessel’s lumen. This process produced a vascular 
graft with a layered structure similar to natural blood vessels. Although 4 weeks were 
required to produce the cell sheets and an additional 8 weeks to allow the layers to 
fuse together, this vessel represented the first TEVG that showed physiologically 
relevant mechanical properties without the presence of a supporting scaffold. The 
vessels demonstrated burst pressures of 2594 ± 501 mmHg, well above the human SV. 
They also displayed physiological behaviour including contractile properties, imparted 
by the medial SMCs.174 In vivo studies in canines as femoral artery interposition grafts 
showed that these grafts could withstand physiological pressures, demonstrating the 
feasibility of the sheet-based technique.66  
Further development saw the removal of the medial SMC layer and an evaluation of 
graft production using age and risk-matched human cells. Through increased culture 
times and media optimisation, grafts produced from elderly donors with 
cardiovascular disease achieved the same mechanical strength as those made from 
young healthy donor cells.64 These vessels were evaluated as arterial interposition 
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grafts in nude rats and in a more biomechanically relevant primate model with patency 
rates of 85%, after up to 225 days, and 100%, after 8 weeks, respectively. The grafts 
showed good integration with the surrounding tissue and resistance to aneurysm 
formation, although the overall production times still remained long at up to 28 weeks.  
Despite this drawback, the results were encouraging and clinical trials were 
undertaken with the grafts utilised as AVFs for haemodialysis access.175 The TEVGs 
were produced using autologous fibroblasts and ECs taken from patient biopsies. They 
ranged between 14 cm and 40 cm long, with internal diameters of 4.8 mm and 
displayed burst pressures of 3512 ± 873 mmHg. Out of an original 10 patients, patency 
rates were 78% at 1 month (n=9) and 60% at 6 months (n=8) (withdrawal from the 
study and a non-graft-related death reduced the cohort size). Graft failures were 
associated with thrombosis or aneurysm formation. Over the 20 month trial, 4 grafts 
remained patent throughout. The results were in line with the currently set objectives 
for conventional procedures of 76% patency at 3 months, across all populations. 
However, the study group represented a particularly challenging patient population 
where AVF failure was expected to be far higher.176 With this in mind, and the fact that 
the AVF may be considered a challenging application for a TEVG given the high 
puncture frequency it is subjected to, the results were considered to be quite 
promising. A second study examining leg revascularisation is now being targeted.175  
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Figure 5. TEVG manufacture by self-assembly. (a) Sheet-based tissue engineering – a 
2D cell sheet is cultured and then shaped around a mandrel forming a tube that is 
matured into a TEVG; (b) Assembly of microtissues - cell aggregates placed in a mould 
and combined to form a TEVG; (c) Bioprinting – cells and supporting material are 
deposited in a layer-by-layer manner, building up a 3D construct.   
 
 
The use of allogeneic cells in sheet-based tissue engineering has subsequently been 
explored. Grafts produced from allogeneic fibroblasts were devitalised and successfully 
implanted in three patients to provide haemodialysis access.177 Although little immune 
response was evident, in line with other reports which have shown allogeneic 
fibroblast constructs to be well tolerated, stenosis developed in 2/3 grafts, with 
intervention required, and failures ultimately occurred due to infection or thrombosis 
at 7 months. Further work is needed to determine if allogeneic cells can be successfully 
utilised to produce a TEVG, but this study clearly represents an important first step. 
Additionally, it has been shown that L’Heureux’s sheet-based TEVGs can be 
manufactured and then stored prior to requirement. A graft was successfully 
devitalised and stored frozen before being rehydrated, seeded with autologous ECs 
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and then successfully employed as an AVF in a patient requiring vascular access.178 This 
result, coupled with the potential use of allogeneic cells, offers real potential for a truly 
off-the-shelf TEVG solution.  
Finally, the group of L’Heureux has recently described a new TESA method for 
producing a TEVG: thread-based tissue engineering. Here, cell synthesised threads are 
produced in vitro and assembled into 3D structures using textile techniques such as 
knitting, braiding or weaving. Grafts produced using this method have been suggested 
to possess greater strengths, and require shorter production times, than their 
sheet-based equivalents; although detailed reports are still outstanding.179,180  
 
Other researchers have also explored the possibilities of sheet-based tissue 
engineering (Table 5). Grafts produced from sheets derived from mesenchymal stem 
cells (MSCs) have shown potential in a rabbit model, where they functioned as 
interposition grafts in the carotid artery for 4 weeks.181 The group of Germain used 
dermal and SV fibroblast cell sheets to generate tubular constructs which were then 
decellularised, leaving behind only ECM, to act as a TEVG.182 When implanted as aortic 
interposition grafts in Sprague-Dawley rats, these decellularised TEVGs remained 
patent for up to 6 months and became populated, although not completely, by host 
SMCs and ECs.183 Additionally, it was shown that decellularised grafts of clinically 
relevant sizes could be stored for up to 3 months with no detrimental effects. Although 
only currently at the early stages of in vivo examination, this method offers the 
potential for an off-the-shelf TEVG solution, similar to Niklason’s, with the 
decellularised matrices being produced from allogeneic cells, stored and then seeded 
with autologous cells just prior to implantation.  
 
Additionally, novel TESA approaches have recently been reported involving the 
production of TEVGs by self-assembly of microtissue aggregates.184 Using hanging drop 
cultures of human artery-derived fibroblasts and human umbilical vein endothelial 
cells (HUVECs), cell aggregates bound by secreted ECM were generated and then 
assembled into tubes. After 14 days under pulsatile flow, these aggregates had fused 
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into confluent structures. In a similar approach, 3D bioprinting was utilised to produce 
simple and branched blood vessel constructs by precise deposition and fusion of 
multicellular spheroids and cylinders.185 After 21 days of culture in a bioreactor, these 
constructs demonstrated burst pressures of 773 mmHg, although this value appeared 
to have plateaued.186 These approaches offer the potential for complex shapes to be 
produced, such as vascular bifurcations, however, whether they can achieve the 
required mechanical strength for use in the circulatory system remains to be seen.  
 
TESA side-steps a number of issues associated with TEVG production using scaffold 
based or decellularised matrix methods. Difficulties associated with the manufacture, 
mechanical properties or breakdown of these supporting structures are removed. The 
major limitation of using TESA is the extended in vitro culture periods required, with 
multiple months needed for sheet-based TEVGs to achieve suitable mechanical 
integrity for vascular applications.64,175 This drawback may be circumvented in the 
future by production in anticipation of individual’s clinical needs, and then storing the 
vessels until required, or by employing allogeneic cells to yield an off-the-shelf graft 
solution. Sheet-based tissue engineering is also potentially limited in terms of the 
geometries it can produce. Thread-based tissue engineering or cell-aggregate methods, 
such as 3D bioprinting, may be more suitable for more complex constructs, but have 
yet to be proven. 
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Table 5. Studies towards the development of a TEVG using TESA. 
TESA manufacturing 
method 
Development 
level 
Cell source Comments Group 
Sheet-based tissue 
engineering 
In vivo 
(human trial) 
Autologous 
fibroblasts and 
ECs 
First clinical trial of a TEVG under 
arterial flow as an AVF.  
4/10 grafts patent for up to 20 
months (in line with current clinical 
targets). 
L’Heureux et 
al.64,66,175 
Sheet-based tissue 
engineering followed by 
decellularisation 
In vivo 
(murine model) 
Human dermal 
and vein 
fibroblasts 
Decellularised grafts consisted of 
ECM components only.  
Patent for 6 months in the murine 
aorta.  
SMCs proliferated successfully on 
decellularised grafts.  
Grafts of clinically relevant sizes could 
be successfully stored for 3 months 
without detrimental effects. 
Germain et al.182,183 
Mircotissue aggregate 
assembly 
In vitro Human artery 
fibroblasts and 
umbilical vein ECs 
Cell aggregates bound by secreted 
ECM assembled into tubes.  
Fused under dynamic culture to form 
tube structures. 
Hoerstrup et al.184 
Bioprinting In vitro Human umbilical 
cord SMCs and 
dermal fibroblasts 
Branched vessel produced from the 
fusion of printed cell cylinders and 
spheroids.  
High cell densities achieved with no 
scaffold. 
Maximum burst pressure values of 
773 mmHg were achieved after 21 
days in bioreactor culture.  
Forgacs et al.185,186 
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 Consideration for the future development of TEVGs 1.3.4
Despite the large differences between the approaches being pursued to develop a 
vascular graft using tissue engineering, a number of similar issues are facing all 
researchers in this field. These include: selecting the most appropriate cell types to use 
in TEVG production, determining how to achieve and maintain the required graft 
mechanical properties and understanding the process of TEVG remodelling and 
integration with the host vasculature.  
 
 Cell source 1.3.5
A number of different cell types have been used in the in vitro preparation of TEVGs 
(Table 6). The type of cells used may directly affect the structure of the graft and 
ultimately how it performs in vivo, along with impacting the graft manufacturing 
process.  
Autologous adult vascular cells, such as SMCs, ECs and fibroblasts have been employed 
in many cases in creating TEVGs. These cells may be cultured for extended periods in 
bioreactors or seeded onto grafts prior to implantation. Despite their popularity, the 
use of these cells has several drawbacks. Their extraction requires blood vessel 
biopsies which are invasive, cause donor site morbidity and in some cases may be 
impossible due to vessel quality or availability.130 Although some researchers have 
explored using non-vascular cells in an effort to overcome these issues,98 adult cells 
are also limited in terms of replicative and regenerative capacity, due to their age.187 
This limits in vitro culture times, may affect graft performance in vivo and is particularly 
pronounced in the elderly, who are involved in the majority of revascularisations. 
Although improvements have been made to the replicative potential of adult vascular 
cells, using gene therapy, little effect on their regenerative properties has been 
achieved.187,188 It has also been shown that extended culture periods and media 
optimisation can allow age and risk-matched human fibroblasts to produce TEVGs of 
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similar quality to those made from young healthy donor cells; yet such methods may 
ultimately be impractical.64 
Given the limitations of autologous adult cells, various stem cell sources have been 
investigated for vascular tissue engineering. These include (i) progenitor cells; (ii) 
BM-MNCs; (iii) MSCs; (iv) adipose, (v) muscle or (vi) hair follicle-derived stem cells and 
(vii) induced pluripotent stem cells (iPSCs).  
 
(i) Progenitor cells 
Compared to adult cells, progenitor cells may be isolated from bone marrow or blood, 
using far less invasive procedures, and demonstrate greater proliferative and 
replicative capacity.103,147,148 Using these cells may allow for longer in vitro culture 
periods, generating more robust TEVGs.189 Ovine bone marrow-derived smooth muscle 
progenitor cells produced stronger and tougher TEVGs, in vitro, compared to using 
adult vascular SMCs directly. Progenitor cell based grafts also produced more 
organised elastin when implanted in vivo as jugular replacements in lambs.101,103 
Additionally, using vascular EPCs may be advantageous, as they induce nitric oxide 
mediated vascular relaxation. This process is more pronounced in arteries than veins 
and has been associated with contributing to the superiority of artery bypass conduits 
compared to veins.190 Vascular EPCs may be depleted in elderly patients however, thus 
making them potentially difficult to obtain.191  
 
(ii) Bone marrow mononuclear cells 
BM-MNCs can be extracted from the bone marrow and include MSCs and 
hematopoietic stem cells. An extract of BM-MNCs has the potential to generate 
various cell types including vascular ECs, SMCs and fibroblasts.192 These cells also lack 
major histocompatibility complexes, along with other important immuno-stimulatory 
molecules, offering potential as allogeneic cells for TEVG production.193 Shin’oka and 
colleagues employed autologous BM-MNCs, extracted from the superior iliac spine, 
with great success in their pioneering clinical trial.55  Additionally, these cells may be 
utilised to generate SMCs and ECs for seeding onto TEVGs in vitro.130,146  
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(iii) Mesenchymal stem cells 
MSCs may be separated from BM-MNC extracts or other tissues including blood, 
adipose tissue, muscle and liver.194–197 They are able to differentiate into SMCs with in 
vitro studies on TEVGs highlighting the effect that mechanical stimulation and certain 
growth factors can have on this process.198 MSCs have demonstrated little potential to 
generate ECs, but work in animal models has suggested that they may have a role in 
assisting EC colonisation of TEVGs.199,200 Additionally, MSCs may possess 
anti-thrombogenic qualities, potentially allowing for their use in TEVGs, in vivo, 
without the requirement for ECs.201  
 
(iv) Adipose-derived stem cells 
Adipose tissue also contains its own stem cells which have been shown to differentiate 
into both SMCs and ECs and have been used as a source of cells for vascular tissue 
engineering.202–204 These cells can be extracted in high quantities from adipose tissue 
aspirate which is often readily available and easy to harvest. Since the majority of 
revascularisation procedures are conducted on elderly patients, utilising 
adipose-derived stem cells may have particular advantages. It has been demonstrated 
that these cells maintain high potency, with their potential to form ECs appearing 
unaffected by age.205 Additionally, their numbers do not appear to diminish with 
advancing age with some evidence suggesting they may actually be more abundant in 
older subjects.205,206   
 
(v) Muscle-derived stem cells 
Muscle-derived stem cells have been utilised in successful in vivo studies of TEVGs.77 
When seeded onto PEUU scaffolds and implanted in rat aortas, these constructs 
demonstrated patency for up to 8 weeks; integrated with the surrounding tissue and 
became populated with ECs and SMCs. Although these results are positive, 
muscle-derived stem cells can only be obtained from muscle biopsies. These 
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procedures are invasive and painful, and therefore the clinical use of this particular 
stem cell source may be limited.  
 
(vi) Hair follicle stem cells 
Recently, hair follicle stem cells have been utilised to recellularise SIS and umbilical 
arteries, following decellularisation, to potentially create vascular grafts.153,207 
Although only early, in vitro, work has been reported, the hair follicle represent an 
abundant and easily harvested potential source of stem cells for use in TEVG 
production.208 Hair follicle stem cells have been suggested to be similar to MSCs from 
bone marrow, although with a greater ability to proliferate in culture.209 They may also 
have low immunogenicity, giving them potential as allogeneic cells.210 
 
(vii) Induced pluripotent stem cells 
The relatively new discovery of induced pluripotency opens up the possibility of 
obtaining suitable cells for vascular tissue engineering by transforming adult cells.211 In 
a recent study, murine iPSCs were differentiated into SMC and EC phenotypes and 
used to construct a TEVG which remained patent for up to 10 weeks when implanted 
in the inferior vena cava of a mouse model.212 Niklason and colleagues generated a 
TEVG from iPSCs derived from neonatal fibroblasts. These remained patent for 14 days 
as abdominal aorta interposition grafts in nude rats.213 Additionally, human iPSCs, 
established from vascular fibroblasts, were used to generate proliferative SMCs which 
were combined with a PLLA scaffold to create a TEVG that demonstrated vascular 
tissue formation when implanted subcutaneously in a mouse model.214  
Although these studies are promising and iPSCs have exciting potential for the 
generation of patient specific TEVGs, significant knowledge has still to be gained 
regarding their use. For example, ECs differentiated from iPSCs derived from adult cells 
have shown reduced proliferation compared to those from embryonic stem cells, 
suggesting that the original source for iPSCs may influence the properties of the 
ultimately derived cells.215 As with other pluripotent cells, iPSCs also carry a risk of 
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teratoma formation. Greater understanding of this revolutionary cell type is required 
and a drive towards achieving this is already clear.216   
 
(vii) Non-autologous cells 
The possibility also exists to employ non-autologous cells in vascular graft tissue 
engineering. This could eliminate the problems with cell quality and variation that are 
associated with patient specific cells and also remove the delay in graft availability that 
is often caused by their culture requirements, potentially making grafts available 
off-the-shelf. Allogeneic cells have been employed successfully in treatments for other 
tissues, particularly the skin, where allogeneic dermal fibroblasts have been used in 
approved products, such as Apligraft® and Dermagraft®, without immunological issues. 
Additionally, BM-MNCs and hair follicle stem cells have both been shown to elicit low 
immune responses in allogeneic applications, thus presenting another possible source 
of donor cells for TEVGs.193,210 L’Heureux and colleagues have trialled a sheet-based 
TEVG produced from allogeneic fibroblasts in the clinic.177 Although patency was 
limited, an adverse immune response did not appear to be present, suggesting there is 
more to be learned about utilising allogeneic cells in vascular graft tissue engineering.  
 
The range of possible cell types that may be utilised in a TEVG has recently been 
widened by the use of decellularisation protocols for producing engineered vessels in 
vitro, using polymer scaffolds or TESA.70,182 With the decellularisation process 
removing the immunogenic cellular material from the grafts, therefore separating the 
cells used to engineer them from the intended patients, restrictions on cell source 
become reduced. Allogeneic, or even xenogeneic, banked cells or cell lines could be 
employed for the in vitro culture of the grafts.  
 
Acellular grafts 
The possibility of generating a TEVG without the need for in vitro cells is also being 
explored by a number of research groups. The earliest commercially available vascular 
grafts based on decellularised tissues did not utilise in vitro seeded cells; however, 
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their performance has been limited. No clear advantage of these products over 
alternative, and less expensive, synthetic conduits has been demonstrated.141–144 The 
complications and failures seen when using these grafts were largely associated with 
thrombosis and aneurysm and, although the specific mechanisms behind these issues 
are not fully understood, the lack of graft cellularity has been suggested as a 
contributory factor.133,139 As such, a number of researchers developing decellularised 
matrix based TEVGs have now taken to adding in vitro cells prior to implantation. 
Despite this, research into developing a TEVG that may be acellular at implant has 
continued. A number of acellular grafts based on synthetic or natural polymer scaffolds, 
along with decellularised matrices, have now been explored, although with varied 
results. Successful cell invasion, remodelling and integration of acellular polymer grafts 
has been reported in some in vivo studies in rats, canines and sheep.79,81,82,154 However, 
other works have reported poor results with similar grafts showing the development of 
substantial intimal hyperplasia and calcification or a reduction in integrity after 
remodelling.85,128 Conflict is seen between studies using similar scaffolds, animal 
models and timescales, but different implantation sites, suggesting that in vivo tissue 
engineering responses are complex and dependent on as yet unknown factors, such as 
the haemodynamic environment, inflammation and the immune response.83,85 
Additionally, numerous reports have shown failures in acellular grafts, implanted in 
vivo, directly associated with thrombosis due to the lack of a lumenal EC 
layer.69,77,130,148,217 Indeed, platelet adhesion assessments in TEVGs have demonstrated 
the success of ECs in reducing thrombosis.128 However, biochemical surface 
modification, such as heparin coating, has been suggested as a means to counter 
thrombosis without the addition of ECs.131  
Removing in vitro cells from the “TEVG equation” has substantial practical and 
economic implications; greatly simplifying the pathway to clinical adoption and 
reducing potential therapy costs. However, it is unclear if in vivo tissue engineering can 
be relied on alone, especially in elderly or diseased patients, to generate successful 
vascular grafts.  
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Table 6. Range of cell types employed in TEVG development. 
Cell type Specific cells Advantages Disadvantages Reference 
Autologous 
somatic adult 
cells 
Vascular SMCs 
Vascular Fibroblasts 
Vascular ECs 
Dermal Fibroblasts 
Proven by a number of groups in 
TEVG manufacture.  
In the case of vascular cells, TEVGs 
are composed of the same cells as 
native blood vessels.  
Harvest of vascular cells is invasive 
and may be limited by vessel 
quality or availability.  
Limited replicative and 
regenerative potential. 
65,70,75,98,102,105,107,118
,125,156,175,185 
Progenitor 
cells 
Bone marrow-derived 
smooth muscle 
progenitor cells 
Vascular EPCs 
May be isolated from bone marrow 
or blood. 
Compared to adult cells, show 
greater replicative and 
regenerative capacity and may be 
cultured for extended periods to 
generate more robust TEVGs.  
Certain progenitor cells may be 
depleted in elderly patients. 
87,103,147,148,189 
Natural stem 
cells 
BM-MNCs Isolated from bone marrow and 
contain various stem cells. 
Can generate SMCs, fibroblasts and 
ECs.  
Bone marrow harvest is invasive. 55,130,146,192 
MSCs May be extracted from bone 
marrow, blood, adipose tissue and 
liver.  
Able to differentiate into SMCs. 
Assist EC colonisation of TEVGs. 
Possess some anti-thrombogenic 
qualities. 
Little ability to differentiate into 
ECs 
198,200,201,218,219 
Adipose-derived stem 
cells 
May be isolated from adipose 
tissue biopsies. 
Able to differentiate into SMCs and 
ECs. 
Patient age appears to have little 
effect on cell numbers and 
differentiation potential.   
Only early, in vitro, work reported. 202,203,205 
Muscle-derived stem 
cells 
Some success shown in vivo with 
seeded TEVGs integrating with the 
native tissue well.  
Muscle biopsies are invasive and 
painful. 
77 
Hair follicle stem cells Hair follicles represent an abundant 
and easily harvested source of stem 
cells.  
Can differentiate into SMCs. 
Greater proliferative potential in 
culture compared to bone marrow-
derived MSCs.  
Only early, in vitro, work reported. 153,207 
iPSCs 
 
Various adult and 
embryonic cell sources 
Great potential to generate cells for 
vascular tissue engineering from 
various adult or embryonic cells.  
Differentiated cells produced from 
iPSCs show varied proliferative 
potential depending on the original 
cells used in iPSC generation, 
highlighting cell source as an 
important factor.   
212,214 
Non-
autologous 
cells 
Allogeneic fibroblasts  
(many other possible 
cells yet to be 
explored) 
Time taken to expand patients own 
cells in culture avoided. Variation in 
cell quality between patients 
avoided. 
Off-the-shelf grafts possible.  
A wide variety of cell types, both 
human and animal, may potentially 
be used. 
Potential immunological issues.  
Regulatory approval may be 
challenging.   
180 
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 Mechanical properties 1.3.6
 Design targets 1.3.6.1
Given the load bearing nature of blood vessels, resulting from the pressurised fluid 
flow they support, the mechanical properties of a TEVG are important design 
requirements. Sufficient mechanical strength to retain integrity and resist permanent 
deformation may be considered one of the most fundamental performance criteria. 
Graft compliance and the way in which deformation under loading occurs is also 
important, as adverse biological responses have been associated with compliance 
mismatch between native vessels and both synthetic and biological vascular grafts.33,38 
Additionally, the ability of the graft to retain sutures must also be considered, given 
the surgical methods that will be employed during implantation. There is, however, a 
lack of agreement over the target values for these particular graft properties among 
researchers developing TEVGs. It has been common to use the current gold standard 
graft, the SV, as a target to emulate, making TEVGs essentially SV substitutes. 
Matching the SV may be beneficial for clinical adoption of a TEVG; however, patency 
may ultimately be limited by the same mechanical inadequacies associated with the SV. 
Using arterial conduits in bypass grafting, such as the ITA, has been shown to produce 
superior patency compared to the SV.10–13 These conduits are not used preferentially 
due to their limited availability and the more severe implications of artery removal 
compared to veins. Although the ITA may be more challenging to replicate through 
tissue engineering, due to its increased strength compared to the SV, a TEVG designed 
to mimic this vessel may also display its improved performance. Figure 6 shows how 
the mechanical properties of some reported TEVGs compare to both the ITA and the 
SV. Based on these reported results, it is clear that no TEVG has yet been produced 
that matches the ITA or SV in terms of vessel burst pressure, suture retention strength 
and compliance. Of those groups reporting all of these metrics, the vessels produced 
by Tranquillo, Niklason, Vorp, Kim, Tan, Chen, McFetridge and L’Heureux may be 
tentatively considered the most promising. Interestingly, these groups span the whole 
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range of TEVG manufacturing methods. Clearly, no single method has yet proven its 
superiority and therefore it is very difficult to suggest the type of TEVG design that may 
ultimately achieve comparable properties to the ITA or SV.  
Another consideration is whether any of the autograft conduits currently used in 
vascular bypass surgery should be used as a target for the mechanical performance of 
a TEVG. Since a vascular bypass is a non-natural construct, it is likely that the optimum 
properties required are different from these vessels. Tissue engineering provides the 
opportunity to work towards this target, but requires additional research to help 
define any target values. More advanced simulations of vascular biomechanics may be 
useful in achieving this in the future. Another issue is the variation in blood vessel 
mechanical properties displayed between different vessels in the human body and 
between different individuals.220 Ultimately, it may be possible to tailor specific graft 
mechanical properties with the intended implantation site.  
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Figure 6. The mechanical properties of reported TEVGs compared to the human ITA and 
SV. The results are arranged by manufacturing method and represent grafts prior to any 
implantation.62,65,70,78,80,84,91,93,99,107,108,118,124,131,151,167,175,186,217,218,221–228 For reference, 
values for burst pressure, suture retention strength and compliance are 3073 mmHg, 
1.72 N and 11.5 %/100 mmHg for the ITA and 2134 mmHg, 1.92 N and 25.6 %/100 mmHg 
for the SV, respectively.62–66,218  
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 The effect of remodelling 1.3.6.2
The picture of TEVG mechanics becomes even more complex when considering the 
remodelling and alteration in mechanical properties that may occur over time, after 
implantation. It is possible to ask not only what mechanical properties are required, 
but also when are they required. A number of in vivo studies have shown that TEVGs 
remodel to demonstrate altered mechanical properties after implantation. Some cases 
have shown a negative result, with conduits becoming weaker or stiffer due to an 
imbalance of ECM deposition and supporting scaffold degradation or calcification.85,229  
However, positive results with grafts becoming more similar to the native tissue are 
also reported.63,70,99,101,151 The question of how different from the target mechanical 
performance the graft can be, at implant, and how quickly it alters in vivo is then raised. 
Given that failures associated with compliance mismatch, such as intimal hyperplasia, 
may occur in the first year of graft implantation, understanding the process of graft 
remodelling and the time taken is crucial and requires further investigation. 
 
 Emulating the native stress-strain response 1.3.6.3
Emulating the mechanical properties of native blood vessels is a challenge, due to their 
complex behaviour. Blood vessels display viscoelasticity and a J-shaped stress-strain 
response. These properties are a result of the different proteins that form the vessel 
walls. Low strains produce only small changes in stress driven by the compliant and 
elastic response of elastin fibres. As strains increase, crimped collagen fibres are 
opened out and engaged in a tensile manner, causing an increase in stress (Figure 
7).230–232 
A number of studies have reported TEVGs with mechanical responses that are similar 
to natural blood vessels. TEVGs produced from natural SIS sheets were shown to have 
a similar, J-shaped, stress strain response to the native ovine carotid artery.153 This 
finding is understandable given their natural soft-tissue ECM structure. Using synthetic 
polymer scaffold based methods, a PU and PEG-fibrin hybrid scaffold seeded with 
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mouse smooth muscle progenitors and cultured under pulsatile flow conditions 
produced a TEVG with a similar stress-strain response to the human coronary artery.87 
Additionally, a composite vessel produced from layered PCL and PGA sheets seeded 
with bovine fibroblasts, SMCs and ECs showed a similar stress-strain response to 
bovine arteries after dynamic culture for 2 weeks.95 In vivo, acellular PGS and PCL 
grafts implanted in Lewis rat aortas remodelled over 90 days, yielding vessels with 
closely matching mechanical responses to the native vessel.82 Mechanical stimulation 
through pulsatile flow, either in vitro or in vivo, may have been key in achieving these 
vessel mechanical behaviours. However, a J-shaped stress-strain response curve 
similar to the coronary artery was also achieved using an electrospun PEUU scaffold, 
with integrated rat vascular SMCs, after only 3 days in dynamic culture in a spinner 
flask.233 This result suggests that such pulsatile flow stimulation is not a prerequisite 
for achieving a TEVG with similar mechanical properties to the native vessel, and that 
scaffold materials may play an important role. Interestingly, an acellular graft 
produced solely from PGA and PU has also been shown to demonstrate mechanical 
behaviour similar to the natural porcine carotid artery, presenting the possibility of 
direct implantation in vivo, without the need for any in vitro cell culture.222 It should be 
noted that it is unclear how the mechanical behaviour of TEVGs produced using 
scaffold based methods will change over time as the scaffolds degrade. In vivo studies 
of sufficient length and with appropriate time points are required to explore this and 
capture changes in graft mechanics associated with scaffold breakdown.81 
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Figure 7. Representative stress-strain responses for the ITA and SV. Both vessels 
exhibit a J-shaped stress-strain response with a linear toe region. 
 
 Elastin 1.3.6.4
Another interesting element in the endeavour to engineer the required TEVG 
mechanical properties is elastin production. Elastin fibres are responsible for the 
elasticity of blood vessels, preventing dynamic tissue creep by stretching under load 
and returning to their original shape after the load is removed. This property prevents 
permanent deformation under pulsatile flow.230  
Although elastin may not be an issue in TEVGs based on decellularised matrices, as 
these constructs often already possess this protein, producing it in in vitro-derived 
TEVGs is poorly understood. Although their grafts are undergoing clinical trials, the 
TEVGs produced by Niklason’s group have been shown to possess little elastin. This 
finding has been suggested to be due to acidic hydrolysis products from the 
breakdown of their graft’s PGA scaffolds reducing elastin synthesis by affecting cell 
proliferation and function, including ECM deposition.234 There is some evidence that 
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scaffold stiffness, degradation rate and topography may influence elastin deposition 
too.82,86,88 Comparing identical PGS and PLGA scaffolds showed the more elastic PGS 
produced a TEVG with organised elastin.88,93 Further to this, the rapid degradation of a 
scaffold produced from PGS was also linked to improved elastin deposition in rats.82 
Organised elastin, in fenestrated sheets, has also been demonstrated when aortic 
SMCs were cultured on hyaluronan gels.235 Additionally, TGF-β1 was shown to cause 
increased elastin synthesis in human SMCs only when they were cultured on 3D 
meshes, not on 2D sheets.86   
Proteins and various factors have also been linked with affecting elastin deposition in 
TEVGs. Elastin production may be enhanced by fibrin, as fibrin gels seeded with rat 
SMCs showed enhanced elastin production compared to collagen gels.236 Ascorbate 
has been used in the production of TEVGs due to its positive effect on collagen 
production.67,70 However, ascorbate may also inhibit elastin production by destabilising 
elastin mRNA.237 Using TGF-β1 and insulin were shown to overcome ascorbate’s 
inhibition of elastin and also further enhance collagenesis.237 Although, interestingly, 
Niklason’s group used TGF-β1 and ascorbate in the culture of a TEVG and saw little 
elastin deposition, suggesting that insulin is critical.198 Adding further to the confusion, 
the groups of Wang and Jockenhoevel  both showed elastin deposition, when using 
ascorbate supplementation in the production of TEVGs, therefore its level of elastin 
inhibition remains unclear.93,125,226 Jockenhoevel and colleagues did use a fibrin 
containing scaffold however, suggesting a possible balance between any positive 
effects of fibrin on elastinogenesis and inhibition by ascorbate.  Additionally, 
elastinogenesis has been shown to be accelerated by retinoic acid and calcitriol. These 
compounds are under further exploration to discern their utility in TEVG 
production.229,238  
The influence of mechanical stimulation on elastin production in TEVGs is also unclear. 
Elastin mRNA expression was shown to be independent of mechanical stimulation in 
collagen scaffolds.239 However, in in vitro culture in a pulsatile flow bioreactor, a TEVG 
based on a gelatin–vinyl acetate copolymer scaffold seeded with rat SMCs achieved an 
elastin content 80% that of the native rat aorta in just 1 week. Although it is unclear 
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how organised this elastin was, gene expression for elastin was upregulated compared 
to static culture controls.84 A synergistic effect between mechanical stimulation and 
the scaffold material may be in operation. Indeed, it is understandable that the 
mechanical properties of the scaffold may affect how any mechanical stimulation is 
transduced onto the cells in a TEVG. Interestingly, in a comparison of PGA and collagen 
scaffolds cultured under pulsatile flow, elastin expression was only upregulated in the 
PGA group, compared to static controls, suggesting a combinatorial effect of scaffold 
and mechanical stimulation.240,241 Recently, Niklason and colleagues have developed a 
novel bioreactor able to provide axial and circumferential strain to TEVGs during in 
vitro culture. This biaxial stimulation produced TEVGs with mature elastin fibres, 
suggesting that axial strain may be another important factor in elastin 
production.242,243 Elastin deposition has also been shown on SIS sheets cultured in vitro 
under simple uniaxial tension, not pulsatile flow. Human hair follicle-derived SMCs 
were utilised, but it remains unclear whether these cells, the mechanical properties of 
the SIS or its embedded chemical cues may have assisted elastinogenesis.153  
Evidence for the influence of cell source on elastin production in TEVGs has also been 
demonstrated. L’Heureux and colleagues were able to achieve elastin deposition in 
vitro, although not quantified, in their sheet-based TEVGs which are based on 
fibroblasts, not SMCs as are commonly used by others.66 Additionally, it was shown 
that using ovine bone marrow-derived smooth muscle progenitor cells, compared to 
using ovine vascular SMCs directly produced more organised elastin in TEVGs 
implanted as jugular interposition grafts in lambs.101,103 Given that elastinogenesis 
varies throughout the mammalian lifespan, from very high levels during gestation to 
very low levels in adults, cell age is also likely to be a significant factor in elastin 
production in a TEVG.244–247  
TEVGs have also been shown to remodel and gain increased elastin content in vivo. A 
decellularised fibrin scaffold based TEVG implanted in the ovine femoral artery 
remodelled to contain 8.8% the elastin content of the native vessel over 24 weeks, 
with these fibres being mature and organised. In a canine model, an acellular TEVG 
placed in the pulmonary artery obtained equal collagen and elastin contents to the 
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native vessel in 12 months.79 Additionally, an acellular graft composed of PGA, PCL, 
PLLA and collagen implanted as a porcine aorta replacement developed 33% the native 
elastin content after 4 months, although elastin production then plateaued.229 
Determining the process of elastin deposition in graft remodelling may assist in 
developing methods to modulate and control this or to improve elastin production in 
TEVGs in vitro. 
It has also been shown that elastin expression in cells cultured on TEVGs can be 
modulated, in vitro. It has been demonstrated that inhibition of certain microRNAs 
resulted in enhanced elastin deposition during the bioreactor culture of TEVGs.248 This 
genetic modulation approach may be adapted to TEVGs in vivo to direct invading host 
cells to generate elastin.  
It may also be possible to circumvent the need to generate elastin, by adding it to 
TEVGs directly. Elastin has been successfully added to scaffolds by electrospinning.228 
Indeed, an electrospun PCL and elastin scaffold has demonstrated mechanical 
properties similar to the ITA and was patent in rabbits for 1 month when implanted in 
an acellular state.62 Producing elastin and understanding how to control this is a key 
challenge in engineering TEVG mechanical properties. 
 
 TEVG haemodynamics 1.3.7
Vascular bypass haemodynamics have been identified as having an effect on graft 
patency. In particular, intimal hyperplasia formation around the distal anastomosis has 
been linked with certain blood flow characteristics, such as flow separation, wall shear 
stress gradients and flow oscillation or stagnation.34,249–251 The occurrence of these 
undesirable haemodynamics has been suggested to be influenced by both anastomosis 
geometry and graft compliance, although the former appears to have a greater 
effect.252,253 To this end, a number of different anastomotic configurations have been 
explored, using both synthetic and autograft conduits, in an attempt to reduce 
undesirable haemodynamics and improve long-term graft patency. Interposition vein 
cuffs, such as the Miller cuff and Taylor Patch, improve graft-host compliance matching 
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and also alter anastomotic haemodynamics.254–256  Their effectiveness is questionable, 
however, with conflicting reports of improved patency restricting their wide scale 
adoption.257–260 Additionally, pre-cuffed synthetic grafts are also in production, again 
with the intention to reduce undesirable haemodynamics; however, their effectiveness 
is also debated.261–263  
More complex anastomotic configurations have been designed and explored through 
simulation work.264–267 Variation in design parameters such as anastomosis angle, flow 
area, bypass plane and graft-host ratio have been investigated in an effort to define 
the ideal geometry in terms of blood flow characteristics.268–271 It is noted in a number 
of these works that the designs may be too complex for surgeons to reproduce using 
current vascular conduits. This difficulty presents a clear opportunity for the TEVG. A 
tissue engineered vessel may allow for more complex anastomotic configurations to be 
created and explored. Scaffold or self-assembly based approaches to generating TEVGs 
could be used to construct more complex vascular grafts with the intention to reduce 
undesirable haemodynamics and improve overall patency. Computer modelling with 
computational fluid dynamics and finite element analysis could be utilised to develop 
optimal graft designs and inform vascular graft tissue engineering.38,50,272,273 Simulation 
work is ideal for exploring complex flow parameters, which can be difficult to measure 
in vivo, and also offers high resolution, repeatability and the option to easily change 
model settings and explore different graft geometry and flow scenarios. It remains for 
such a strategy to be examined by researchers in the field of vascular graft tissue 
engineering, but the potential power of this approach should not be overlooked.  
It is also important to note that graft haemodynamics may also have an influence on 
TEVG integration and remodelling. Indeed, the difference between the blood flow in 
the carotid artery and the aorta was suggested to be the reason for the largely 
different calcification and graft cellularisation observed between two similar 
electrospun PCL grafts implanted in an acellular state in a rat model.83,85 The role that 
haemodynamics may play in graft integration remains to be determined. In the future, 
it may advantageous to design TEVGs with consideration of conduit haemodynamics in 
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relation to both graft integration and remodelling along with the suppression of 
undesirable flow characteristics associated with causing intimal thickening.  
 
 
 TEVG remodelling and integration in vivo 1.3.8
Although a number of TEVGs have been implanted in vivo, in humans and in a number 
of animal models, the mechanism by which these grafts integrate into the host’s 
circulatory system and remodel into functional blood vessels is largely unclear. 
Evidence suggests that the host’s immune cells, particularly monocytes, macrophages 
and neutrophils may be the major mediators of graft remodelling and neotissue 
formation through a modified inflammatory response. Immediately after TEVG 
implantation, neutrophils and monocytes migrate into the anastomosis and an 
inflammatory response occurs with the removal of debris, resulting from the surgical 
trauma, by phagocytosis. This process may last several weeks. Subsequently, signals 
are produced to direct a shift from inflammation to tissue remodelling and repair. 
Tissue engineered graft integration appears to consist of an atypical response to 
vascular injury, including intimal thickening and neointima development, along with 
biomaterial related effects, in some cases, such as foreign body reaction, fibrosis and 
the formation of a vascular media.274 
Monocytes may be particularly important in early graft remodelling. These cells may 
be attracted to the implantation site due to chemoattractants released by activated 
neutrophils.275 In studies using polymer scaffold based TEVGs, it has been shown that 
monocytes may remain at the implantation site until the scaffold is fully degraded (up 
to 100 weeks has been observed) with localisation around residual polymer 
fragments.76 This finding suggests they may be involved in the complete remodelling 
process. Monocytes may produce cytokines, growth factors and enzymes important 
for vascular cell proliferation and tissue remodelling, such as Interleukins 6 and 10 and 
matrix metalloproteases.276 Additionally, macrophage invasion has been observed in a 
number of acellular TEVGs when implanted in vivo.82,85,99,227 These macrophages may 
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be derived from monocytes attracted to the implant site and have been suggested to 
be critical for neovessel formation in a mouse model, although the method by which 
this occurs is unclear.277 The role of different macrophage phenotypes in biomaterial 
integration has become clear over recent years and is reviewed more thoroughly 
elsewhere.278  
Progenitor cells have also been suggested as having an important role in TEVG 
integration. There is evidence that circulating progenitor cells from the bone marrow 
contribute to TEVG colonisation. When acellular silk fibroin scaffolds were implanted 
as aorta replacements in genetically modified rats, with bone marrow cells modified to 
express GFP, GFP positive SMCs were found as a major cellular component of the 
grafts medial layer after 12 weeks.106 Circulating progenitor cells were also suggested 
to be the source of the intimal cells that invaded an acellular PGA and PLLA graft 
implanted in the carotid artery of a canine model.81 Evidence suggests that invasion of 
TEVGs by host cells occurs at the anastomosis, and not via the graft lumen.147 It is 
possible that the host’s immune cells around the anastomosis may modulate this 
process by recruiting circulating progenitors. Interestingly, there is evidence that 
monocytes themselves may give rise to endothelial progenitor cells.279 These cells have 
been shown to be important in graft endothelialisation and thus may represent an 
additional method by which monocytes contribute to graft remodelling.  
Another important question relating to TEVG remodelling and integration is the role of 
any seeded cells present on the implanted graft. There is evidence that cells present 
on TEVGs at implant are quickly lost or replaced by the host’s own. GFP labelling of ECs 
seeded onto a decellularised TEVG showed most were lost and replaced by host cells 
after 30 days in vivo in a porcine model.69 Another study showed only 10% of seeded 
endothelial progenitor cells remained present on a decellularised graft after 130 days 
implanted in the ovine carotid artery.148 Additionally, studies in rats with PEUU grafts 
seeded with human pericytes found most were lost from the graft after 8 weeks and 
replaced by the host ECs and SMCs.78 It is unclear how cells present on TEVGs at 
implant may interact with the host and influence graft remodelling, although this 
process is likely to be dependent on the specific cells involved. Interestingly, human 
51 
 
BM-MNCs seeded onto polymer scaffolds were found to be replaced by monocytes 
within just a few days of in vivo circulation in a mouse model. These monocytes were 
later replaced by SMCs and ECs. It was noted that the BM-MNCs secreted significant 
amounts of monocyte chemoattractant protein 1 (MCP-1), as a result of their contact 
with the polymer scaffold. This may have contributed to monocyte recruitment.280 It 
may be possible to exploit this process and encourage monocyte invasion into TEVGs 
by using MCP-1. Polymer scaffolds have been created with bound MCP-1 releasing 
microparticles in an effort to achieve this.280 
The cellular and molecular mechanisms of graft integration and remodelling remain 
largely unclear. Gaining understanding in this field is vital for the future development 
of TEVGs and may ultimately allow modulation and engineering of this process.  
 
 
 Conclusions and research opportunities 1.3.9
It is clear that a number of different approaches are being explored to produce a TEVG 
and, with clinical results being reported for a wide range of techniques, the best 
solution is yet to be determined. Despite the range of technologies all apparently 
poised for success in this field, similar problems are faced by all developers, 
particularly in relation to understanding graft integration with the host. 
 
Based on this review of the field of TEVGs, two interesting research opportunities are 
apparent. These are the production of grafts with suitable mechanical properties and 
the generation of TEVGs with varied or bespoke geometries.     
Although the ideal mechanical properties for a TEVG have yet to be properly defined, 
and could indeed be variable depending on implantation site and the individual 
recipients, no TEVG has been produced with mechanical properties that match the 
current gold standard vessels (autograft veins and arteries). In relation to burst 
pressure, compliance and suture retention strength, it has not yet been possible for a 
single TEVG design to equal the performance of the gold standard vessels, in all three 
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areas. Compliance behaviour appears to demonstrate the greatest shortfall and this 
has been strongly linked with the elastin content of TEVGs. Elastin plays a major role in 
dictating the mechanical behaviour of blood vessels; however, producing TEVGs with 
suitable elastin content and organisation has yet to be achieved.   
Additionally, to date, TEVGs have been almost exclusively manufactured as simple 
tubes. Although tubes may be adequate for a number of applications in vascular 
surgery, advancing TEVG geometry beyond this simple shape may allow superior 
modulation of haemodynamics, present additional therapy options and provide the 
possibility of tailoring TEVG design to specific individuals. It is noteworthy that a 
number of the manufacturing methods used to produce TEVGs, while able to produce 
tubes, may be difficult to adapt to producing more complex shapes, such as tapers, 
bends and bifurcations. Therefore it is important to consider the production of 
complex vascular graft shapes at the outset of developing a method for producing any 
TEVG.  
 
  
53 
 
 Research aims 1.4
This research aimed to develop a method of manufacturing TEVGs with mechanical 
properties more similar to the current gold standard vessels. The mechanical 
properties of interest were burst pressure, suture retention strength and compliance. 
The TEVGs would be biocompatible, non-immunogenic and able to grow and remodel 
in vivo. Additionally, the TEVG manufacturing process would also be readily adaptable 
to producing more complex geometric shapes than simple tubes.  
 
A synthetic polymer scaffold based approach was selected as the method for 
producing the TEVGs. The use of synthetic polymer scaffolds has been a widely 
adopted approach in the field of vascular tissue engineering (as discussed previously 
in ‎1.3.1.1). This method is also compatible with a range of manufacturing processes, 
has the potential to be adapted to produce a graft in a variety of predefined 
geometries and has shown success in a variety of in vivo studies, including human trials. 
A scaffold would be developed with properties, such as elasticity, degradation rate and 
porosity, specifically optimised towards the development of a TEVG with the 
aforementioned mechanical performance.    
Using a proven approach, TEVGs would be produced in vitro in a bioreactor by seeding 
cells onto the synthetic polymer scaffold and then culturing them under physiologically 
relevant flow to encourage cell proliferation and appropriate ECM deposition.  
  
54 
 
 Objectives 1.4.1
 Select and characterise a suitable synthetic polymer for use as the scaffold 
material for generating the TEVGs. 
 Develop a method for producing tissue engineering scaffolds in a variety of 
shapes from the selected material.   
 Design and manufacture a bespoke bioreactor capable of supporting the 
culture of TEVGs under dynamic conditions.  
 Seed appropriate cells onto the scaffolds and culture in the bioreactor to 
generate TEVGs 
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Chapter 2 - Synthesis and 
Characterisation of Poly(glycerol 
sebacate)-methacrylate as a scaffold 
material for TEVGs 
 Introduction 2.1
In the previous chapter, a review of the literature identified that a TEVG has not yet 
been produced that has equal or closely matching mechanical properties to the 
current gold standard autograft vessels used in vascular surgery. Producing a TEVG 
with these properties was identified as the primary aim of this body of work.  
A synthetic polymer scaffold based approach was selected to produce the TEVG. This 
method was chosen out of the varied manufacturing methods that have been 
employed to produce TEVGs previously. This was because it was compatible with a 
range of materials and manufacturing processes; has shown success previously, 
including in human trials; and has the potential to produce TEVGs of different 
geometries, which was the secondary aim of this work. The synthetic polymer scaffold 
would be seeded with cells and cultured in a bioreactor to generate a TEVG.   
 
The material from which the synthetic scaffold was produced was of particular 
importance. To produce a TEVG with similar mechanical properties to autograft vessels, 
a number of requirements for the synthetic scaffold material were identified. The 
scaffold material was required to be biocompatible. This would allow it to support the 
culture of cells inside the bioreactor in order to generate a TEVG.281 The elasticity of 
the scaffold was also identified as an important factor. It has been demonstrated that 
the compliance of TEVGs was improved by using scaffolds produced from more elastic 
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materials, with a Young’s modulus of ~300 kPa appearing to produce the best 
results.93,282 Additionally, the degradation rate of the scaffold has also been shown to 
influence TEVG development. More rapidly degrading scaffolds appeared to improve 
TEVG development during in vitro culture.88 Finally, it was determined that the scaffold 
material should be easy to produce and process into a variety of scaffold shapes.  
 
An examination of the literature revealed that poly(glycerol sebacate) (PGS) appeared 
to be an attractive potential scaffold material. This material had demonstrated suitable 
biocompatibility, mechanical properties and degradation rates in previous studies. PGS 
is a polyester produced from glycerol and sebacic acid monomers. The monomers are 
combined in a polycondensation reaction to produce a soluble prepolymer which is 
then thermally crosslinked into an insoluble matrix. The original development of this 
material was conducted by Wang and Langer.282 They determined that the thermally 
crosslinked polymer was highly elastic; exhibiting a Young’s modulus of 282 ± 25 kPa 
which was within the range of various soft tissues, including ligaments, veins and 
arteries. This was also well below the Young’s moduli of various other polyesters 
commonly used as biomaterials, such as PLA, PLGA and PCL, which have values on the 
order of MPa. PGS also appeared to degrade rapidly, with subcutaneous implants 
being completely absorbed after 60 days in rats. The polymer appeared to illicit a 
similar inflammatory response to that of PLGA, but without the generation of a fibrous 
capsule. Subsequently, PGS scaffolds appeared to support the growth and proliferation 
of various cell types including fibroblasts, SMCs, ECs and hepatocytes.283–285 Wang and 
colleagues further developed porous PGS scaffolds for use in TEVGs. Indeed, a scaffold 
produced from PGS was used to produce the most compliant TEVGs yet reported. 
These TEVGs contained extensive organised elastin fibres and displayed a stress-strain 
response similar to that of natural blood vessels.82,88,93,286 This was attributed to the 
elasticity of the PGS, as a stiffer PLGA scaffold tested in parallel did not show the same 
elastin content or mechanical properties, and the rapid degradation of the scaffold 
which encouraged ECM deposition.  
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Interestingly, the studies by Wang and colleagues on PGS scaffold-based TEVGs were 
focused on ultimately using the PGS scaffolds in an acellular capacity and directly 
implanting them as vascular conduits. This approach would then rely on invasion by 
the host to cellularise the scaffolds. As such, TEVGs produced, in vitro, using the PGS 
scaffolds have only been for developmental purposes and used short bioreactor 
culture periods (21 days). Producing TEVGs in vitro that equalled the mechanical 
performance of the current vascular graft gold standards was not the goal of the 
research. The PGS scaffold-based TEVGs possessed inferior burst pressures compared 
to the gold standard vessels.    
It was hypothesised that extending the culture periods for PGS scaffold-based TEVGs 
may produce mechanical properties similar to the gold standard vessels. Indeed, 
increasing in vitro culture lengths has been shown to increase the burst pressures and 
suture retention strengths of various TEVG designs to equal those of the gold standard 
autograft vessels.61,64,66,67 TEVG compliance still remained limited in these studies, 
however. Since PGS scaffold-based TEVGs demonstrated excellent compliance, 
extending their bioreactor culture periods may generate grafts equal to the gold 
standard autograft vessels in terms of mechanical performance.   
 
It was noted that the processing capabilities of PGS may be limited. PGS is simple to 
produce as a soluble prepolymer, through the melt-polycondensation reaction of 
sebacic acid and glycerol. However, to crosslink PGS into an insoluble matrix requires 
the application of high temperatures for extended periods of time to thermally cure 
the polymer.282 These conditions make the creation of accurate shapes difficult and 
may limit the design of tissue engineering scaffolds produced from PGS.   
To counter this limitation, a novel photocurable form of PGS was produced by 
methacrylating the free hydroxyl groups of the PGS prepolymer. This new polymer, 
PGS methacrylate (PGS-M), could be rapidly crosslinked (photocured) by exposure to 
UV light. Photocuring avoided the high temperatures required to thermally cure PGS 
and offered greater flexibility with regards to the design of the scaffolds for the TEVG.  
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In this chapter, the synthesis and characterisation of PGS-M is presented including 
analyses of the polymer’s molecular composition, degradation behaviour and 
mechanical performance.  
 
 Materials and Methods 2.2
In the following methods, all chemical reagents were obtained from Sigma Aldrich, UK 
unless otherwise stated. These reagents were measured and utilised in inert vessels.  
 
 Synthesis of PGS prepolymer 2.2.1
PGS prepolymer was formed via the melt-polycondensation reaction of equimolar 
amounts of sebacic acid and glycerol (Fisher Scientific, UK)(Figure 8). These were 
combined and stirred in a 1 l, 3-neck, round bottom, flask under nitrogen gas, flowing 
at 1 l/min, at 120°C for 24 hours. A vacuum was then applied at 9 mbar, to remove 
water, and the reaction continued for a further 24, 36 or 48 hours to yield prepolymer 
of varied molecular weights.   
 
 
 
Figure 8. Synthesis of PGS prepolymer by melt-polycondensation.  
 
 Characterisation of PGS prepolymer using gel permeation chromatography 2.2.2
The molecular weight of the PGS prepolymer was analysed using gel permeation 
chromatography (GPC) (Viscotek GPC Max VE 2001). Samples of prepolymer were 
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taken from three batches after the polycondensation reaction had proceeded for 48, 
60 and 72 hours. These samples were dissolved in 1 ml of tetrahydrofuran (Fisher 
Scientific, UK) at 0.5% (w/v) with 0.35 ml of toluene added as a reference. Samples 
were analysed at 40 °C using a 650 mm PLgel 5 µm Mixed C column with an injection 
volume of 100 µl and a flow rate of 1 ml/min, calibrated using a 66,000 Da polystyrene 
standard. Chromatograph peaks were analysed to deduce the prepolymer molecular 
weights as number average (Mn) and weight average (Mw) along with the 
polydispersity index (PDI) (Mw/Mn).  
 
 Synthesis of PGS-M prepolymer 2.2.3
To produce a photocurable polymer, the free hydroxyl groups of the PGS prepolymer 
were methacrylated. The molar mass of the PGS prepolymer repeat unit (glycerol + 
sebacic acid) was 258.314 g. It was assumed that two of the three hydroxyl groups 
present in glycerol reacted with sebacic acid. Therefore, 3.9 mmol of hydroxyl groups 
per gram of PGS prepolymer were available for methacrylation.287,288 
 
Two different molecular weights of PGS prepolymer were methacrylated. Low 
molecular weight PGS prepolymer (further denoted as Low Mw PGS) was produced by 
polycondensation of glycerol and sebacic acid for 48 hours, as described previously 
(‎2.2.1). High molecular weight PGS prepolymer (further denoted as High Mw PGS) was 
produced by polycondensation of glycerol and sebacic acid for 72 hours, as described 
previously (‎2.2.1).  
The PGS prepolymer (either Low Mw or High Mw) was dissolved in dichloromethane 
(Fisher Scientific, UK) 1:4 (w/v) and methacrylic anhydride, with an equimolar amount 
of triethylamine, slowly added (Figure 9). Three different concentrations of methacrylic 
anhydride were used (0.3, 0.5 and 0.8 mol/mol of PGS prepolymer hydroxyl groups) in 
an effort to vary the degree of methacrylation (DM) of the resulting PGS-M from 30% 
to 50% to 80%. 4-methoxyphenol was also added at 1 mg/g of PGS prepolymer. The 
reaction was performed at 0°C and allowed to rise to room temperature over 24 hours. 
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Additional 4-methoxyphenol was then added at 0.5 mg/g of PGS prepolymer and the 
solution washed three times with 30 mM hydrochloric acid (Fisher scientific, UK) at 1:1 
(v/v). Water was then removed from the solution using granular calcium chloride 
(Fisher scientific, UK), at 0.4 g/g of PGS prepolymer, and filtration through a 6 µm pore 
cellulose filter (Whatman - Grade 3, GE Healthcare Life Sciences, UK). Finally, the 
dichloromethane was removed via rotary evaporation, under a vacuum pressure of 
9 mbar, at 8°C to yield PGS-M prepolymer as a viscous liquid. This was stored at -8°C 
prior to use.  
 
 
Figure 9. Synthesis of PGS-M prepolymer. 
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 Characterisation of PGS-M prepolymers by proton nuclear magnetic 2.2.4
resonance spectroscopy 
PGS-M prepolymers were characterised using proton nuclear magnetic resonance 
(NMR) spectroscopy (Burker AVIIIHD 400 NMR spectrometer) at 400 MHz and 
compared to PGS prepolymer. Prepolymer samples were dissolved in 1 ml of 
deuterated chloroform (CDCl3) at 1% (w/v). Chemical shifts were referenced to CDCl3 
at 7.27 ppm. The chemical composition was determined by calculating signal integrals 
of -COCH2CH2CH2- at 1.2, 1.6 and 2.3 ppm for sebacic acid, -CH2CH- at 3.7, 4.2 and 5.2 
ppm for glycerol and -CH3,CH2 at 1.9, 5.6 and 6.2 ppm for the protons on the 
methacrylate groups. The signal integrals of the sebacic acid methylene groups 
(1.2 ppm) and the methacrylate groups (1.9, 5.6 and 6.2 ppm) were used to calculate 
the degree of methacrylation (DM) within each sample.  
 
 Manufacture of flat disks of photocured PGS-M 2.2.5
PGS-M prepolymers of Low and High Mw and varied degrees of methacrylation, 
synthesised as described in (‎2.2.3), were mixed 1% (w/w) with the photoinitiator 
diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide/2-hydroxy-2-methylpropiophenone 
(50/50 blend) (further denoted as Photoinitiator) and placed between two sheets of 
2 mm thick plate soda-lime glass held 1 mm apart by an aluminium spacer. The PGS-M 
was then exposed to UV light (100 W, OmniCure Series 1000 curing lamp) in a sealed 
container lined with reflective foil for 10 minutes, being turned upside-down after 
5 minutes. The upper glass plate was then removed and the 1 mm thick cured PGS-M 
polymer sheet peeled away from the lower glass plate. Using a dissection punch, 7 mm 
disks were cut from the PGS-M polymer sheet.  
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 Determination of the soluble fraction of photocured PGS-M 2.2.6
PGS-M prepolymers of Low and High Mw and varied degrees of methacrylation were 
photocured and processed into 7 mm diameter, 1 mm thick, flat disks, as described in 
(‎2.2.5). These disks were dried at 70°C and weighed until reaching a constant mass. 
They were then placed in methanol to solubilise any unreacted prepolymer. After 
24 hours, the disks were removed and the drying process repeated. Methanol washing 
and drying was repeated until the disks reached a constant mass again. Controls were 
subjected to the same drying regime, but without methanol washing.  
Experiments were performed three times with triplicate samples. Results were 
statistically analysed using two-way ANOVA (paired samples) with Tukey multiple 
comparisons analysis. P<0.05 was considered significant.  
 
 Characterisation of PGS-M by attenuated total reflectance Fourier transform 2.2.7
infrared spectroscopy 
0.1 ml PGS-M prepolymer samples, synthesised as described in (‎2.2.3), were examined 
by attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) 
(Thermo Scientific iS50R FT-IR with germanium crystal), between wavenumbers of 
4000 and 400 cm-1, and compared to PGS prepolymer, synthesised as described in 
(‎2.2.1).  ATR-FTIR was conducted in absorbance mode, with spectra obtained at a 
resolution of 8 cm-1, gain 1 and amplification 6 with 512 scans performed. The data 
was analysed using OMNIC software.  
Additionally, 7 mm diameter disks of photocured PGS-M, manufactured as described in 
(‎2.2.5), were washed in methanol for 24 hours, to remove any unreacted prepolymer, 
dried at 70°C for 1 hour and then also examined by ATR-FTIR.     
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 Characterisation of PGS-M by Raman spectroscopy 2.2.8
PGS-M prepolymers and photocured disks were examined by Raman spectroscopy 
(Thermo Scientific Nicolet DXR with 532 nm laser at 2 cm-1 resolution), between 
Raman shifts of 4000 and 400 cm-1, using a 532 nm laser at 10 mW. The exposure time 
was 10 seconds, with 20 exposures taken per sample, and the spectrograph aperture 
set at 50 µm. Fluorescence correction was also applied. The data was analysed using 
OMNIC software.  
PGS-M prepolymer samples (0.1 ml), synthesised as described in (‎2.2.3), were 
examined; along with 7 mm diameter disks of photocured PGS-M, manufactured as 
described in (‎2.2.5), then washed in methanol for 24 hours, to remove any unreacted 
prepolymer, and dried at 70°C for 1 hour.  
 
 In vitro degradation of photocured PGS-M 2.2.9
PGS-M prepolymers of Low and High Mw and varied degrees of methacrylation were 
photocured and processed into 7 mm diameter, 1 mm thick, flat disks, as described in 
(‎2.2.5). These disks were then placed in methanol, to remove any soluble prepolymer, 
for 24 hours and subsequently dried to constant mass, at 70°C.  
In vitro degradation was assessed using 3 different treatments: cholesterol esterase 
enzyme (porcine pancreas) (40 units/ml), lipase enzyme (Thermomyces lanuginosus) 
(40 units/ml) and PBS. PGS-M disks were placed in the wells of 12-well plates (Greiner 
bio-one, Germany), in triplicate, and 1 ml of each treatment solution added. Controls 
were left in wells untreated. Well plates were placed on an orbital shaker (SeaStar, 
Heathrow Scientific, USA) operating at 90 rpm in an incubator at 37°C.  
The disks were treated for 8 days in total. After every 2 days, they were removed from 
their wells, rinsed in PBS and then dried to constant mass, at 70°C. They were then 
placed in new wells with fresh treatment solution added and returned to the orbital 
shaker.  
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The results were statistically analysed using one-way ANOVA with Tukey multiple 
comparisons analysis. P<0.05 was considered significant (*), P<0.01 was considered 
very significant (**) and P<0.001 was considered extremely significant (***). 
 
 Examination of degraded photocured PGS-M using scanning electron 2.2.10
microscopy 
The PGS-M disks subjected to degradation for 8 days, as described in (‎2.2.9), were 
examined using scanning electron microscopy (SEM). At the conclusion of the 
degradation study, the dry PGS-M disks were affixed to aluminium stubs, using carbon 
tape, and coated with gold using a sputter coater (Edwards S150B). The gold coated 
disks were then examined in a scanning electron microscope (Philips XL-20) at 13-15 kV.  
 
 Tensile testing of PGS-M 2.2.11
The mechanical properties of PGS-M were assessed by tensile testing (Hounsfield 
H100KS tensile testing machine). Procedures were performed as specified in BS ISO 
37:2011 using Type 2 dumb-bell test pieces.289 PGS-M prepolymers were mixed 1% 
(w/w) with photoinitiator and cast into silicon moulds. These were then exposed to UV 
light (100W, OmniCure Series 1000 curing lamp) in a sealed container lined with 
reflective foil for 10 minutes, being turned upside-down after 5 minutes. The 
photopolymerised PGS-M test pieces were then placed in methanol, to remove any 
soluble prepolymer, for 24 hours and subsequently dried to constant mass, at 70 °C, 
before use. Tensile testing was performed at a crosshead speed of 500 mm/min with 
samples elongated to failure. Three experiments were performed with triplicate 
samples of each PGS-M variant. The results were statistically analysed using one-way 
ANOVA with Tukey multiple comparisons analysis. P<0.05 was considered significant 
(*), P<0.01 was considered very significant (**) and P<0.001 was considered extremely 
significant (***).  
65 
 
Further testing was conducted on 30% Low Mw PGS-M following sterilization by 
autoclaving and peracetic acid. Methanol washed 30% Low Mw PGS-M test pieces were 
placed in dH2O and autoclaved at 121°C for 30 minutes. Additional samples were also 
subsequently washed in 0.5% peracetic acid for 1 hour and then rinsed in dH2O. Tensile 
testing was performed on all samples immediately following their removal from dH2O.  
Three experiments were performed with triplicate samples of each PGS-M variant. The 
results were statistically analysed using one-way ANOVA with Tukey multiple 
comparisons analysis. P<0.05 was considered significant (*), P<0.01 was considered 
very significant (**) and P<0.001 was considered extremely significant (***). 
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 Results 2.3
 Characterisation of PGS prepolymer using GPC 2.3.1
PGS prepolymer was synthesised by the polycondensation reaction of glycerol with 
sebacic acid at 120°C. The duration of the reaction was varied from 48 to 72 hours to 
determine the effect on the resulting PGS prepolymer. GPC analysis demonstrates that 
the reaction duration has an effect on the molecular weight of the prepolymer. 
Molecular weight, calculated as both Mn and Mw, increased as the reaction duration 
was increased from 48 to 72 hours (Figure 10 and Figure 11).  
Mean average molecular weights were 2,227, 2,774 and 3,356 Da for Mn and 5,419, 
8,957 and 17,339 Da for Mw at reaction lengths of 48, 60 and 72 hours, respectively. 
Variation was seen between different batches of PGS prepolymer, with standard 
deviations of 43, 98 and 54 Da for Mn and 435, 844 and 760 Da for Mw at reaction 
lengths of 48, 60 and 72 hours, respectively.  
The polydispersity index (PDI) was also calculated (Mw/Mn) and shown to increase with 
increasing reaction duration (Figure 12). Mean average values were 2.43, 3.22 and 5.17 
at reaction lengths of 48, 60 and 72 hours, respectively. 
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Figure 10. Variation in PGS prepolymer number average molecular weight as a result of 
increased polycondensation reaction time (n = 3). 
 
Figure 11. Variation in PGS prepolymer weight average molecular weight as a result of 
increased polycondensation reaction time (n = 3). 
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Figure 12. Variation in PGS prepolymer polydispersity index as a result of increased 
polycondensation reaction time (n = 3). 
 
 Characterisation of PGS-M prepolymers by proton NMR spectroscopy 2.3.2
Low Mw and High Mw PGS prepolymers were methacrylated to produce photocurable 
PGS-M prepolymer. Note that it was not possible to produce a High Mw PGS-M with a 
DM greater than 50%, due to spontaneous polymerisation during synthesis. Following 
methacrylation, the molecular structure of the PGS-M prepolymers was examined 
using proton NMR and compared to the PGS prepolymer. The spectra for the PGS 
prepolymer was comparable with those published in previous studies.287,288,290 The 
chemical composition was determined by calculating signal integrals of -CH2CH- at 3.7, 
4.2 and 5.2 ppm for glycerol and –COCH2CH2CH2- at 1.2, 1.6 and 2.3 ppm for sebacic 
acid. The incorporation of methacrylate groups into the PGS-M prepolymers was 
confirmed by the appearance of peaks at 1.9, 5.6 and 6.2 ppm which are associated 
with the hydrogen environments of this group (Figure 13). These peaks were absent 
from the spectra of the PGS prepolymer.  
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Peaks associated with organic solvents were also present in some spectra. In the Low 
Mw PGS-M spectra, peaks at 5.3 ppm were associated with dichloromethane. This was 
likely a residue from the PGS-M synthesis process. Additionally, the spectra for 30% 
and 80% Low Mw PGS-M and the PGS prepolymer also showed peaks at 2.2 ppm. These 
correspond to acetone and were likely residues from the cleaning of the sample 
vessels used in the NMR equipment.  
  
The DM of the PGS-M prepolymer was calculated by comparing the integrals of the 
peaks for the methylene groups of sebacic acid (1.3 ppm) with those of the 
methacrylate group hydrogens. DM was found to correlate well with the molar ratio of 
methacrylic anhydride to PGS prepolymer hydroxyl groups used in the methacrylation 
process (Figure 14). Strong agreement was shown between the results and a 1:1 
relationship between the molar ratio of methacrylic anhydride to PGS prepolymer 
hydroxyl groups and the resulting DM suggested, with an R2 value of 0.9485.   
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Figure 13. Proton NMR analysis of PGS and PGS-M prepolymers. Spectra of PGS and PGS-M prepolymer at varied DM (30%, 50% and 
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Figure 14. Molar ratio of methacrylic anhydride to PGS prepolymer hydroxyl groups 
compared to the resulting DM of the PGS-M prepolymers. The data show strong 
agreement with the line y = x (R2 = 0.9485). Error bars are SEM (n = 3).  
 
 Determination of the soluble fraction of photocured PGS-M 2.3.3
Disks of photopolymerised PGS-M, of varied Mw and DM, were washed in methanol to 
determine the soluble fraction of polymer they contained. After 24 hours, all test 
samples showed a statistically significant (P<0.001) reduction in mass compared to 
their corresponding controls (Figure 15). The percentage mass remaining correlated 
with the DM, and with the Mw of the PGS-M. Within the Low Mw samples, the 30% DM 
PGS-M showed the least mass remaining (mean = 72.6%) and the 80% DM PGS-M 
showed the greatest mass remaining (mean = 97.9%). A similar trend was seen within 
the High Mw PGS-M also. All differences in remaining mass within samples of the same 
Mw were significant (P<0.001). Comparing samples of the same DM showed that Low 
Mw PGS-M retained less mass than High Mw PGS-M, with these differences also being 
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significant (P<0.001). There was no significant effect of the interaction between Mw 
and DM on the remaining mass the PGS-M samples after 24 hours in methanol.  
After 48 hours in methanol, no significant reduction in mass was seen in any sample 
compared to the mass at 24 hours.  
 
 
Figure 15. Soluble fraction of photocured PGS-M, of various Mw and DM, in methanol. 
Significant mass loss was seen after 24 hours in methanol in all samples, compared to 
unwashed controls (P<0.001). All differences in remaining mass between samples of 
the same Mw or the same DM were significant (P<0.001). There was no significant 
effect of the interaction between Mw and DM. No further significant changes in sample 
mass occurred after a further 24 hours in methanol. Error bars are SEM (n = 3).    
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 Characterisation of PGS-M by ATR-FTIR 2.3.4
The molecular structure of the PGS-M prepolymers was further examined using 
ATR-FTIR. A broad peak associated with the hydroxyl groups was present around 
3460 cm-1 and sharp peaks associated with the methyl and alkane groups were present 
at 2924 cm-1 and 2851 cm-1.291,292 A distinct peak at 1735 cm-1 was associated with 
ester bonds, while the peaks around 1291-1050 cm-1 where associated with the stretch 
vibrations of carboxyl bonds.291–293    
Peaks associated with the methacrylate group were seen in PGS-M prepolymer 
samples at 940 cm-1 (=C-H bending) and 1640 cm-1 (C=C stretching) (Figure 16).294 
These peaks were absent from the PGS prepolymer. The magnitude of these peaks also 
correlated well with the DM of the PGS-M prepolymer samples. Comparing PGS-M 
prepolymer and photocured polymer showed the removal of these peaks after 
photopolymerisation (Figure 17).    
Additionally, some prominent peaks appeared in the Low Mw PGS-M prepolymer 
spectra, at 700 cm-1, which were not seen in the other spectra. These peaks were 
associated with C-Cl bonds, likely present in residual dichloromethane from the PGS-M 
synthesis process.  
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Figure 16. ATR-FTIR spectra for PGS-M and PGS prepolymer at various molecular weights and DM. Highlighted are the regions around 
940 and 1639 cm-1 showing the absorbance peaks associated with the methacrylate group C=C bond present in the PGS-M 
prepolymers. The magnitudes of these peaks correlate well with the DM of the associated PGS-M.  
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 Figure 17. ATR-FTIR spectra for PGS-M prepolymer and photocured polymer. Peaks associated with the methacrylate group, at 940 
and 1639 cm-1 are not present after photopolymerisation.    
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 Characterisation of PGS-M by Raman spectroscopy 2.3.5
The molecular structure of PGS-M was further examined using Raman spectroscopy. 
Peaks associated with the methacrylate group were seen in all PGS-M prepolymer 
samples at 1650 cm-1 (C=C stretching).295 The magnitude of these peaks also correlated 
well with the DM of the PGS-M prepolymer samples (Figure 18). Additional peaks 
associated with the methacrylate group were also seen at 3000 cm-1(C=C stretching), 
although these were only apparent in the 50% and 80% DM prepolymers. Comparing 
PGS-M prepolymers and photocured polymers showed the removal of the 
methacrylate group associated peaks after photopolymerisation.  
Additionally, prominent peaks at 700 cm-1 appeared in the 80% DM Low Mw 
prepolymer spectra and both 50% DM PGS-M prepolymer spectra. These signals were 
largely absent in the other spectra. As in the ATR-FTIR analysis, these peaks were 
associated with C-Cl bonds, likely present in residual dichloromethane from the PGS-M 
synthesis process.295 
 
 
 
 
Figure 18. Raman spectra for PGS-M prepolymer and photocured polymer. Peaks associated with the methacrylate group, at 1650 cm-
1 and 3000 cm-1 are not present after photopolymerisation. 
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 In vitro degradation of photocured PGS-M 2.3.6
The degradation of PGS-M was examined in vitro using the enzymes cholesterol 
esterase and lipase, both of which are known to hydrolyse ester bonds, along with PBS. 
These are physiologically relevant enzymes, although the concentrations used may 
have differed from those present in vivo due to the complex nature of enzyme 
expression in different tissues and under different conditions. After 8 days, significant 
mass loss was seen in 30% Low Mw PGS-M and 30% and 50% High Mw PGS-M treated 
with cholesterol esterase (P<0.001) (Figure 19). The rate of this degradation appeared 
to be linear when examining the previous time points. Significant mass loss was also 
seen in 30% Low and High Mw PGS-M treated with lipase (P<0.01). PGS-M treated with 
PBS did not show any significant mass loss compared to untreated controls. 
Cholesterol esterase treatment appeared to produce greater degradation compared to 
lipase in all treatments, although this was only significantly different within 30% Low 
and High Mw PGS-M samples (P<0.001, in both cases). The greatest degradation was 
seen in 30% High Mw PGS-M treated with cholesterol esterase, with 79.1% mass 
remaining after 8 days. This result was significantly different to all others (P<0.001).  
 
The PGS-M samples that had been treated for 8 days were further examined using 
SEM (Figure 20 and Figure 21). Both the 30% Low and High Mw PGS-M samples treated 
with cholesterol esterase showed evidence of surface degradation. Compared to the 
controls, the surfaces of these samples displayed pits and cracks. No evidence of 
degradation was apparent in any of the other PGS-M samples when treated with lipase 
or PBS, compared to the controls.   
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Figure 19. Degradation of PGS-M treated with cholesterol esterase, lipase and PBS. 
After 8 days, cholesterol esterase produced significant degradation in both 30% DM 
polymers and the 50% High Mw PGS-M. Lipase only produced significant degradation in 
the 30% DM polymers. PBS did not produce significant degradation in any sample. 
Error bars are SEM (n = 3). 
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Figure 20. Representative SEM images of Low Mw PGS-M following degradation by cholesterol esterase, lipase and PBS for 8 days. 
Controls were PGS-M in air.   
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Figure 21. Representative SEM images of High Mw PGS-M following degradation by cholesterol esterase, lipase and PBS for 8 days. 
Controls were PGS-M in air.   
 
 
8
1
 
82 
 
 Tensile testing of PGS-M 2.3.7
Tensile testing revealed that the mechanical properties of PGS-M varied depending on 
the polymers composition. Young’s modulus was shown to increase significantly with 
increasing DM, for both Low and High Mw (P<0.001 and <0.05, respectively) (Figure 22). 
The 30% Low Mw PGS-M demonstrated the smallest value, with a mean average of 
0.43 MPa. The 80% Low Mw PGS-M demonstrated the largest value with a mean 
average of 6.74 MPa. A similar trend was also seen in the ultimate tensile strength 
(UTS) of PGS-M, although in a less pronounced manner (Figure 23). The 80% Low Mw 
PGS-M demonstrated the greatest strength with a mean average of 3.80 MPa. This was 
significantly stronger than the 50% and 30% Low Mw PGS-M polymers (P<0.001), 
although these were not significantly different from each other. No significant 
difference was seen between the UTS of the 30% and 50% High Mw PGS-M polymers 
either.    
Polymer Mw did not appear to have a significant effect on the Young’s modulus or UTS 
of PGS-M. Additionally, the interaction between the DM and Mw had no significant 
effect on the Young’s modulus or UTS of PGS-M.   
 
Sterilisation of 30% Low Mw PGS-M resulted in some modification to its mechanical 
properties. Following sterilisation by autoclave, the Young’s modulus of the polymer 
was significantly reduced from 0.43 to 0.37 MPa (P<0.001) (Figure 24). Further 
treatment with 0.5% peracetic did not result in any further significant changes in 
Young’s modulus. The UTS of 30% Low Mw PGS-M was not significantly altered by 
autoclave sterilisation or subsequent peracetic acid treatment (Figure 25).  
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Figure 22. Young’s modulus of PGS-M. Error bars are SEM (n = 3).  
 
 
Figure 23. Ultimate tensile strength of PGS-M. Error bars are SEM (n = 3).  
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Figure 24. Young’s modulus of 30% Low Mw PGS-M after sterilisation by autoclave and 
peracetic acid. Error bars are SEM (n = 3). 
 
Figure 25. Ultimate tensile strength of 30% Low Mw PGS-M after sterilisation by 
autoclave and peracetic acid. Error bars are SEM (n = 3).   
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 Discussion 2.4
PGS prepolymer was synthesised by the polycondensation reaction of glycerol with 
sebacic acid (molar ratio 1:1) at 120°C. Analysis using GPC demonstrated that 
increasing the duration of this reaction resulted in an increase in prepolymer molecular 
weights, calculated as Mn and Mw. Mean average molecular weights were 2,227, 2,774 
and 3,356 Da for Mn and 5,419, 8,957 and 17,339 Da for Mw at reaction lengths of 48, 
60 and 72 hours, respectively. Increasing the reaction duration allowed the 
polymerisation process to continue for longer and more bonds to form between the 
glycerol and sebacic acid, lengthening the polymer chains and increasing the molecular 
weight. Comparable results are seen in other studies where PGS prepolymer was 
synthesised. Ifkovits et al. synthesised PGS prepolymer from a 1:1 molar ratio of 
glycerol and sebacic acid, using similar conditions to those herein, and generated 
prepolymers with molecular weights (Mw) increasing from 4,060 to 23,460 Da after 
increasing reaction lengths of between 28 and 65 hours, respectively.288  
 
Although the glycerol monomer is trifunctional, due to its three hydroxyl groups, the 
secondary hydroxyl group is less reactive than the two primary hydroxyl groups. 
Therefore increased reaction duration favours increased polymer chain extension 
rather than chain branching.296 An increase in chain branching can be achieved by 
modifying the ratio of glycerol to sebacic acid in the polycondensation reaction. A ratio 
of 2:3 resulted in a totally crosslinked PGS which was insoluble in organic solvents.297 It 
was desirable, in the present study, to generate a PGS prepolymer that was soluble in 
organic solvents, to permit further functionalisation and processing into defined 
structures. Therefore, a ratio of 1:1 was selected for the polycondensation reaction, as 
this had been demonstrated to minimize chain branching and produce a soluble 
prepolymer.282,287,288  
 
The melt-polycondensation reaction of glycerol with sebacic acid is an example of 
step-growth polymerisation.298 Monomers, small chain fragments (dimers, trimers and 
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oligomers) and larger chains may all react with each other to produce longer polymer 
chains. As such, an exponential growth curve for the prepolymer molecular weight 
with increasing reaction time might be expected. The results suggest exponential 
growth of the PGS prepolymer when molecular weight is calculated as Mw. However, 
when the molecular weight is calculated as Mn, a linear relationship between this and 
increasing reaction duration is apparent. Due to the nature by which Mn and Mw are 
calculated, Mw ≥ Mn, therefore, an exponential growth relationship may more easily 
manifest.298,299 The reaction may not have progressed for a long enough duration for 
the exponential growth phase to become apparent when calculating polymer 
molecular weight as Mn.  
 
Although previous work on the synthesis of PGS prepolymer has shown a trend 
towards increasing polymer molecular weight with increasing reaction duration, as in 
this study, there is some variability between the actual polycondensation reaction 
lengths and resulting prepolymer molecular weights. Although reporting the same 
reaction conditions as in this study, Nijst et al. produced a PGS prepolymer with Mn 
6,500 Da and Mw 23,000 Da after a reaction length of just 53 hours.
287  Similarly, the 
group of Burdick produced a PGS prepolymer with Mn 5,330 Da and Mw 23,460 Da 
after a reaction length of 65 hours and later a PGS prepolymer with Mn 3,740 Da and 
Mw 24,240 Da after a reaction length of 72 hours.
288,300 The apparent irreproducibility 
of PGS prepolymer synthesis was investigated in depth by Li et al.290 They determined 
that the evaporation of glycerol from the reaction mixture during the 
polycondensation reaction was a major cause of this. Glycerol evaporation may be 
affected by the vacuum pressure applied to the reaction flask and the flow rate of any 
inert gas used at the early stages of the reaction. These factors are often not detailed 
or quantified in published methods of synthesis, leading to the differing results 
reported.  
 
The PDI values for the PGS prepolymer samples, calculated from the ratio of Mw/Mn, 
were consistent with those of a polymer produced by step-growth 
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polymerisation.288,298 Mean averages were 2.43, 3.22 and 5.17 at reaction lengths of 48, 
60 and 72 hours, respectively. Step-growth polymerisation generates a wide 
distribution of different length polymer chains and thus produces non-uniformity with 
respect to the polymer molecular weight within a sample.298 The PDI reflects this 
non-uniformity, with values exceeding 2 considered as representing a broadly 
distributed polymer sample. Similar polydispersity (ranging from 2-6.6) has been 
reported in other studies on PGS prepolymer synthesis.287,288,300,301       
 
Reasonable consistency was seen between the PGS prepolymer molecular weights and 
the reaction durations for the different prepolymer batches. Between batches, the 
standard deviations were 43, 98 and 54 Da for Mn and 435, 844 and 760 Da for Mw at 
reaction lengths of 48, 60 and 72 hours, respectively. These equate to 1.9, 3.5 and 1.6% 
for Mw and 8.0, 9.4 and 4.4% at reaction lengths of 48, 60 and 72 hours, respectively. 
Such variation between batches is not unexpected, given the melt-polycondensation 
reaction progresses by step-growth. As all of the different length molecules in the 
reaction, from monomers to polymer chains, are able to react with each other, 
different polymer chain length profiles can be generated after equal reaction lengths, 
resulting in variations in the calculated average molecular weight. This is also reflected 
in the PDI results for the PGS prepolymer samples, which suggest high variation 
between the lengths of the polymer chains within each sample. Additionally, errors 
associated with the synthesis apparatus may also have contributed to the observed 
variation between prepolymer batches. Although the different batches were produced 
using the same apparatus with the same conditions, some equipment error is expected. 
This may have been particularly prominent in the analogue equipment without 
feedback systems, such as the vacuum pump and N2 flow regulator. Small variations 
(1-2%) in these may have occurred between the different batch reactions and such 
variations were hypothesised to effect the consistency of PGS prepolymer synthesis by 
Li et al.290   
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Proton NMR spectroscopy demonstrated the successful methacrylation of the PGS 
prepolymer, forming PGS-M prepolymer. Characteristic peaks associated with the 
hydrogen environments present in the methacrylate group were present in PGS-M 
samples and absent from the PGS prepolymer spectra.  
Comparable results are seen in the literature where PGS prepolymer was 
functionalised in a similar way. Nijst et al. and Ifkovits et al. both produced 
photocurable PGS by adding acrylate groups to PGS prepolymer, producing PGS 
acrylate (PGS-A).287,288 Both studies utilised proton NMR spectroscopy to confirm the 
successful addition of the acrylate groups. Comparing the spectra for PGS prepolymer 
with PGS-A showed the clear appearance of peaks associated with the acrylate group 
hydrogen environments. Comparing spectra for PGS-M with PGS-A shows peaks 
associated with the hydrogen environments common between acrylate and 
methacrylate groups appeared in similar locations. 
The DM of the PGS-M prepolymer, calculated by comparing the integrals of the peaks 
for the methylene groups of sebacic acid with those of the methacrylate group 
hydrogens, showed a strong correlation with the molar ratio of methacrylic anhydride 
to PGS prepolymer hydroxyl groups used in the methacrylation process. This 
relationship appeared linear and directly proportional. This suggests that all of the 
methacrylate groups supplied to the reaction by methacrylic anhydride were 
incorporated into the PGS-M prepolymer. In the synthesis of PGS-A, a linear 
relationship between the supplied acrylate groups and the resulting degree of 
acrylation (DA) of the prepolymer was also seen. However, this was not directly 
proportional, suggesting that not all of the acrylate groups supplied to the reaction 
were incorporated into the prepolymer.287 PGS appears to be more susceptible to 
methacrylation than to acrylation.  
 
Subsequent analysis of PGS-M using ATR-FTIR also showed peaks associated with the 
methacrylate group in PGS-M prepolymer spectra. These were not present in the 
spectra for the PGS prepolymer. The magnitude of these peaks also correlated well 
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with the DM for the associated PGS-M prepolymer sample, although only a qualitative 
assessment could be made.   
PGS-M samples were also examined using Raman spectroscopy. This is a 
complementary technique to ATR-FTIR, generating spectra that show less polarisable 
chemical bonds (symmetric vibrations) more prominently.295  
Similar to the ATR-FTIR spectra, Raman spectra showed peaks associated with the 
methacrylate group C=C bond in the PGS-M prepolymers. The magnitude of these 
peaks also qualitatively correlated well with the DM of the associated PGS-M 
prepolymer sample. Interestingly, the spectra for the 30% DM prepolymers lacked a 
peak at 3000 cm-1, which was present in the samples of higher DM. A peak at 
3000 cm-1 is indicative of C=C bond stretching and might have been expected, given 
the presence of the methacrylate group in the prepolymers and the peak seen at 
1650 cm-1, which is also associated with C=C stretching, in all the PGS-M prepolymer 
samples. It may be that, due to the reduced quantity of methacrylate groups in the 
30% DM prepolymers, the signal at 3000 cm-1 was simply too small to deduce from the 
larger peak adjacent to it, which corresponded to the methylene backbone of the 
sebacic acid subunit in the PGS-M polymer chains.295  
Comparing samples of PGS-M before and after photopolymerisation showed the 
removal of the methacrylate group peaks. Since both peaks were associated with the 
C=C bond in this group and this bond is opened during photopolymerisation, allowing 
crosslinking between polymer chains, the disappearance of these peaks after UV 
exposure is expected. Similar results were also seen in other methacrylated polymers, 
where spectral peaks associated with the methacrylate groups disappeared after 
polymerisation.302 
 
Washing photocured PGS-M in methanol revealed the fraction of soluble polymer 
present. The soluble fraction represents the polymer chains not chemically bound 
within the crosslinked polymer matrix. These are free to move when solubilised and 
can be washed out of the sample, thus resulting in a loss of mass. Methanol washing 
revealed the soluble fraction present within PGS-M samples of varied Mw and DM. 
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Within polymers of the same Mw, the soluble fraction decreased with increasing DM. 
This might be expected given the DM represents the number of methacrylate groups 
present in the polymer sample and that it is through crosslinking of these groups, 
through photopolymerisation, that an insoluble polymer matrix forms. With increasing 
DM, more crosslinks can form and the probability of unbound chains being present in 
the sample decreases, thus decreasing the soluble fraction.  
Additionally, within samples of the same DM, the soluble fraction decreased with 
increasing Mw. Again, this is likely associated with the quantity of chemical bonds 
present within the polymers. As Mw increases, the quantity of ester bonds within the 
prepolymer increases, as the polymer chains become longer. As chain lengths increase, 
there are more possible sites for methacrylate group attachment and therefore a 
greater possibility of crosslink formation. The number of unbound polymer chains is 
reduced, resulting in a reduced soluble fraction.     
Similar results are seen in PGS-A. Within samples of photocured PGS-A of the same Mw, 
the soluble fraction decreased with increasing DM.300 The magnitude of the soluble 
fractions with relation to the Mw and DM was also comparable with this study. PGS-A 
of Mw 24,240 Da and a DA of 23.5% demonstrated a soluble fraction of 13.3%. 
Although the molecular weight was greater than those studied here and acrylation was 
applied to the prepolymer, the behaviour would fit with that observed for PGS-M.  
In PGS, soluble fractions of between 19.8 and 40.7% have been reported, although 
these are for thermally crosslinked matrices, not photopolymerised matrices as in 
PGS-M and PGS-A.300,303,304 
Comparing samples of PGS-M before and after photopolymerisation using ATR-FTIR 
showed the removal of the methacrylate group peaks. Since both peaks were 
associated with the C=C double bond in this group (=C-H bending at 940 cm-1 and C=C 
stretching 1640 cm-1) and this bond is opened during photopolymerisation, allowing 
crosslinking between polymer chains, the disappearance of these peaks after UV 
exposure is expected. Similar results were also seen in the photopolymerisation of 
PGS-A, where spectral peaks associated with the acrylate groups disappeared after UV 
exposure.287,288  
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Photocured PGS-M was susceptible to enzymatic degradation, in vitro, over 8 days, 
although this was dependent on the Mw and DM of the polymer. Cholesterol esterase 
treatment resulted in the greatest degradation in all variants of PGS-M examined, 
although this was only significant in the 30% DM samples and the 50% High Mw PGS-M. 
Examination of the PGS-M samples using SEM only showed surface damage in the 30% 
DM samples treated with cholesterol esterase.  
Increasing the DM of PGS-M appeared to reduce the rate of degradation. This was 
likely due to the increase in the number of crosslinks present within the polymer which 
reduced the ability of chain fragments to be cleaved out by the enzymes. A longer 
study length may be required to show significant degradation in all of the PGS-M 
variants. Interestingly, it was the 30% high Mw PGS-M which exhibited the greatest 
degradation, not the 30% Low Mw PGS-M, which contains fewer chemical bonds. It 
may have been possible that the longer polymer chains present in the high Mw 
polymer may have allowed larger fragments to be released from the matrix once freed 
by the enzyme, resulting in an increased loss of mass.  
The degradation rates appeared linear in both 30% DM polymers. This suggests only 
degradation by surface erosion occurred and enzymes were not able to penetrate the 
surface and cause bulk degradation, which usually results in an exponential loss of 
mass.305 Indeed, this is common for enzymatic degradation processes, due to the 
relatively large size of the enzymes which limits their penetration into polymer 
matrices.305 Degradation by surface erosion may be considered more favourable in 
polymers being utilised as tissue engineering scaffolds, as the mechanical strength of 
the polymer is reduced over a longer time period, maintaining the structural integrity 
of the scaffold. This is because only the surface is subjected to weakening by erosion 
and this produces little reduction in the strength of the complete scaffold structure. 
Bulk degradation results in more rapid reductions in mechanical strength leading to a 
loss of scaffold integrity. This is due to the scaffold material being weakened 
throughout its structure, not just at the surface.306,307    
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Cholesterol esterase has been shown to cause the degradation of various polyesters in 
previous studies.287,308–311 This enzyme has been shown to be identical to the esterases 
produced by macrophages which are known to degrade polyesters in vivo.311 
Cholesterol esterase, at the same concentration as in this study, was shown to degrade 
PGS-A, with the rate of degradation dependant on the DA of the polymer. Similar to 
the results here, a lower DA resulted in increased enzymatic degradation. The overall 
rate of degradation appeared more rapid, with 30% DM PGS-A reduced in mass by 40% 
in just 48 hours, compared to the 5% mass reduction seen in 30% High Mw PGS-M over 
the same time. These results are not directly comparable, as the PGS-A polymer was of 
a higher molecular weight than the PGS-M. Additionally, the shape of the PGS-A 
samples was not reported and since the surface area of the substrate has a great effect 
on the rate of an enzyme catalysed reaction, it is unknown how this may have affected 
the degradation rate. The same study also demonstrated that thermally cured PGS 
polymer degraded more rapidly than PGS-A, reducing in mass by 60% in 48 hours. It 
was suggested that the acrylate group may restrict the enzymes’ access to the ester 
linkages within the polymer. A similar effect may be seen in PGS-M.    
 
PGS-M also appeared to be degraded by lipase, although the reduction in mass caused 
by the activity of this enzyme over 8 days was only significant in the 30% DM PGS-M. 
No difference was seen between the Low and High Mw 30% PGS-M samples, both 
showing a reduction in mass of ~4% over the study period. Similar to cholesterol 
esterase, the effect of lipase appeared to reduce with increasing DM and this may have 
been due to similar reasons, with the increase in the number of crosslinks present 
within the polymer, as the DM increases, reducing the ability of chain fragments to be 
released. Lipase may have a lower specificity for PGS-M compared to cholesterol 
esterase, resulting in its reduced rate of degradation. A longer study length may result 
in significant degradation by lipase in all PGS-M variants.  
Lipase has also been shown to degrade various polyester biomaterials in other 
studies.301,305,312,313 In examining thermally cured PGS, lipase treatment produced a 
reduction in mass of ~12% after 8 days and ~30% after 31 days, in vitro.312 Notably, this 
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study used a much lower concentration of lipase enzyme (110 units/µl) than herein. 
This suggests that lipase has a much greater effect on thermally cured PGS compared 
to PGS-M. Similar to cholesterol esterase, this may be due to the methacrylate groups 
limiting the enzymes’ access to ester bonds.  
 
PBS appeared to have no significant effect on the degradation of any of the PGS-M 
variants examined in this study. Since degradation in PBS alone would be the result of 
uncatalysed hydrolysis, it was expected that this treatment would result in the least 
mass loss from the PGS-M polymers. It is likely that significant degradation in PBS 
would occur over a long enough study period. In examining PGS-A, a 22% reduction in 
mass was seen after 18 weeks.300 The samples were 10 x 2 x 1 mm and had a DA of 23% 
and a Mw of 24,240 Da. Considering the differences in crosslink density and Mw, 30% 
High Mw PGS-M may show similar degradation over the same time period. Thermally 
cured PGS also showed degradation in PBS, reducing in mass by 10% over 31 days.312 
Additionally, a number of different photopolymerisable biomaterials have 
demonstrated degradation in PBS, with this also being dependent on the degree of 
crosslinking within their matrices.314–316      
 
It must be noted that the rates of degradation observed in this simple study may be 
different to those produced in more complex in vitro environments containing living 
cells or in vivo.305 The types of enzymes produced by different cells and their 
concentrations vary greatly and this can have a great effect on the degradation rate of 
a biomaterial.305 Environmental factors such as the surrounding pH, presence of 
enzyme inhibitors and the application of flow, mechanical loading or agitation to the 
material can also have an impact. Indeed, this has been demonstrated in both PGS-A 
and PGS, with implanted materials degrading at a faster rate than in vitro 
counterparts.282,288     
 
Variation in the DM and Mw of PGS-M had an effect on the mechanical properties of 
the photocured polymer. Tensile testing demonstrated that the mechanical properties 
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of PGS-M were more dependent on the DM of the polymer than the Mw. Significant 
increases in Young’s modulus resulted from increasing the DM from 30% to 50% to    
80% in Low Mw PGS-M polymers and from 30% to 50% in High Mw PGS-M polymers. 
Changes in UTS also followed a similar trend, although only resulting in significantly 
different results for the Low Mw 80% PGS-M compared to the other Low Mw polymers. 
Interestingly, variation in Mw was not found to have a significant effect on the Young’s 
modulus or UTS of PGS-M.  
As the DM is increased, more crosslinks are able to form within the polymer matrices 
resulting in an increase in crosslink density. Increasing the crosslink density reduces 
the mobility of the individual polymer chains within the matrix, resulting in an increase 
in the stiffness of the bulk polymer and an increase its Young’s modulus.306,317 The 
effect of increased crosslink density on Young’s modulus is evident in the behaviour of 
PGS-M at varied DM. Additionally, due to the crosslinks containing covalent bonds, an 
increase in crosslink density commonly results in an increase in the UTS of a polymer, 
as additional chemical bonds must be broken to produce failure.317 This behaviour 
manifested to a lesser extent in PGS-M, with no significant difference observed 
between the UTS of 30% and 50% DM polymers of the same Mw. These findings may 
have been due to the limited number of test pieces examined, since the mean average 
values for these polymers did fit with the classical behaviour. 
 
As the Mw of a polymer is increased the average length of its constituent chains 
increases. This results in an increase in the number of chemical bonds present within 
the bulk material and an increase in stiffness and strength.306,317 Additionally, as chain 
length increases, chain entanglement also increases, further increasing the polymers 
resistance to deformation. This behaviour was not evident in PGS-M. No significant 
differences in Young’s modulus or UTS were found between Low and High Mw 
polymers of the same DM. It may be that the difference between the chain lengths of 
the Low and High Mw polymers was not great enough for any significant change in 
polymer stiffness or strength to be detected. Additionally, the increasingly disperse 
nature of the PGS prepolymer as Mw is increased likely resulted in a photopolymerised 
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PGS-M composed of a large range of different polymer chain lengths. This dispersity 
may also have affected the mechanical properties of the bulk materials with the 
combination of various chain lengths not ultimately resulting in an increase in stiffness 
or strength.  
Similar results have been reported in the literature for PGS-A. Varying the DA of PGS-A, 
between 1% and 88%, while maintaining constant Mw resulted in an increase in 
Young’s modulus and UTS in three different studies.287,288,300 These reported values 
were also comparable with those produced by PGS-M (Table 7). Additionally, variation 
in the Mw of PGS-A did not result in any significant changes in Young’s modulus or 
UTS.288 Other photopolymerisable biomaterials have also displayed similar behaviour 
with an increase in crosslinking density resulting in an increase in stiffness and 
mechanical strength.316,318,319   
 
Table 7. Mechanical properties of PGS-M compared to reported values for PGS-A 
(± denotes standard deviations).  
Polymer DM/DA (%) Mw (Da) Young’s Modulus (MPa) UTS (MPa) Ref 
PGS-M 30 5,419 ± 435 0.43 0.73  
(herein)  17,339 ± 760 0.69 0.45  
 50 5,419 ± 435 1.47 0.82  
  17,339 ± 760 1.39 0.77  
 80 5,419 ± 435 6.74 3.80  
PGS-A 21 4,060 0.6 - 288 
  7,020 0.6 - 288 
 34 23,000 0.568 0.270 287 
 54 23,000 1.375 0.498 287 
 88 4,060 13.2 - 288 
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The mechanical properties exhibited by 30% Low Mw PGS-M coupled to its degradation 
rate and more rapid synthesis compared to the 30% High Mw polymer suggested that it 
was the most suitable variant of PGS-M for manufacturing a scaffold for producing a 
TEVG. Therefore, an investigation into the mechanical properties of 30% Low Mw 
PGS-M following sterilisation was conducted. Autoclave sterilisation resulted in a 
significant reduction in the Young’s modulus of the polymer, from 0.43 to 0.37 MPa. 
However, no significant change in the UTS was apparent. This suggests that the 
autoclave treatment did not cause degradation of the polymer matrix and covalent 
bonds were largely unbroken. The partial solvation of the polymer following removal 
from dH2O immediately prior to tensile testing may have resulted in a disruption of the 
intermolecular forces between the polymer chains. This could have resulted in a 
reduction in the stiffness of the material.317 Additionally, the high temperature and 
aqueous environment of the autoclave may have resulted in the reorientation of the 
polymer chains within the bulk material. Chain entanglement may have been reduced 
and this can affect the stiffness of the polymer.317  
Subsequent treatment with peracetic acid did not cause any significant changes in the 
mechanical properties of 30% Low Mw PGS-M. Although the hydrolysis of ester bonds 
is known to increase in acidic environments, it is likely that the exposure time of 1 hour 
was not sufficient to cause significant degradation of the bulk material and alter the 
mechanical properties.307       
 
  
97 
 
 Conclusions 2.5
A novel photocurable form of PGS, PGS-M was synthesised and characterised for 
potential application as the material for a scaffold to support the growth of a TEVG in 
vitro.  
Different variants of PGS-M were produced, with a range of molecular weights and 
degrees of methacrylation and their compositions confirmed using various analytical 
chemistry techniques. It was determined that both the molecular weight and DM could 
be controlled by altering the reaction conditions used in the synthesis of the polymers. 
The degradation of the different variants of PGS-M was examined and revealed that 
the polymers were susceptible to enzymatic degradation with increasing the DM 
appearing to have an inverse effect on this. Finally, the mechanical properties of 
PGS-M were assessed and found to largely depend on the DM of the polymer and not 
the molecular weight.  
30% Low Mw PGS-M was selected as the most suitable variant for producing a scaffold 
for use in culturing a TEVG. This polymer displayed the required properties identified 
for the scaffold material (Young’s modulus of ~300 kPa, rapid degradation rate, and 
simple processing).   
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Chapter 3 - 2D Cell Culture on PGS-M 
Surfaces 
 Introduction 3.1
In the previous chapter, the novel polymer PGS-M was successfully synthesised and 
characterised in terms of its structural, mechanical and degradation properties. It was 
found that the mechanical and degradation properties could be modulated, by altering 
the structure of the polymer by changing its molecular weight and DM. It was 
determined that a PGS-M polymer with a 30% DM and a Mw of ~5,400 Da (30% Low 
Mw PGS-M) was the most suitable for producing a scaffold for use in culturing a TEVG. 
 
In this chapter, the interaction of 30% Low Mw PGS-M with living cells in simple 2D 
cultures is presented. Three different cell types relative to vascular graft tissue 
engineering were selected and cultured on PGS-M surfaces. These were fibroblasts, 
adipose-derived stem cells (ADSCs) and smooth muscle cells. Fibroblasts and smooth 
muscle cells are both major cellular components of arteries and veins, being found in 
the tunica adventitia and tunica media, respectively. As such, both cell types have 
been commonly employed in the production of tissue engineered blood vessels for use 
as vascular grafts.61,66,76,92,94,95,97,108,125,146 
 
In recent years, ADSCs have attracted interest in a number of tissue engineering 
applications.320,321 These cells offer similar differentiation potential to bone marrow 
and mesenchymal stem cells, however, they are more easily harvested. A number of 
studies have explored using stem cells in producing TEVGs.55,77,198,202,203,207,212,214 These 
aimed to take advantage of the multi/pluripotency of these cells and induce 
differentiation towards vascular cell lineages during culture to generate tissue 
engineered blood vessels. Studies using ADSCs are limited in the field of TEVGs 
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however, therefore they were also selected for study when cultured on PGS-M 
surfaces to determine their potential for use in the future generation of a TEVG using 
PGS-M as a scaffold material.  
 
The three different cell types were cultured on PGS-M surfaces for several days. Their 
metabolic activity and proliferation was examined at various time points and used to 
assess their response to the novel polymer surface. Additionally, the expression of 
phenotypic cell markers was examined in SMCs to determine the effects of PGS-M on 
these.  
 
 Materials and Methods 3.2
In the following methods, all chemical reagents were obtained from Sigma Aldrich, UK 
unless otherwise stated. These reagents were measured and utilised in inert vessels.  
 
 Surface coating of glass coverslips with PGS-M 3.2.1
Borosilicate glass coverslips (13 mm diameter, No 2 thickness)(Scientific Laboratory 
Supplies, UK) were cleaned in a 3:1 (v/v) solution of sulphuric acid (95.0-98.0%) and 
hydrogen peroxide (30 wt% in H2O) for 1 hour and then rinsed with five washes of 
dH2O and three washes of methanol. The coverslips were then immersed in a 10% (w/v) 
solution of 3-methacryloxypropyltrimethoxysilane in toluene for 24 hrs, in the absence 
of light, before being rinsed in methanol three times, and dried at room temperature. 
 50 µl of 30% Low Mw PGS-M prepolymer, synthesised as described in (‎2.2.3), 
containing 1% (w/w) photoinitiator, was applied to the centres of individual coverslips 
by pipetting and then distributed evenly across their surfaces by spin coating (Laurell 
Technologies WS-400B-6NPP/Lite) at 4,000 rpm for 40 seconds. PGS-M coated 
coverslips were photocured by exposure to UV light (100W, OmniCure Series 1000 
curing lamp) in a sealed container lined with reflective foil for 5 minutes. Following this, 
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the coated coverslips were washed in methanol for 4 days (changed daily) followed by 
dH2O for 4 days (changed daily). Coverslips were then sterilised by autoclave at 121°C 
for 30 minutes, prior to cell seeding.  
 
 Preparation of fibroblast growth medium 3.2.2
Dulbecco’s modified eagle’s medium (DMEM) AQmedia was modified with 10% (v/v) 
foetal calf serum, 1% (v/v) Penicillin (10,000 units/ml), 1% (v/v) Streptomycin 
(10 mg/ml) and 0.25% (v/v) Amphotericin B (250 µg/ml). 
 
 Preparation of smooth muscle cell growth medium 3.2.3
SMC growth medium with supplements was purchased from PromoCell, Germany. 
Smooth Muscle Cell Growth Medium 2 was combined with a supplement mixture as 
described by the manufacturer. Final supplement concentrations in the medium were 
5% (v/v) foetal calf serum, 0.5 ng/ml epidermal growth factor (recombinant human), 
2 ng/ml basic fibroblast growth factor (recombinant human) and 5 µg/ml insulin 
(recombinant human).  
Additionally, 1% (v/v) Penicillin (10,000 units/ml), 1% (v/v) Streptomycin (10 mg/ml) 
and 0.25% (v/v) Amphotericin B (250 µg/ml) were also added to the growth medium.  
 
 Culture of human dermal fibroblasts and human adipose-derived stem cells 3.2.4
on PGS-M surfaces.  
Human dermal fibroblasts and human ADSCs from primary dermal tissue or 
lipoaspirate, respectively, were obtained with informed consent (ethics 
reference: 15/YH/0177) and processed and stored in accordance with the Human 
Tissue Act 2004 (licence number 12179). Isolated cells were cultured on tissue culture 
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plastic (TCP) in fibroblast growth medium, prepared as described in (‎3.2.2), at 37 0C 
and 5% CO2 in an incubator.  
Cells between passage 4 and 6 were harvested using trypsin (0.025%)/EDTA (0.01%) 
solution at 0.067 ml/cm2 of culture area. This was quenched after 5 minutes with an 
equal volume of fibroblast growth medium and the cell suspension centrifuged at 
1,000 rpm for 5 minutes (Hettich Zentrifugen Rotofix 32A with 131 mm rotor radius) 
before being resuspended in fibroblast growth medium at 50000 cells/ml.  
Suspended cells were then seeded onto PGS-M coated coverslips, prepared as 
described in (‎3.2.1), in 12-well tissue culture plates (Greiner bio-one, Germany), at 
50,000 cells per well. The cells were allowed to attach for 6 hours and then the 
coverslips were transferred to new wells for further culture, ensuring only cells 
attached to the coverslips were included in future analyses.  
Untreated glass coverslips, sterilised by autoclave at 121°C for 30 minutes, were also 
seeded with cells, in an equivalent manner to the PGS-M coated coverslips, to act as 
positive controls. Additionally, unseeded PGS-M coated coverslips were cultured in 
fibroblast growth medium, in parallel with the seeded coverslips, to act as negative 
controls. Each culture well contained 1 ml of growth medium and this was changed 
every second day.  
Fibroblast seeded coverslips, and associated control samples, were cultured for 1, 3 or 
7 days before being analysed. ADSC seeded coverslips, and associated control samples, 
were cultured for 1, 7 or 14 days before being analysed.  
 
 Culture of human coronary artery smooth muscle cells on PGS-M surfaces.  3.2.5
Human coronary artery SMCs were obtained commercially from PromoCell, Germany. 
The SMCs were cultured on TCP in SMC growth medium, prepared as described in 
(‎3.2.3), at 37 0C and 5% CO2 in an incubator.  
Cells between passage 9 and 11 were harvested using trypsin (0.025%)/EDTA (0.01%) 
solution at 0.067 ml/cm2 of culture area. This was quenched after 5 minutes with an 
equal volume of trypsin inhibitor (PromoCell, Germany) and the cell suspension 
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centrifuged at 1,200 rpm for 4 minutes (Hettich Zentrifugen Rotofix 32A with 131 mm 
rotor radius) before being resuspended in SMC growth medium at 50,000 cells/ml.  
 
Suspended cells were then seeded onto PGS-M coated coverslips, prepared as 
described in (‎3.2.1), in 12-well tissue culture plates (Greiner bio-one, Germany), at 
50,000 cells per well. The cells were allowed to attach for 6 hours and then the 
coverslips were transferred to new wells for further culture, ensuring only cells 
attached to the coverslips were included in future analyses.  
Untreated glass coverslips, sterilised by autoclave at 121°C for 30 minutes, were also 
seeded with cells, in an equivalent manner to the PGS-M coated coverslips, to act as 
positive controls. Additionally, unseeded PGS-M coated coverslips were cultured in 
fibroblast growth medium, in parallel with the seeded coverslips, to act as negative 
controls. Each culture well contained 1 ml of growth medium and this was changed 
every second day.  
The seeded coverslips, and associated control samples, were cultured for 1, 3 or 7 days 
before being analysed.  
 
 Resazurin reduction assay for cell viability on PGS-M surfaces 3.2.6
The viability of cells cultured on PGS-M surfaces, as described in (‎3.2.4) and ‎3.2.5), was 
assessed using the resazurin reduction (RR) assay. Resazurin sodium salt is the active 
ingredient in the commercially available cell viability assay reagent alamarBlue®. 
0.0251% (w/v) resazurin sodium salt was dissolved in dH2O. The solution was filter 
sterilised using a 0.22 µm filter and mixed 10% (v/v) with the appropriate cell growth 
medium (fibroblast growth medium for use with fibroblasts or ADCSs and SMC growth 
medium for use with SMCs).  
At the time points described in (‎3.2.4) and (‎3.2.5), the growth medium was removed 
from the culture wells containing the cell seeded coverslips, and parallel controls, and 
replaced with the same volume of resazurin-containing growth medium. Samples were 
then returned to the incubator. An equivalent sample of the resazurin-containing 
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growth medium was also incubated, in parallel, for use as a blank. After 4 hours, 
samples were removed from the incubator and 200 µl of solution was extracted from 
each well, in triplicate, and placed in the wells of a 96-well plate. This plate was then 
read using a fluorescence plate reader (Bio-tek instruments FLX800) at 540 nm 
excitation and 635 nm emission, with the reading from the blank subtracted. Each time 
point was examined three times, using cells sourced from different donors for the 
fibroblasts and ADSCs, with triplicate samples for each cell type and control.    
The results were statistically analysed using two-way ANOVA with Tukey multiple 
comparisons analysis. P<0.05 was considered significant (*), P<0.01 was considered 
very significant (**) and P<0.001 was considered extremely significant (***).  
 
 Production of a standard curve for the PicoGreen® DNA quantification assay  3.2.7
The Quant-iTTM PicoGreen® dsDNA quantification assay was purchased as a kit 
(Thermo Fisher Scientific, USA). The assay measures the quantity of double stranded 
DNA present in a sample by means of fluorescence. In accordance with the 
manufactures instructions, a standard curve of fluorescence values was produced 
using dilutions of a 10 µg/ml λDNA standard in a 0.25% (v/v) solution of TE buffer 
(10 mM Tris-HCl, 1 mM EDTA) in dH2O. Dilutions were made to produce solutions 
containing 200, 400, 600, 800 and 1,000 ng/ml DNA. An equivalent sample containing 
none of the λDNA standard was also produced to act as a blank. 100 µl, in triplicate, of 
each dilution was then extracted and placed in the wells of a black 96-well plate. This 
plate was then read using a fluorescence plate reader (Bio-tek instruments FLX800) at 
480 nm excitation and 520 nm emission with gain 20. The reading from the blank was 
then subtracted from the value for each well. A standard curve describing the 
relationship between the quantity of sample DNA and the fluorescence detected was 
then produced using the values obtained and nonlinear regression using a second 
order polynomial.   
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 PicoGreen® DNA quantification assay for cells cultured on PGS-M surfaces 3.2.8
The quantity of cells present on PGS-M surfaces cultured, as described in (‎3.2.4) and 
(‎3.2.5), was assessed using the PicoGreen® DNA quantification assay, purchased as a 
kit (Thermo Fisher Scientific, USA). The assay measures the quantity of double 
stranded DNA present in a sample by means of fluorescence. This can be used to infer 
the number of cells present.  
At the time points described in (‎3.2.4) and (‎3.2.5), the growth medium was removed 
from the culture wells containing the cell seeded coverslips, and parallel controls. The 
coverslips were washed with PBS, three times, within their wells and then 500 µl of 
dH2O added to each well. Samples were then refrigerated at 4°C for 12 hours before 
being frozen at -80°C. Frozen samples were then thawed in an incubator at 37°C 
before being re-frozen at -80°C. Freeze-thawing was conducted three times. After the 
final thawing, the solution was removed from each sample well and placed in a 1 ml 
microcentrifuge tube. These tubes were agitated in a vortex mixer for 15 seconds 
before being centrifuged at 10,000 rpm for 5 minutes (Sanyo MSE Micro Centaur 
MSB010.CX2.5 with 64 mm rotor). 180 µl was then extracted from each 
microcentrifuge tube and mixed with 180 µl of a 5% (v/v) TE buffer and 0.5% (v/v) 
PicoGreen® solution in dH2O, in accordance with the manufacturer’s instructions. 
180 µl of dH2O was also mixed with 180 µl of the 5% (v/v) TE buffer and 0.5% (v/v) 
PicoGreen® solution in dH2O to act as a blank. All samples were wrapped in silver foil 
and agitated in a vortex mixer for 5 seconds before being incubated at room 
temperature for 10 minutes. 100 µl, in triplicate, was then extracted from each sample 
and placed in the wells of a black 96-well plate. This plate was then read using a 
fluorescence plate reader (Bio-tek instruments FLX800) at 480 nm excitation and 
520 nm emission with gain 20. The reading from the blank was then subtracted from 
the value for each well. Each time point was examined three times, using cells sourced 
from different donors with triplicate samples for each cell type and control. The results 
were statistically analysed using two-way ANOVA with Tukey multiple comparisons 
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analysis. P<0.05 was considered significant (*), P<0.01 was considered very significant 
(**) and P<0.001 was considered extremely significant (***). 
   
 Visualisation of cell proliferation on PGS-M surfaces 3.2.9
Borosilicate glass coverslips coated in 30% Low Mw PGS-M were prepared and 
sterilised as described in (‎3.2.1). The sterile coverslips were placed individually in the 
wells of a 12-well plate and a stainless steel (316L medical grade) cylinder (4 mm 
diameter, 4 mm length), sterilised by autoclave at 121°C for 30 minutes, placed in the 
centre of each. This stainless steel cylinder would act as a mask, preventing cell 
adhesion to an area at the centre of each coverslip.  
Cells (Fibroblasts, ADSCs and SMCs) were cultured on TCP and harvested as described 
in (‎3.2.4) and (‎3.2.5), respectively. Suspended cells were seeded into the wells 
containing the masked coverslips at 50,000 cells per well. The cells were allowed to 
attach for 6 hours and then the stainless steel masks were removed and the coverslips 
were transferred to new wells for further culture, ensuring only cells attached to the 
coverslips were included in future analyses.  
Additionally, masked PGS-M coated coverslips were cultured in parallel with seeded 
coverslips, in an equivalent manner, to act as negative controls. Each culture well 
contained 1 ml of the appropriate growth medium for the cell type and this was 
changed every second day.  
The seeded coverslips, and associated unseeded control samples, were cultured for up 
to 14 days. They were imaged using light microscopy (Olympus IX73) every other day 
to examine the extent of cell proliferation. The size of the remaining masked area was 
calculated from the images using software (ImageJ, version 1.45s). The boundary 
between the proliferating cells and the masked area was determined visually and 
traced using the Freehand Selection tool. The area of the defined section was then 
calculated in pixels and converted to mm2 using the scale bar for calibration.      
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 Fixation and sectioning of human umbilical cord tissue 3.2.10
Human umbilical cords, collected with informed consent (ethics number: STH15599), 
were used to provide positive control samples for various tissue analysis assays. Cords 
were rinsed with PBS and squeezed longitudinally to remove coagulated blood from 
the umbilical vein and arteries. Lengths of ~5 mm were then cut and placed in 3.7 % 
formaldehyde (methanol free) for 24 hours, to fix the tissue. Following fixation, the 
tissue was rinsed with PBS, three times, and then immersed in optimal cutting 
temperature (OCT) compound (Tissue-Tek, Sakura, Japan) and frozen at -20 °C. Frozen 
samples were mounted on stubs and cryosectioned (Lieca CM1860 UV), at -25°C, 
across their cross-sections, at a thickness of 5 µm. Sections were mounted on glass 
slides (Superfrost® Plus, Menzel-Gläser, Germany) and, after 24 hours, rinsed in dH2O 
to remove the OCT compound.      
 
 Immunofluorescence  staining of SMCs for alpha-smooth muscle actin  3.2.11
SMCs seeded and cultured on glass coverslips coated in 30% Low Mw PGS-M for 7 days, 
as described in (‎3.2.5), were examined for the presence of alpha-smooth muscle actin 
(α-SMA) using immunohistochemistry. The growth medium was removed from each 
culture well and the coverslips washed with PBS, three times, before being fixed with 
1 ml of 3.7% formaldehyde (methanol free). After 1 hour of fixation, the formaldehyde 
was removed and the samples washed with PBS, three times, before staining 
commenced. The staining process began by permeablising the samples with 100 µl of a 
0.5% (v/v) solution of Triton X 100 (Fisher Scientific, UK) in PBS. After 1 hour of 
permeablisation, the Triton X 100 solution was removed and the samples washed with 
PBS, three times, before being blocked with 100 µl of a 5% (w/v) solution of bovine 
serum albumin (BSA) in PBS. After 1 hour, the BSA solution was removed and 100 µl of 
a 0.2% (v/v) anti α-SMA mouse monoclonal antibody conjugated with Cy3™ and 5% 
(w/v) BSA in PBS solution was added to each sample. After incubation at room 
temperature, in the absence of light for 2 hours, the antibody solution was removed 
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and each well again washed with PBS, three times. Finally, all samples were rinsed with 
dH2O, to remove any remaining salts. The coverslips were then imaged, in their wells, 
using a fluorescence microscope (Olympus IX73) with 550-570 nm excitation and 
600-660 nm emission.  
Various controls were also produced and imaged. PGS-M coated coverslips, with 
attached SMCs, that were fixed, permeablised and blocked, but not treated with 
antibody, were used to establish the effect of any background fluorescence. 
Additionally, unseeded PGS-M coated coverslips, cultured in parallel with the SMC 
seeded coverslips, in an equivalent manner, were fixed and stained to act as negative 
controls. Finally, sections of human umbilical cord, prepared as described in (‎3.2.10), 
were stained to act as a positive control. Experiments were conducted three times 
with triplicate samples. 
 
 Immunofluorescence staining of SMCs for calponin 3.2.12
SMCs seeded and cultured on glass coverslips coated in 30% Low Mw PGS-M for 7 days, 
as described in (‎3.2.5), were examined for the presence of calponin using 
immunohistochemistry. The seeded coverslips were prepared, permeablised and 
blocked as described in (‎3.2.11). Following the removal of the BSA blocking solution, 
100 µl of a 0.4% (v/v) anti calponin 1 rabbit polyclonal antibody conjugated with FITC 
(Insight Biotechnology, UK) and 5% (w/v) BSA in PBS solution was added to each 
sample. After incubation at room temperature, in the absence of light, for 2 hours the 
antibody solution was removed and the sections again washed with PBS, three times, 
followed by once with dH2O, to remove any remaining salts. The coverslips were then 
imaged, using a fluorescence microscope (Olympus IX73) with 480-500 nm excitation 
and 510-550 nm emission.  
Control coverslips and sections of human umbilical cord artery were also produced as 
described in (‎3.2.11). Experiments were conducted three times with triplicate samples. 
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 Results 3.3
 RR assay for cell viability on PGS-M surfaces 3.3.1
Human dermal fibroblasts, human ADSCs and human coronary artery SMCs were 
cultured on glass coverslips coated in 30% Low Mw PGS-M. Cell viability was assessed 
by reduction of resazurin sodium salt to resorufin, measured using fluorescence 
detection.  
Fibroblasts were cultured on PGS-M surfaces for 1, 3 and 7 days. The results for each 
time point are shown in Figure 26. The fluorescence detected increased over the 
duration of the study. The results at day 7 were significantly different to days 1 and 3 
(P<0.001 and 0.05, respectively), although these were not significantly different to 
each other. Similar results were seen in the positive controls, where fibroblasts were 
cultured on borosilicate glass. The fluorescence signal at day 7 was significantly 
different to days 1 and 3 (P<0.001 and 0.05, respectively), and these were not 
significantly different to each other. Comparing the results for cultures on PGS-M and 
glass at each time point showed no significant differences between the two surfaces. 
There was also no significant interaction between the type of surface and the time 
points assessed. All the results for fibroblasts cultured on PGS-M and glass surfaces 
were statistically significantly different to the negative controls (unseeded PGS-M 
coated coverslips) which showed negligible fluorescence.  
 
ADSCs were also cultured on PGS-M surfaces. Due to their slower growth rate, time 
points at 1, 7 and 14 days were examined. The results for each time point are shown in 
Figure 27. The fluorescence signal detected over the duration of the study increased, 
although a significant difference was only seen between days 1 and 14 (P<0.05). 
Similar results were seen in the positive controls (ADSCs cultured on borosilicate glass), 
although with a slightly greater degree of significant difference between days 1 and 14 
(P<0.01). As in the culture of fibroblasts, comparing the results for ADSCs cultured on 
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PGS-M and glass at each time point showed no significant differences between the two 
surfaces, along with no significant interaction between the type of surface and the 
time points assessed. All the results for the ADSC cultures were statistically 
significantly different to the negative controls (unseeded PGS-M coated coverslips) 
which showed negligible fluorescence.  
 
Finally, SMCs were cultured on PGS-M surfaces for 1, 3 and 7 days. The results for each 
time point are shown in Figure 28. As in the cultures of fibroblasts and ADSCs, the 
fluorescence signal detected over the duration of the study increased. The results at 
days 3 and 7 were significantly different from day 1 (P<0.001, in both cases), although 
these were not significantly different from each other.  In the positive controls (SMCs 
cultured on borosilicate glass) the results at day 7 were significantly different to days 1 
and 3 (P<0.001, in both cases), although these were not significantly different to each 
other.  
As in the culture of fibroblasts and ADSCs, comparing the results for SMCs cultured on 
PGS-M and glass at each time point showed no significant differences between the two 
surfaces. However, unlike in the culture of fibroblasts and ADSCs, a significant 
interaction was shown between the type of surface and the time points assessed 
(P<0.01). The results across the time points were dependent on the type of surface.   
All the results for the SMC cultures were statistically significantly different to the 
negative controls (unseeded PGS-M coated coverslips) which showed negligible 
fluorescence.  
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Figure 26. RR assay for fibroblast viability on 30% Low Mw PGS-M surfaces after 1, 3 
and 7 days in culture. Positive controls were fibroblasts cultured on borosilicate glass 
(Fibroblasts on glass). Negative controls were unseeded PGS-M surfaces (PGS-M only). 
Error bars are SEM (n = 3). 
 
Figure 27. RR assay for ADSC viability on 30% Low Mw PGS-M surfaces after 1, 7 and 14 
days in culture. Positive controls were ADSCs cultured on borosilicate glass (ADSCs on 
glass). Negative controls were unseeded PGS-M surfaces (PGS-M only). Error bars are 
SEM (n = 3). 
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Figure 28. RR assay for SMC viability on 30% Low Mw PGS-M surfaces after 1, 3 and 7 
days in culture. Positive controls were SMCs cultured on borosilicate glass (SMCs on 
glass). Negative controls were unseeded PGS-M surfaces (PGS-M only). Error bars are 
SEM (n = 3).  
 
 PicoGreen® DNA quantification assay for cells cultured on PGS-M surfaces 3.3.2
The quantity of fibroblasts, ADSCs and SMCs present on PGS-M surfaces in culture was 
assessed using the commercially available PicoGreen® DNA quantification assay. The 
assay measured the quantity of dsDNA present in each sample by means of 
fluorescence. This was then used to infer the number of cells present using a standard 
curve (Figure 29). The standard curve was generated through fitting a second order 
polynomial to the fluorescence values generated from known quantities of λDNA 
(0-1,000 ng/ml DNA). The fitted curve showed strong agreement with the data 
(R2 = 0.99).  
 
Fibroblasts were cultured on PGS-M surfaces for 1, 3 and 7 days. The results for each 
time point are shown in Figure 30. The fluorescence detected increased over the 
duration of the study. The results at day 7 were significantly different to days 1 and 3 
(P<0.001 and 0.01, respectively), although these were not significantly different to 
each other. In the positive controls, where fibroblasts were cultured on borosilicate 
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glass, the fluorescence signal also increased across the time points studied. At day 7, 
the result was significantly different to days 1 and 3 (P<0.001, in both cases), and these 
were also significantly different to each other (P<0.01). Comparing the results for 
cultures on PGS-M and glass at each time point showed no significant differences at 
day 1, but significant differences at day 3 (P<0.05) and day 7 (P<0.001), with the 
positive controls showing the greater values. There was a significant interaction 
between the type of surface and the time points assessed (P<0.05). The results across 
the time points were dependent on the type of surface.  
Using a standard curve, the mass of DNA present on each coverslip surface at each 
time point was determined. This was then used to infer the number of cells present on 
each surface, based on a single cell containing 3.5 pg of dsDNA.322 At day 1, PGS-M 
surfaces supported 4,500 ± 200 cells, rising to 37,700 ± 3,000 cells, by day 7. Glass 
surfaces supported 10,000 ± 600 cells at day 1 and 69,900 ± 5,400 cells by day 7.     
All of the results for fibroblasts cultured on PGS-M and glass surfaces were statistically 
significantly different to the negative controls (unseeded PGS-M coated coverslips) 
which showed negligible fluorescence.  
 
ADSCs were cultured on PGS-M surfaces for 1, 7 and 14 days. The results for each time 
point are shown in Figure 31. Over the three time points, the fluorescence signal 
detected increased. A significant difference was only seen between days 1 and 14 
(P<0.01) and not between days 1 and 7 or days 7 and 14. In the positive controls 
(ADSCs cultured on borosilicate glass), significant differences were seen between the 
results at day 1 and days 7 and 14 (P<0.01 and 0.001, respectively), but not between 
day 7 and day 14.    
Unlike in the culture of fibroblasts, comparing the results for ADSCs cultured on PGS-M 
and glass at each time point showed no significant differences between the two 
surfaces, along with no significant interaction between the type of surface and the 
time points assessed.  
Using a standard curve, the mass of DNA, and subsequently the number of cells 
present, on each surface was determined. PGS-M surfaces supported 9,200 ± 1,300 
ADSCs at day 1 and 27,200 ± 2,800 ADSCs, by day 14. Glass surfaces supported 
8,400 ± 400 ADSCs at day 1 and 32,400 ± 1,600 cells by day 14.  
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All of the results for the ADSC cultures were statistically significantly different to the 
negative controls (unseeded PGS-M coated coverslips) which showed negligible 
fluorescence.  
 
Finally SMCs were cultured on PGS-M surfaces for 1, 3 and 7 days. The results for each 
time point are shown in Figure 32. As seen in the other two cell types examined, the 
fluorescence signal detected over the duration of the study increased. Similar to the 
results seen in the culture of fibroblasts, the fluorescence signal at day 7 was 
significantly different from those measured at days 1 and 3 (P<0.001, in both cases). 
The results at days 1 and 3 were not significantly different from each other. A similar 
trend was seen in the positive controls (SMCs cultured on borosilicate glass) with the 
results at day 7 being significantly different to days 1 and 3 (P<0.001, in both cases) 
and these not being significantly different to each other.  
Comparing the results for the two different culture surfaces across the time points 
showed significant differences at day 7 only (P<0.001). A significant interaction was 
shown between the type of surface and the time points assessed (P<0.001). The results 
across the time points were dependent on the type of surface.    
Using a standard curve, the mass of DNA, and subsequently the number of cells 
present, on each coverslip was determined. PGS-M surfaces supported 8,500 ± 1,300 
SMCs at day 1 and 43,400 ± 1,600 SMCs, by day 7. Glass surfaces supported 
4,700 ± 500 SMCs at day 1 and 65,700 ± 3,000 cells by day 7.  
All the results for the SMC cultures were statistically significantly different to the 
negative controls (unseeded PGS-M coated coverslips) which showed negligible 
fluorescence.  
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Figure 29. PicoGreen® assay standard curve produced from known concentrations of 
λDNA standard (n = 2).  
 
 
 
Figure 30. PicoGreen® assay for Fibroblast dsDNA on 30% Low Mw PGS-M surfaces 
after 1, 3 and 7 days in culture. Positive controls were Fibroblasts cultured on 
borosilicate glass (Fibroblasts on glass). Negative controls were unseeded PGS-M 
surfaces (PGS-M only). Error bars are SEM (n = 3). 
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Figure 31. PicoGreen® assay for ADSC dsDNA on 30% Low Mw PGS-M surfaces after 1, 7 
and 14 days in culture. Positive controls were ADSCs cultured on borosilicate glass 
(ADSCs on glass). Negative controls were unseeded PGS-M surfaces (PGS-M only). 
Error bars are SEM (n = 3). 
 
 
Figure 32. PicoGreen® assay for SMC dsDNA on 30% Low Mw PGS-M surfaces after 1, 3 
and 7 days in culture. Positive controls were SMCs cultured on borosilicate glass (SMCs 
on glass). Negative controls were unseeded PGS-M surfaces (PGS-M only). Error bars 
are SEM (n = 3). 
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 Visualisation of cell proliferation on PGS-M surfaces 3.3.3
To visualise the proliferation of fibroblasts, ADSCs and SMCs on PGS-M surfaces, the 
cells were cultured on polymer coated coverslips on which a central region was 
masked during cell seeding. This produced a cell free region which was observed to see 
how it was invaded by proliferating cells over time.   
Figure 33 shows representative images of the proliferation of fibroblasts on PGS-M 
surfaces at 0, 2, 4 and 6 days after the masked area was uncovered. The masked area 
is free from cells initially, at day 0. Fibroblasts moved into the masked area from the 
edges over the time points, reaching its centre by day 6. The fibroblasts appeared to 
form confluent sheets of evenly distributed cells. They displayed a long thin, 
spindle-like, morphology. Negative controls (unseeded PGS-M coated coverslips) did 
not show the presence of fibroblasts at any time point.  
 
Figure 34 shows representative images of the proliferation of ADSCs on PGS-M 
surfaces at 0, 4, 8 and 13 days after the masked area was uncovered. The masked area 
is free from cells initially, at day 0. ADSCs moved into the masked area from the edges 
over the time points. The cells reached the centre of the masked area by day 8 and 
completely covered it by day 13. The ADSCs presented a non-uniform distribution with 
areas of higher cell density clearly visible. Their morphology was spindle-like with 
multiple focal adhesions and long, thin processes. Negative controls (unseeded PGS-M 
coated coverslips) did not show the presence of ADSCs at any time point. 
 
Figure 35 shows representative images of the proliferation of SMCs on PGS-M surfaces 
at 0, 2, 4 and 6 days after the masked area was uncovered. The masked area is free 
from cells initially, at day 0. SMCs moved into the masked area from the edges over 
the time points, having completely covered it by day 4. The SMCs were uniformly 
distributed and showed spindle-like morphology with multiple focal adhesions and 
long, thin processes. Negative controls (unseeded PGS-M coated coverslips) did not 
show the presence of SMCs at any time point.  
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The size of the masked area remaining at each time point during the culture of 
fibroblasts, ADSCs and SMCs on PGS-M surfaces was measured semi-quantitatively. 
Using software (ImageJ), the boundary between the masked area and the proliferating 
cells was traced and the area, in mm2, of the section produced determined. The results 
for the culture of all three cell types are shown in Figure 36. SMCs appeared to 
proliferate at the fastest rate, completely covering the masked area after 4 days. The 
ADSCs demonstrated the slowest rate of proliferation, taking 13 days to cover the 
masked area.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33. Representative images of the proliferation of fibroblasts on PGS-M surfaces. The cylindrical stainless steel masks were removed at Day 
0, 24 hours after cells had been seeded. Fibroblasts proliferated into the masked areas over 6 days. Controls were masked and unseeded PGS-M 
surfaces. Scale bars are 500 µm.      
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Figure 34. Representative images of the proliferation of ADSCs on PGS-M surfaces. The cylindrical stainless steel masks were removed at Day 0, 24 
hours after cells had been seeded. ADSCs proliferated into the masked areas over 13 days. Controls were masked and unseeded PGS-M surfaces. 
Scale bars are 500 µm.      
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Figure 35. Representative images of the proliferation of SMCs on PGS-M surfaces. The cylindrical stainless steel masks were removed at Day 0, 24 
hours after cells had been seeded. SMCs proliferated into the masked areas over 6 days. Controls were masked and unseeded PGS-M surfaces. 
Scale bars are 500 µm.       
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Figure 36. Semi-quantitative analysis of cell proliferation on PGS-M surfaces. In all 
three cell types, the size of the remaining masked area was determined from optical 
microscopy images, using software (ImageJ), at each time point. SMCs demonstrated 
the highest rate of proliferation, having completely covered the masked area by day 4. 
ADSCs proliferated at the slowest rate, taking 13 days to cover the masked area (n = 3).      
 
 
 Immunofluorescence staining of SMCs for α-SMA 3.3.4
Immunohistochemistry was used to assess the expression of α-SMA in SMCs cultured 
on PGS-M surfaces. α-SMA is a strong marker for contractile phenotype in SMCs. After 
7 days in culture on PGS-M, SMCs stained positive for α-SMA (Figure 37). α-SMA was 
present throughout the cytoplasm. Sections of human umbilical cord artery were used 
as a positive control. These also stained strongly for α-SMA. Negative controls were 
blocked, but unstained, SMCs cultured on PGS-M surfaces and unseeded PGS-M 
surfaces with and without any staining treatment. Some background fluorescence was 
present in the blocked, but unstained, SMC cultures and the unseeded and stained 
PGS-M surfaces; however, this did not constitute a strong signal. Unseeded and 
unstained PGS-M surfaces displayed negligible fluorescence.   
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Figure 37. Representative images of SMCs cultured on PGS-M surfaces, for 7 days, 
stained positive for α-SMA (SMCs + antibody) (n = 3). Human umbilical cord arteries 
were stained as a positive control (Umbilical cord + antibody). Negative controls were 
blocked, but unstained, SMC cultures on PGS-M surfaces (Blocked) and unseeded 
PGS-M surfaces with and without any staining treatment (PGS-M + antibody and 
PGS-M only, respectively). All images were captured and processed using equal 
exposure and display settings. Scale bars are 200 µm.    
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 Immunofluorescence staining of SMCs for calponin 3.3.5
Immunohistochemistry was also used to assess the expression of calponin in SMCs 
cultured on PGS-M surfaces. Calponin is another strong marker for contractile 
phenotype in SMCs. After 7 days in culture on PGS-M, SMCs stained positive for 
calponin (Figure 38). This was present throughout the cytoplasm. Sections of human 
umbilical cord artery were used as a positive control and also stained strongly for 
calponin. Negative controls were blocked, but unstained, SMCs cultured on PGS-M 
surfaces and unseeded PGS-M surfaces with and without any staining treatment. Some 
background fluorescence was present in the blocked, but unstained, SMC cultures and 
the unseeded and stained PGS-M surfaces; however, this did not constitute a strong 
signal. Unseeded and unstained PGS-M surfaces displayed negligible fluorescence.   
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Figure 38. Representative images of SMCs cultured on PGS-M surfaces, for 7 days, 
stained positive for calponin (SMCs + antibody) (n = 3). Human umbilical cord arteries 
were stained as a positive control (Umbilical cord + antibody). Negative controls were 
blocked, but unstained, SMC cultures on PGS-M surfaces (Blocked) and unseeded 
PGS-M surfaces with and without any staining treatment (PGS-M + antibody and 
PGS-M only, respectively). All images were captured and processed using equal 
exposure and display settings. Scale bars are 200 µm.      
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 Discussion 3.4
Human dermal fibroblasts, human ADSCs and human coronary artery SMCs were all 
cultured on 30% Low Mw PGS-M coated glass coverslips. The proliferation of these cells 
was examined by measuring the metabolic activity of the cells on each surface, using 
the RR assay; the quantity of dsDNA present on each surface, using the PicoGreen® 
DNA quantification assay, and by a visual examination of each surface, over several 
days.   
 
The metabolic activity of fibroblast cultures on PGS-M surfaces appeared to increase 
over time. The RR assay showed a significant increase in the reduction of resazurin to 
resorufin, detected as a fluorescence signal at 635 nm, over 7 days. Viable cells 
maintain a reducing environment in their cytosol. Resazurin is able to pass through cell 
membranes and is reduced to its fluorescent form in the cytosol of viable cells. The 
increase in the quantity of resazurin reduced by the fibroblasts cultured on PGS-M 
surfaces demonstrates an increase in the metabolic activity of these cultures. This 
suggests an increase in the number of cells present; however, it is possible for other 
factors, such as changes in the growth medium over time and the advancing age of the 
cells to have an effect on their metabolic rate. To complement the results from the RR 
assay, the number of fibroblasts attached to the PGS-M coated coverslips was assessed 
by measuring the quantity of dsDNA present using the PicoGreen® DNA quantification 
assay. The results showed a significant increase in the quantity of dsDNA present in the 
fibroblast cultures between 1 and 7 days. Accept during mitosis, the quantity of dsDNA 
in a human somatic cell remains relatively constant, at ~3.2 x 108 base pairs 
(~3.5 pg).322 Therefore an increase in dsDNA is associated with cell division and an 
increase in cell numbers. The PicoGreen® assay results were therefore evidence of the 
proliferation of fibroblasts on PGS-M surfaces over 7 days. This finding was supported 
by the results from the RR assay, with the increase in cell numbers producing an 
increase in the metabolic activity of each culture. The RR assay results also 
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demonstrated that the fibroblasts remained viable at day 7, which the PicoGreen® 
assay cannot determine.  
The findings of the RR and PicoGreen® assays were further supported by visually 
examining fibroblast cultures on PGS-M surfaces over time. Observing initially cell-free 
regions of the PGS-M surfaces, produced by masking during cell seeding, 
demonstrated how the fibroblasts proliferated over time. The size of the initially 
masked areas reduced over 6 days, as the surrounding fibroblasts proliferated into 
them. The fibroblasts demonstrated characteristic morphology throughout the culture 
period, suggesting that they remained viable.287,323 
Similar results are reported in the literature. Primary human foreskin fibroblasts 
demonstrated proliferation on PGS-A surfaces when cultured in a similar growth 
medium to that employed in the present study.287 Cell proliferation was measured by 
counting the cells present in randomly selected areas of the culture surface over 
12 days. The number of cells present increased from an initial ~2950 cells/cm2 to 
~15,000 cells/cm2 over 6 days. This represented ~2.3 population doublings. This is 
comparable to the present study, where ~3.1 population doublings occurred over the 
same time period (~4500 cells/coverslip on day 1 rising to ~37,700 cells/coverslip on 
day 7). The primary foreskin fibroblasts cultured on PGS-A also maintained a 
fibroblastic morphology and this was similar to that demonstrated in control cultures 
on TCP.   
Additionally, cultures of NIH 3T3 fibroblasts on thermocured PGS surfaces 
demonstrated an increase in metabolic activity over 6 days, when measured using the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and this 
exceeded the performance of the associated positive controls (fibroblasts cultured on 
PLGA).282 No quantification of the actual number of cells present in each culture was 
presented, however. The morphology of the fibroblasts remained normal throughout 
the culture period.     
 
Similar to fibroblasts, the metabolic activity of ADSC cultures on PGS-M surfaces also 
appeared to increase over time. The RR assay showed a significant increase in the 
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reduction of resazurin over 14 days. The PicoGreen® assay results also showed a 
significant increase in the quantity of dsDNA present in the cultures over 14 days. 
These results coupled together demonstrate that ADSCs proliferated on PGS-M 
surfaces and remained viable for 14 days. Visual examination of initially masked 
regions of PGS-M surfaces seeded with ADSCs also demonstrated how the cells 
proliferated. The ADSC clearly colonised the initially cell-free region, completely 
covering it after 13 days. The cells also maintained a characteristic morphology 
throughout the culture period, suggesting that they remained stem-like and did not 
differentiate.324–326   
In the literature, human stem cells have been shown to proliferate on PGS-A surfaces. 
Commercially available MSCs were cultured for up to 7 days on PGS-A and their 
metabolic activity was shown to increase, using the alamarBlue® assay. This coupled to 
a semi-quantitative assessment of the actin present on each culture surface suggested 
that the cells had indeed proliferated on the polymer and remained viable.300   
 
In the culture of SMCs on PGS-M surfaces the results of the RR assay demonstrated a 
significant increase in the metabolic activity of the cultures over 7 days. This was 
consistent with the other two cell types examined. The PicoGreen® assay results also 
showed a significant increase in the quantity of dsDNA present in the cultures over the 
same time period. Taken together, these results show that SMCs proliferate when 
cultured on PGS-M surfaces and remain viable for up to 7 days. This finding is further 
supported by examining the images taken of the initially masked regions of PGS-M 
over the 6 day culture period. SMCs can be seen to proliferate and invade the initially 
masked area, completely covering it after 4 days. The cells maintained a characteristic 
SMC morphology, suggesting they remained viable.189,327 
Additionally, staining for α-SMA and calponin showed that this continued to be 
expressed throughout the cytoskeleton of the SMCs cultured on PGS-M surfaces. Both 
α-SMA and calponin are considered strong markers for the SMC phenotype and 
therefore suggests that the phenotype was unchanged by culture on PGS-M.328,329  
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SMCs have also been cultured successfully on thermocured PGS surfaces. Primary 
baboon carotid artery SMCs were cultured on PGS for 6 days.189 An assessment of their 
viability over the culture duration was conducted using the MTT assay. The results 
showed an increase in the metabolic activity present on each PGS surface culture. 
Imaging of the SMCs showed they possessed the characteristic spindle-shaped 
morphology and also stained positive for the SMC phenotypic marker α-SMA.      
 
Examining the PicoGreen® assay results for the three different cell types cultured on 
PGS-M gives some insight into the different growth rates of the cells on the material. 
The Fibroblasts demonstrated the fastest growth rate, increasing from a population of 
4,500 ± 200 cells on day 1 to 37,700 ± 3,000 cells by day 7. That equated to ~3.1 
population doublings over a 6 day period. The SMCs proliferated from 8,500 ± 1,300 
cells, on day 1, to 43,400 ± 1,600 cells, by day 7. That equated to ~2.4 population 
doublings over the 6 days. The ADSCs demonstrated the slowest growth rate. Between 
days 1 and 7 their population grew from 9,200 ± 1,300 to 18,400 ± 4,100 cells. That 
equated to only ~1 population doubling. The ADSCs demonstrated an even slower 
growth rate between days 7 and 14, only experiencing ~0.6 population doublings. This 
was likely due to their increased confluency by this time point reducing their rate of 
proliferation. Visually examining the rates at which the three different cell types 
colonised the initially masked areas of the PGS-M coated coverslips suggested that the 
SMCs had the fastest growth rate. These cells were able to completely cover the cell 
free region in just 4 days. However, the semi-quantitative nature of this examination of 
cell proliferation means that the actual number of cells is not quantified at each time 
point imaged and no account is made for the difference in size or packing density 
between the cell types. The fibroblasts appeared to pack more densely together than 
the SMCs. The size of the fibroblast population can therefore increase without 
covering the same area as an equivalent number of the SMCs would.   
 
In both the RR and PicoGreen® assays, fibroblasts, ADSCs and SMCs were also cultured 
on borosilicate glass coverslips. These parallel cultures acted as positive controls. 
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When comparing the assay results for the three different cell types cultured on PGS-M 
with their corresponding positive controls, at each time point, interesting behaviours 
are demonstrated.  
In the culture of fibroblasts, no significant differences were seen between the 
fibroblast cultures on PGS-M and those on glass, at any time point, in the RR assay. 
However, in the PicoGreen® assay, significant differences were seen between 
fibroblast cultures on PGS-M and glass at day 3 and day 7, with the glass surfaces 
supporting greater numbers of cells. There was also significant interaction between 
the type of culture surface and the time points assessed, suggesting the results across 
the time points were dependent on whether the fibroblasts were attached to PGS-M 
or glass. The SMCs showed similar results, with no significant differences between the 
PGS-M and glass surface cultures, at any time point, in the RR assay, but a significant 
difference between the two surfaces in the PicoGreen® assay at day 7, again with the 
glass surface supporting the greater number of cells.   
Finally, unlike in the culture of fibroblasts and SMCs, no significant differences were 
seen between the ADSC cultures on PGS-M and the positive control cultures on glass, 
at any time point, in the RR assay or the PicoGreen® assay.  
 
It might be expected that differences in the number of cells present on the culture 
surfaces, as measured by the PicoGreen® assay would equate to similar differences in 
the metabolic activity of the cultures, as measured by the RR assay. This does not 
appear to be the case. Regarding the fibroblasts, cultures for 7 days on PGS-M 
produced similar results to cultures for 3 days on glass, in the PicoGreen® assay, 
suggesting a similar number of fibroblasts were present on each surface at these time 
points. However, the RR assay results showed approximately double the metabolic 
activity in the PGS-M cultures when comparing these same time points. A similar effect 
is present in the ADSC cultures, with similar results in the PicoGreen® assay linked to 
far different results in the RR assay. In the SMC cultures, the PGS-M and glass surfaces 
appeared to support a significantly different number of cells, after 7 days in culture, in 
the PicoGreen® assay, but did not show significantly different metabolisms in the RR 
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assay. A comparison of the results from the RR and PicoGreen® assays is shown in 
Figure 39. Little correlation is visible between the results from the cultures on PGS-M 
and glass surfaces for the three different cell types. 
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Figure 39. Comparison of the relative fluorescence values for the RR and PicoGreen® 
DNA quantification assays for Fibroblasts, ADSCs and SMCs cultured on PGS-M and 
glass surfaces over three time points. Values are mean averages. 
 
Taken together, these results suggest that the metabolic activities of the different cells 
cultured may be substrate specific. The metabolic activities of fibroblasts and ADSCs 
may be increased when cultured on PGS-M compared to glass. This would account for 
the mismatch between the RR and PicoGreen® assay results, with a given number of 
cells attached to PGS-M able to reduce the same quantity of resazurin as a greater 
number of equivalent cells attached to glass. The metabolic activity of SMCs may also 
be different when cultured on PGS-M compared to glass, again accounting for the 
differences between the results of the RR and PicoGreen® assays across the time 
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points. Cell confluency may also play a part. As confluency increases, the metabolic 
activity of the cells may reduce leading to a mismatch between the RR assay and 
PicoGreen® assay results. This effect may also be cell specific and could be more 
pronounced in the fibroblasts and ADSCs compared to the SMCs, which would account 
for the results observed.  
 
It is common in the literature to measure the metabolic activity of cell cultures on 
biomaterials, and associated positive controls, and to infer that increased activity, over 
time, is related to comparable increases in cell numbers.189,282,300 The data presented 
here suggest that there may be subtle, but significant, differences between the 
metabolic activities of different cell types on different surfaces and that measuring this 
alone is not sufficient to draw conclusions about cell proliferation and to make direct 
comparisons between the performance of novel and known materials. Cell culture 
surfaces may affect the metabolism of different cells cultured on them due to a 
number of different factors, such as stiffness, hydrophilicity, topography and surface 
chemistry.330–334 The cell surface interface has been identified as having an important 
influence on cell phenotype. In the present study, it appears that PGS-M has a cell 
specific effect on the metabolic activities of fibroblasts, ADSCs and SMCs. The reasons 
for these behaviours are somewhat unclear, however, and would warrant further 
investigation.   
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 Conclusions 3.5
The findings of this chapter have demonstrated that flat surfaces of 30% Low Mw 
PGS-M are able to support the growth and proliferation of human dermal fibroblasts, 
human ADSCs and human coronary artery SMCs for several days in culture. 
Additionally, growth on PGS-M does not appear to alter the SMC phenotype.  
Culture on PGS-M surfaces may also have effects on the metabolic activities of the 
three cell types. These effects may be subtle and cell specific.  
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Chapter 4 - Manufacture of PGS-M 
Scaffolds for use in TEVGs 
 Introduction 4.1
In the previous chapters, PGS-M was identified as a suitable material for producing 
scaffolds for TEVGs. This material demonstrated suitable mechanical properties, 
degradation rate and processing capabilities and also supported the in vitro culture of 
vascular cell types.  
 
Porous scaffolds are utilised in tissue engineering to direct the development of tissues 
into defined 3D architectures. Scaffold porosity is required to support the culture of 
cells in 3D and allow sufficient diffusion of oxygen and nutrients through the 
developing tissue constructs. Various methods have been explored in the literature to 
generate porous scaffolds for use in tissue engineering. These include porogen 
leaching, freeze drying, emulsion templating, gas foaming and 3D printing.281,335  
 
To generate PGS-M scaffolds suitable for use in the production of TEVGs a porogen 
leaching method was selected. In this method, the scaffold material is mixed with 
particles (porogens) and shaped into the macroscopic scaffold geometry. The porogens 
are then dissolved and removed using a solvent in which the scaffold material is 
insoluble, leaving voids (pores). Porogen leaching is simple, compatible with a variety 
of scaffold materials, and allows modulation of the sizes of the pores by selection of 
different sized porogen particles. Porogen leaching is also compatible with a variety of 
shaping methods which may be used to define the macroscopic shape of the scaffold. 
Porogen leaching has been employed successfully to produce a number of scaffolds for 
generating TEVGs.86,94,286,336   
 
134 
 
In this chapter, the development of methods of fabricating porous PGS-M scaffolds 
suitable for use in generating TEVGs is presented. Scaffolds were initially produced as 
simple disks to evaluate properties such as pore size, porosity, wettability and 
biocompatibility, before being produced as uniform tubes for use in TEVGs. 
Additionally, a proof-of-concept method for producing porous PGS-M scaffolds using a 
hybrid 3D printing and porogen leaching method is presented.    
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 Materials and methods 4.2
In the following methods, all chemical reagents were obtained from Sigma Aldrich, UK 
unless otherwise stated. These reagents were measured and utilised in inert vessels.  
 
 Mould fabrication using polydimethylsiloxane 4.2.1
Moulds for producing various scaffold structures from PGS-M were fabricated from 
polydimethylsiloxane (further denoted as Silicone). The silicone was purchased as a kit 
(Sylgard® 186, Dow Corning, USA) containing an elastomer and curing agent. These 
were mixed thoroughly at a ratio of 10:1 and then cast into negatives of the required 
moulds, produced by 3D printing (Shapeways, USA). Air bubbles were removed from 
the cast silicone by exposing it to cyclic pressure changes, from atmospheric to vacuum 
at 1 µbar, in a vacuum oven, three times. The silicone was then cured at 60°C for 
2 hours, before being removed from the negative moulds, yielding moulds suitable for 
producing scaffolds.    
 
 Fabrication of porous PGS-M disk scaffolds using porogen leaching   4.2.2
A porogen leaching method was used to produce porous PGS-M scaffolds suitable for 
tissue engineering. To produce disk shaped scaffolds, 30% Low Mw PGS-M prepolymer 
was prepared with photoinitiator as described in (‎2.2.5). The PGS-M was then mixed 
thoroughly with sucrose particles (Tate & Lyle, UK). These sucrose particles were 
prepared in 4 different size ranges using mechanical sieving (Endecotts Minor 200, UK): 
100-200 µm (further denoted as Large), 50-100 µm (further denoted as Medium), a 1:1 
blend of 50-100 µm and 38-50 µm (further denoted as Mixed) and 38-50 µm (further 
denoted as Small). The PGS-M and sucrose particles were mixed at different ratios 
(w/w) depending on the particle size range used (Table 8). These ratios were selected 
based on the handling characteristics of the PGS-M and sucrose mixtures and the final 
scaffolds, in an effort to determine the optimum ratios. Scaffolds produced form each 
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different mixture ratio were produced in triplicate. The PGS-M and sucrose mixture 
was packed into 13 mm diameter x 2 mm deep silicone moulds, produced as described 
in (‎4.2.1). The mixture was then photocured, to form composite disks, by exposure to 
UV light (100 W, OmniCure Series 1000 curing lamp) in a sealed container lined with 
reflective foil for 5 minutes. The partially cured PGS-M and sucrose composite disks 
were then removed from their moulds and turned upside-down before being 
photocured again, for a further 5 minutes.  
The photocured PGS-M and sucrose composite disks were then washed in dH2O for 
4 days, to dissolve the sucrose particles and produce a porous scaffold structure, then 
methanol for 4 days, to remove any soluble PGS-M prepolymer and photoinitiator, and 
finally in dH2O again, to remove any residual methanol. Washes of dH2O and methanol 
were refreshed daily.  
 
Table 8. PGS-M:sucrose particle ratios (w/w) used to produce porous disk scaffolds. 
Scaffolds produced form each different ratio were produced in triplicate. 
Sucrose particle size range PGS-M:sucrose particle ratios (w/w) produced 
Large  
(100-200 µm) 
1:1.8, 1:2, 1:2.2, 1:2.4, 1:2.6, 1:2.8, 1:3 
Medium  
(50-100 µm) 
1:2, 1:2.2, 1:2.4, 1:2.6, 1:2.8, 1:3, 1:3.2 
Mixed  
(1:1 blend of 50-100 µm and 38-50 µm) 
1:2, 1:2.2, 1:2.4, 1:2.6, 1:2.8, 1:3, 1:3.2, 1:3.4, 1:3.6, 1:3.8, 1:4 
Small (38-50 µm) 1:2, 1:2.2, 1:2.4, 1:2.6, 1:2.8, 1:3, 1:3.2, 1:3.4, 1:3.6 
 
 Sectioning and examination of porous PGS-M disk scaffolds  4.2.3
Porous PGS-M disk scaffolds, produced as described in (‎4.2.2), were removed from 
dH2O and then immersed in OCT compound (Tissue-Tek, Sakura, Japan) and frozen 
at -20°C. Frozen samples were mounted on stubs and cryosectioned (Lieca CM1860 
UV), at -25°C, across planes perpendicular to their cross-sections, at a thickness of 
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5 µm. Sections were mounted on glass slides (Superfrost® Plus, Menzel-Gläser, 
Germany) and, after 24 hours, rinsed in dH2O to remove the OCT compound.      
The triplicate sections from each scaffold replicate were imaged using light microscopy 
(Motic B5 professional series).  
 
 Examination of porous PGS-M disk scaffolds using SEM 4.2.4
The structure of the porous PGS-M disk scaffolds was examined using SEM. Only 
scaffolds produced from the optimum PGS-M:sucrose particle ratios, determined in 
(‎4.2.2), were examined. These selected ratios were 1:2.8, 1:3, 1:3.8 and 1:3.4 for 
scaffolds produced from large, medium, mixed and small sucrose particles, 
respectively.  
The 13 mm diameter scaffolds were removed from dH2O and 4 mm diameter disks 
were cut out of each of them using a dissection punch. These 4 mm diameter disks 
were then frozen at -80°C for 24 hours before being freeze dried at room temperature 
and 1 µbar, in a vacuum oven, for 24 hours. The dry scaffolds were then affixed to 
aluminium stubs, using carbon tape, and coated with gold using a sputter coater 
(Edwards S150B). The gold coated scaffolds were then examined in a scanning electron 
microscope (Philips XL-20) at 13-15 kV.  
 
 Determination of porous PGS-M disk scaffold pore sizes 4.2.5
The sizes of the pores present in the different PGS-M disk scaffolds were 
semi-quantitatively assessed using SEM images, obtained as described in (‎4.2.4), and 
image analysis software (ImageJ, version 1.45s).  
Firstly, a grid of 60 equally spaced crosses was overlaid onto each SEM image. Then, 
using the freehand selection tool, the outline of the pore within which each cross 
resided was traced to determine the pore area (Figure 40). Where a cross did not 
appear to reside within a pore, or the complete pore was not visible, the closest pore 
to the cross was selected. 3 images from triplicate scaffold samples were examined.  
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For each different scaffold type, the mean average pore area based on the image 
analysis was determined. This average was then multiplied by a statistical correction 
factor of 1.333 (pores assumed to be spherical) to adjust for the arbitrary, 
nonequatorial location of the sections. This generated the average pore area, in the 
equatorial plane, for each scaffold type examined. Additionally, the average pore 
diameter was also calculated, after the application of the correction factor.337  
The results were statistically analysed using one-way ANOVA with Tukey multiple 
comparison analysis. P<0.05 was considered significant (*), P<0.01 was considered 
very significant (**) and P<0.001 was considered extremely significant (***).  
 
 
Figure 40. Representative image of the selection of pore outlines for the determination 
of average pore sizes in PGS-M disk scaffolds. A grid of equally spaced crosses (green) 
was overplayed onto SEM images of the scaffold surfaces. Pores were then selected 
(blue) based on their proximity to the crosses.   
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 Examination of the wettability of porous PGS-M disk scaffolds 4.2.6
Porous PGS-M disk scaffolds, produced using different PGS-M:sucrose particle ratios,  
were prepared and freeze dried as described in (‎4.2.4). The PGS-M:sucrose particle 
ratios used were 1:2.8, 1:3, 1:3.8 and 1:3.4 for scaffolds produced from large, medium, 
mixed and small sucrose particles, respectively. 
The wettability of the scaffolds was examined by applying 20 µl of PBS containing 0.5% 
(v/v) blue food dye (Tesco, UK) to the centre of each scaffold and observing the 
absorption behaviour after 5 minutes, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours 
and 2 hours 30 minutes. Scaffold types were examined in triplicate. Additionally, 20 µl 
of dyed PBS was also applied to 3 glass coverslips and examined in parallel with the 
PGS-M scaffolds to control for evaporation. The mass of the PBS on the coverslips was 
measured at the start and end of the experiment.    
 
 Determination of the porosity of PGS-M disk scaffolds using helium 4.2.7
pycnometry 
The porosity of the PGS-M disk scaffolds produced from the different size ranges of 
sucrose particles was determined using a helium pycnometer (AccuPyc 1340, 
Micromeritics, USA). Scaffolds were produced as described in (‎4.2.2). For each 
different sucrose particle size range, scaffolds were produced from two different ratios 
of PGS-M:sucrose particles. These ratios were 1:2.6 and 1:2.8, 1:2.8 and 1:3, 1:3.6 and 
1:3.8, and 1:3.2 and 1:3.4 for scaffolds produced from large, medium, mixed and small 
sucrose particles, respectively. The 13 mm diameter disk scaffolds were removed from 
dH2O and 4 mm diameter disks were cut out of each of them using a dissection punch. 
These 4 mm diameter disks were then frozen at -80°C for 24 hours before being freeze 
dried at room temperature and 1 µbar, in a vacuum oven, for 24 hours. The diameters 
and heights of the dry scaffolds were then measured using digital callipers. These 
dimensions were used to define the macroscopic volume of the scaffolds, ignoring the 
porosity. The scaffolds were then placed in the pycnometer using a 0.1 cm3 chamber 
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insert. The chamber was pressurised with helium, at 19,500 psi, and the volume 
occupied by the scaffolds determined. This was the true volume of the scaffolds, 
including the porosity. Finally, the true volume:macroscopic volume ratio was 
calculated to determine the scaffold porosity.  
Nine scaffolds from each PGS-M:sucrose particle ratio were examined. The results 
were statistically analysed using one-way ANOVA with Tukey multiple comparison 
analysis. P<0.05 was considered significant (*), P<0.01 was considered very significant 
(**) and P<0.001 was considered extremely significant (***).   
 
 Characterisation of porous PGS-M disk scaffolds by Raman spectroscopy 4.2.8
PGS-M disk scaffolds were examined by Raman spectroscopy (Thermo Scientific 
Nicolet DXR with 532 nm laser at 2 cm-1 resolution) to determine the effectiveness of 
the sucrose removal process.  
PGS-M disk scaffolds were produced using mixed sucrose particles at a PGS-M:sucrose 
particle ratio of 1:3.8, as described in (‎4.2.2). These scaffolds were referred to as 
Washed. Additional scaffolds were also produced, in a similar manner, but without 
being washed in dH2O or methanol following photocuring to allow complete retention 
of the sucrose. These scaffolds were referred to as Unwashed.  
The washed and unwashed scaffolds were cut longitudinally and their interiors were 
analysed by Raman spectroscopy, between Raman shifts of 4000 cm-1 and 400 cm-1, 
using a 532 nm laser at 10 mW. The exposure time was 10 seconds, with 20 exposures 
taken per sample, and the spectrograph aperture set at 50 µm. Fluorescence 
correction was also applied.  
In addition to the scaffolds, mixed sucrose particles alone were also examined, as a 
material control.  
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 Culture of SMCs on porous PGS-M disk scaffolds 4.2.9
Porous PGS-M disk scaffolds of 13 mm diameter and 2 mm depth were produced as 
described in (‎4.2.2), using mixed sucrose particles and a PGS-M:sucrose particle ratio 
of 1:3.8. These scaffolds were removed from dH2O and 4 mm diameter disks were cut 
out of each of them using a dissection punch. These 4 mm diameter disk scaffolds 
were then placed in autoclave bags and sterilised by autoclave at 121°C for 30 minutes. 
The sterile scaffolds were placed individually in the wells of 12-well tissue culture 
plates (Greiner bio-one, Germany) and 2 ml of SMC growth medium added to each 
well. The scaffolds were placed in an incubator at 37°C and 5% CO2, for 24 hours, in 
preparation for cell seeding.   
Human coronary artery SMCs (Promocell, Germany) were expanded on TCP in flasks, 
as described in (‎3.2.5). SMCs between passage 8 and 10 were harvested using trypsin 
(0.025%)/EDTA (0.01%) solution at 0.067 ml/cm2 of culture area. This was quenched 
after 5 minutes with an equal volume of trypsin inhibitor (PromoCell, Germany) and 
the cell suspension centrifuged at 1,200 rpm for 4 minutes (Hettich Zentrifugen Rotofix 
32A with 131 mm rotor radius) before being resuspended in SMC growth medium at 
12.6 x 106 cells/ml.   
The scaffolds were removed from the incubator and 20 µl of the cell suspension was 
applied to each. This equated to a cell seeding density of 2 x 106 cells/cm2 of scaffold 
surface. The cell seeding was performed using modified pipette tips. These tips had 
their ends removed prior to sterilisation, using scissors, so as to widen the end orifice 
to ~3 mm. During SMC seeding, the modified pipette tips were pressed down, 
concentrically, over the PGS-M disk scaffolds while the cell suspension was delivered. 
This was intended to deliver cells into the scaffold interiors. The seeded scaffolds were 
returned to the incubator for 6 hours, to allow for cell attachment, and then placed in 
fresh wells with 2 ml of SMC growth medium. The scaffolds were cultured for a further 
18 hours (producing a culture period of 1 day post seeding) or 7 days. Unseeded 
scaffolds were also incubated, in parallel with the seeded scaffolds, as negative 
controls. The growth medium was replaced every other day.   
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 Resazurin reduction assay for SMC viability on porous PGS-M disk scaffolds 4.2.10
Porous PGS-M disk scaffolds seeded with SMCs, or left unseeded as controls, and 
cultured as described in (‎4.2.9) were examined for metabolic activity, and thus cell 
viability, using the RR assay. 0.0251% (w/v) resazurin sodium salt was dissolved in 
dH2O. The solution was filter sterilised using a 0.22 µm filter and mixed 10% (v/v) with 
the SMC growth medium. At the end of the culture periods, the SMC seeded scaffolds 
and unseeded control scaffolds were removed from the incubator and the growth 
medium removed from their wells and replaced with 2 ml of the resazurin-containing 
growth medium. The scaffolds were then returned to the incubator. An equivalent 
sample of the resazurin-containing growth medium was also incubated, in parallel, for 
use as a blank. After 4 hours, the scaffolds were removed from the incubator and 200 
µl of solution was extracted from each well, in triplicate, and placed in the wells of a 
96-well plate. This plate was then read using a fluorescence plate reader (Bio-tek 
instruments FLX800) at 540 nm excitation and 635 nm emission, with the reading from 
the blank subtracted. Each time point was examined twice, with 4 replicate scaffold 
samples.     
The results were statistically analysed using two-way ANOVA with Tukey multiple 
comparisons analysis. P<0.05 was considered significant (*), P<0.01 was considered 
very significant (**) and P<0.001 was considered extremely significant (***). 
 
 Haematoxylin and Eosin staining of sections of PGS-M disk scaffolds seeded 4.2.11
with SMCs 
Porous PGS-M disk scaffolds seeded with SMCs, or left unseeded as controls, and 
cultured as described in (‎4.2.9) were examined using Haematoxylin and Eosin (H&E) 
staining to examine the distribution of the cells within the scaffolds.  
At the end of the culture periods, the seeded scaffolds and unseeded controls were 
rinsed with PBS, three times, and then fixed with 3.7 % formaldehyde (methanol free) 
for 24 hours. After this, they were rinsed with PBS, three times, and then immersed in 
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OCT compound (Tissue-Tek, Sakura, Japan) and frozen at -20°C. Frozen samples were 
mounted on stubs and sectioned as described in (‎4.2.3). Following the removal of the 
OCT compound, the sections were immersed in Modified Harris haematoxylin solution 
for 90 seconds and then rinsed in H2O for 4 minutes. They were then immersed in 
eosin Y solution for 5 minutes before being rinsed with H2O, twice, followed by 70% 
industrial methylated spirit (IMS) (Fisher Scientific, UK) solution in H2O, then IMS and 
then Xylene. Samples were then coated with DPX mountant, covered with glass 
coverslips and allowed to dry for 12 hours. The sections were imaged using light 
microscopy (Motic B5 professional series). Each time point was examined twice, with 
triplicate scaffold samples. Staining was conducted on 4 sections taken from each 
scaffold sample.     
 
 Examination of PGS-M disk scaffolds seeded with SMCs using SEM 4.2.12
Porous PGS-M disk scaffolds seeded with SMCs, or left unseeded as controls, and 
cultured for 7 days, as described in (‎4.2.9), were examined using SEM. At the end of 
the culture periods, the seeded scaffolds and unseeded controls were rinsed with PBS, 
three times, and then fixed with 3.7 % formaldehyde (methanol free) for 24 hours. 
After this, they were rinsed with PBS, three times, and then dehydrated by the 
addition of a series of ethanol solutions (v/v) in dH2O for 15 minutes. The order of the 
ethanol solutions was 50%, 70%, 90% and 100%. The dehydrated scaffolds were then 
air dried for 7 days. Once dry, the scaffolds were affixed to aluminium stubs, using 
carbon tape, and gold coated and examined by SEM as described in (‎4.2.4).  
 
 Fabrication of porous tubular PGS-M scaffolds using porogen leaching 4.2.13
Porous tubular PGS-M scaffolds were produced for use in the culture of TEVGs. 30% 
Low Mw PGS-M was used in all cases. In total, 6 different methods were examined. In 
method i, a silicone mould was used to shape the outer surface of the scaffolds. In 
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methods ii-vi, 1 ml polypropylene syringes (Terumo, USA) with their ends removed 
were used to shape the outer surface of the scaffolds.   
 
Method i) PGS-M prepolymer was mixed thoroughly with sucrose particles and the 
mixture packed around a 3 mm diameter x 80 mm length stainless steel (316L medical 
grade) rod (Figure 41). The mixture and rod were then shaped by insertion into a 
silicone mould with a semi-cylindrical cavity, produced as described in (‎4.2.1). The 
mixture was then photocured, in the mould, by exposure to UV light (100 W, 
OmniCure Series 1000 curing lamp) in a sealed container lined with reflective foil for 
5 minutes. The partially cured PGS-M and sucrose composite was then removed from 
the mould, rotated 180° about its central axis, and photocured again, for a further 
5 minutes.  
 
Method ii) PGS-M prepolymer was mixed thoroughly with sucrose particles and the 
mixture packed around a 3 mm diameter x 40 mm length polyvinyl acetate (PVA) rod, 
inside a 1 ml syringe (Figure 41). The PVA rod was maintained concentrically inside the 
syringe and the syringe plunger retracted incrementally to allow the addition of the 
PGS-M and sucrose mixture. Once the PVA rod was fully contained within the syringe 
and surrounded by PGS-M and sucrose mixture, the syringe plunger was depressed 
and the contents, now referred to as a compact, was extruded out onto a 5 mm deep 
layer of sucrose particles. The compact, on top of the sucrose particle layer, was then 
photocured as described in method i, with 180° rotation about its central axis between 
UV light exposures.  
 
Method iii) PGS-M prepolymer was mixed thoroughly with sucrose particles and the 
mixture packed into a 1 ml syringe (Figure 42). The syringe plunger was retracted 
incrementally to allow the addition of the PGS-M and sucrose mixture. Once the 
syringe was half full, a 3 mm diameter core was cut out from the compact contained 
within the syringe, using an ultra-thin walled stainless steel tube as a corer. The corer 
was aligned concentrically with the syringe using a 3D printed guide (Shapeways, USA). 
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With the core removed, the compact now took the form of tube contained within the 
syringe. The tubular compact was extruded out of the syringe, by depressing the 
plunger, onto a 5 mm deep layer of sucrose particles. The compact, on top of the 
sucrose particle layer, was then photocured as described in method i, with 180° 
rotation about its central axis between UV light exposures.   
      
Method iv) A tubular compact of PGS-M prepolymer and sucrose particles was 
prepared within a 1 ml syringe as described in method iii, however, the compact was 
not extruded out of the syringe and instead was photocured while retained within it 
(Figure 42). The photocuring process was as described in method i, with 180° rotation 
of the compact about its axis of rotation between UV light exposures. Once 
photocuring was complete, the compact was extruded out of the syringe by depressing 
the plunger.  
 
Method v) A tubular compact of PGS-M prepolymer and sucrose particles was 
prepared within a 1 ml syringe as described in method iii, however, before being 
extruded out of the syringe, the cavity left by the removal of the core of the compact 
was packed with sucrose particles (Figure 43). The tubular compact, with 
sucrose-packed internal cavity was extrude and photocured as described in method iii) 
 
Method vi) PGS-M prepolymer was mixed thoroughly with sucrose particles and the 
mixture packed into a 1 ml syringe (Figure 43). The syringe plunger was retracted 
incrementally to allow the addition of the PGS-M and sucrose mixture. Once the 
syringe was half full, the cylindrical compact was extruded out, by depressing the 
plunger, onto a 5 mm deep layer of sucrose particles. The compact, on top of the 
sucrose particle layer, was then photocured as described in method i, with 180° 
rotation about its central axis between UV light exposures. Once photocured, the 
cylindrical compact was reinserted into the syringe and the centre cut out using a pillar 
drill with a 3 mm twist drill bit. The compact, now in the form of a tube, was then 
extruded out of the syringe again. 
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With the exception of method i, all tubular scaffolds were produced using mixed size 
sucrose particles and a PGS-M:sucrose particle ratio of 1:3.8. In method i, large size 
sucrose particles were used at a PGS-M:sucrose particle ratio of 1:2.2.     
Following fabrication, all photocured scaffold compacts were washed in dH2O for 4 
days, to dissolve the sucrose particles and produce a porous scaffold structure, then 
methanol for 4 days, to remove any soluble PGS-M prepolymer and photoinitiator, and 
finally in dH2O again, to remove any residual methanol. Washes of dH2O and methanol 
were refreshed daily. In method i, the stainless steel core was removed from the 
scaffolds prior to washing in methanol. In method ii, the initial 4 washes in dH2O were 
conducted with the dH2O at 80°C to dissolve the PVA core from the scaffold compact. 
In each method, scaffolds were produced in triplicate.    
 
 
 
 
Figure 41. Fabrication of porous tubular PGS-M scaffolds using methods i and ii.    
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Figure 42. Fabrication of porous tubular PGS-M scaffolds using methods iii and iv.   
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Figure 43. Fabrication of porous tubular PGS-M scaffolds using methods v and vi.    
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 Examination of porous tubular PGS-M scaffolds using scanning electron 4.2.14
microscopy 
Porous tubular PGS-M scaffolds were prepared using the methods described in (‎4.2.13). 
The scaffolds were removed from dH2O and sectioned axially and longitudinally, using 
a scalpel, before being frozen at -80°C for 24 hours and then freeze dried at room 
temperature and 1 µbar, in a vacuum oven, for 24 hours. The dry scaffolds were then 
affixed to aluminium stubs, using carbon tape, and coated with gold using a sputter 
coater (Edwards S150B). The gold coated scaffolds were then examined in a scanning 
electron microscope (Philips XL-20) at 15-20 kV.  
 
 Manufacture of porous PGS-M scaffolds using a hybrid additive 4.2.15
manufacturing and porogen leaching method 
PGS-M scaffolds were produced using an additive manufacturing approach similar to 
selective laser sintering (SLS) (Figure 44). A 50 ml polypropylene syringe (Terumo, USA) 
with the end removed acted as a build chamber for the scaffold. With the plunger 
positioned 3 mm from the open end, the syringe build chamber was filled with a 
mixture of PGS-M prepolymer and sucrose particles. The mixture was produced using 
large size sucrose particles at a PGS-M:sucrose particle ratio of 1:2.8. The PGS-M and 
sucrose mixture was packed flush with the open end of the syringe build chamber and 
then a cap placed over this. This cap had an 8 mm diameter hole cut into it, offset 4 
mm from the cap’s centre. The capped syringe build chamber was then exposed to UV 
light (100 W, OmniCure Series 1000 curing lamp) in a sealed container lined with 
reflective foil, for 5 minutes. The light was directed down into the hole in the cap 
placed over the syringe build chamber. The cap ensured that only the area of the 
PGS-M and sucrose mixture under the hole was exposed to UV light (selective 
photocuring). Following UV exposure, the cap was removed from the syringe build 
chamber and the plunger retracted 1 mm. Additional PGS-M and sucrose mixture was 
then added to the syringe build chamber until this was flush with the end again. The 
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cap was then reapplied, but with the hole position rotated 10° clockwise from the 
previous position. The capped syringe build chamber was then exposed to UV light 
again, as previously. The process of adding 1 mm layers of PGS-M and sucrose mixture 
to the build chamber and selectively photocuring part of these by rotating the hole in 
the syringe build chamber cap was repeated until the cap had completed a full rotation 
and the hole was returned to the first position. The contents of the syringe build 
chamber were then extruded into 100 ml of methanol, by depressing the plunger. The 
methanol dissolved the PGS-M prepolymer that had not been photocured, leaving 
behind the photocured PGS-M with included sucrose particles as a 3D printed 
construct. The 3D printed construct (a spiral of disks) was then washed in dH2O for 
4 days, to dissolve the sucrose particles and produce a porous scaffold structure, then 
methanol for 4 days, to remove any remaining soluble PGS-M prepolymer and 
photoinitiator, and finally in dH2O again, to remove any residual methanol. Washes of 
dH2O and methanol were refreshed daily.  
 
 
 
 
Figure 44. Hybrid additive manufacturing and porogen leaching method for porous PGS-M scaffolds.  
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 Results 4.3
 Fabrication of porous PGS-M disk scaffolds using porogen leaching   4.3.1
Porous scaffolds for tissue engineering were produced from 30% Low Mw PGS-M by 
porogen leaching. The PGS-M prepolymer was combined with sucrose particles and 
photocured forming a composite structure. The sucrose was then dissolved to produce 
a porous structure composed of PGS-M only.  
Initially, disk shaped PGS-M scaffolds were produced using the porogen leaching 
method with 4 different sizes of sucrose particles: large, medium, mixed and small. The 
PGS-M and sucrose particles of each size range were combined at different ratios to 
determine the optimum for producing a scaffold. The initial ratios examined were the 
highest that produced a PGS-M and sucrose particle mixture that could be handled 
suitably and did not adhere to tools or gloves while manipulated. The PGS-M:sucrose 
particle ratios were decreased from the initial ratios, incrementally, until the disk 
scaffolds produced were no longer self-supporting and collapsed under their own 
weight when wet (Figure 45). The lowest ratio of PGS-M:sucrose particles that 
produced a self-supporting scaffold was considered the optimum.  
Sections from the disk scaffolds produced form the different ratios of PGS-M:sucrose 
particles were examined by light microscopy. Figure 46 shows a selection of the results 
for each sucrose particle size range, including the highest ratio examined, the optimum 
ratio and the ratio at which scaffolds failed to be self-supporting. The sizes of the 
scaffold pores decreased as the size range of the sucrose particles used to produce 
them decreased. The interconnectivity between pores also appeared to increase with 
decreasing ratios of PGS-M:sucrose particles. The optimum ratios of PGS-M:sucrose 
particles determined were 1:2.8, 1:3, 1:3.8 and 1:3.4 for the scaffolds produced from 
the large, medium, mixed and small sucrose particle sizes, respectively.  
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Figure 45. PGS-M disk scaffolds produced from mixed sucrose particles. (Left) 
self-supporting scaffold produced from the optimum ratio of PGS-M:sucrose particles, 
1:3.8. (Right) scaffold produced from a PGS-M:sucrose particle ratio of 1:4 was not 
self-supporting. Scale bar is 1 cm.  
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Figure 46. Representative sections of PGS-M disk scaffolds produced with large, 
medium, mixed and small sucrose particles (n = 3). (Left) initial PGS-M:sucrose particle 
ratios. (Centre) optimum PGS-M:sucrose particle ratios. (Right) PGS-M:sucrose particle 
ratios that produced scaffolds that were not self-supporting. Scale bars are 500 µm.    
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 Examination of porous PGS-M disk scaffolds using scanning electron 4.3.2
microscopy 
The structure of the PGS-M disk scaffolds was examined using SEM. The scaffolds were 
produced using the optimum ratio of PGS-M:sucrose particles determined for each 
sucrose particle size. The scaffolds appeared to be porous even at low magnification 
(Figure 47). At increased magnification the porosity was visible in detail and a 
difference in pore size was seen between scaffolds produced from the different sized 
sucrose particles (Figure 48). These differences in pore size appeared to correlate well 
with the different sizes of porogen particles used to produce the scaffolds. Comparing 
at the same magnification, the scaffolds produced using the large sucrose particles 
appeared to have the largest pores, whereas scaffolds produced using the small 
sucrose particles appeared to have the smallest pores. The scaffolds produced using 
the medium sized sucrose particles appeared to have pore sizes between those of the 
large and small particle scaffolds. The scaffolds produced using the mixed sucrose 
particles appeared similar to the medium particle scaffolds with the addition of smaller 
pores, similar in size to those present in the small particle scaffolds. Interconnectivity 
between pores was visible in all scaffolds.  
The sizes of the pores present in the different PGS-M disk scaffolds was determined 
from the SEM images. The pore size distributions, measured as both pore area and 
diameter, within the different scaffolds are shown in Figure 49. The scaffolds produced 
using the Large sucrose particles demonstrated the largest range of pore sizes while 
the scaffolds produced using the Small sucrose particles demonstrated the smallest 
range of pore sizes. The scaffolds produced using the Medium and Mixed sucrose 
particles appeared to possess a similar range of pore sizes. Average pore size was 
calculated as both equatorial area and diameter (Figure 50), both of which assumed 
the pores were spherical. The average pore sizes appeared to correlate well with the 
size of the sucrose particles used to produce the scaffolds. Large sucrose particles 
produced the largest pores. Medium sucrose particles produced the second largest 
pores. Mixed sucrose particles produced the third largest pores and small sucrose 
particles produced the smallest pores. Pore sizes between the different scaffold types 
were significantly different to each other (P<0.05).   
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Figure 47. Representative SEM images of porous PGS-M disk scaffolds produced using 
large, medium, mixed and small sucrose particles at the optimum ratios of 
PGS-M:sucrose particles determined. 
  
158 
 
 
Figure 48. Representative SEM images of the pore structures of porous PGS-M disk 
scaffolds produced using large, medium, mixed and small sucrose particles at the 
optimum ratios of PGS-M:sucrose particles determined (n = 3).  
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Figure 49. Pore size distributions in PGS-M disk scaffolds produced from large, medium, 
mixed and small sucrose particles at the optimum ratios of PGS-M:sucrose particles 
determined. Pore size was calculated as pore area (above) and pore diameter, 
assuming spherical pores (below). Error bars are standard deviation (n = 3). 
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Figure 50. Average pore sizes in PGS-M disk scaffolds produced from large, medium, 
mixed and small sucrose particles at the optimum ratios of PGS-M:sucrose particles 
determined. Pore size was calculated as equatorial pore area (above) and pore 
diameter (below), both assuming spherical pores. Error bars are SEM (n = 3).   
L
a
rg
e
M
e
d
iu
m
M
ix
e
d
S
m
a
ll
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
1 0 0 0 0
1 2 0 0 0
S u c ro s e  p a r t ic le  s iz e s  u s e d  in  P G S -M  s c a ffo ld s
A
v
e
ra
g
e
 e
q
u
a
to
ri
a
l 
p
o
re
 a
re
a
 (

m
2
)
L
a
rg
e
M
e
d
iu
m
M
ix
e
d
S
m
a
ll
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
S u c ro s e  p a r t ic le  s iz e s  u s e d  in  P G S -M  s c a ffo ld s
A
v
e
ra
g
e
 p
o
re
 d
ia
m
e
te
r 
( 
m
)
* 
* 
161 
 
 Examination of the wettability of porous PGS-M disk scaffolds 4.3.3
The wettability of the porous PGS-M disk scaffolds produced using the large, medium, 
mixed and small sucrose particle sizes at their optimum ratio of PGS-M:sucrose 
particles was examined qualitatively. A 20 µl droplet of blue dyed PBS, placed onto the 
surface of each scaffold, was observed over 2 hours 30 minutes, as it was absorbed 
(Figure 51). Initially, the PBS droplets formed tight beads on the surfaces of all of the 
scaffolds. These beads had contact angles with the surfaces exceeding 90°. Over the 
time points examined, the PBS appeared to be absorbed into the scaffolds, with the 
contact angles between it and the scaffold surfaces reducing. The results suggested 
that the scaffolds produced using the small sucrose particles had the greatest 
wettability, as the PBS was completely absorbed into these after 2 hours. This was 
ahead of the other scaffolds, which took a further 30 minutes to fully absorb the PBS. 
There was a change in the mass of the dyed PBS placed on the glass coverslips and 
examined in parallel with the scaffolds. This appeared to reduce in mass by ~16%, as a 
result of evaporation. This suggested that although some evaporation of the dyed PBS 
may have occurred over the course of the experiment, this was not the overriding 
effect. 
     
 
 
 
 
 
 
Figure 51. Representative images of the wettability of porous PGS-M disk scaffolds. Scaffolds were produced using large, medium, 
mixed and small size sucrose particles at the optimum ratios of PGS-M:sucrose particles determined (n = 1). Absorption of dyed PBS 
was observed for 2 hours 30 minutes. Scale bars are 5 mm.  
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 Determination of the porosity of PGS-M disk scaffolds using helium 4.3.4
pycnometry 
The porosity of the PGS-M disk scaffolds was quantified using helium pycnometry. 
Scaffolds produced using large, medium, mixed and small sucrose particles were 
examined. The scaffolds were produced using the optimum ratios of PGS-M:sucrose 
particles determined for each particle size range, along with the ratios preceding the 
optimum ratios (sub-optimum) produced in the original scaffold fabrication 
experiments, described in (‎4.2.2).  
The results demonstrated that the scaffolds produced using the mixed size sucrose 
particles, at their optimum PGS-M:sucrose particle ratio (1:3.8), possessed the greatest 
porosity (Figure 52). The porosity of these scaffolds was 81.9% ± 0.7 and this was 
significantly different to all of the other scaffolds examined (P<0.01). Comparing 
scaffolds produced from optimum and sub-optimum ratios of PGS-M:sucrose particles 
using the same sucrose particle size showed that the only significant difference was 
found between the scaffolds produced using the mixed sucrose particles (P<0.001).      
 
Figure 52. Porosity of PGS-M disk scaffolds produced using large, medium, mixed and 
small sucrose particles, at optimum and sub-optimum PGS-M:sucrose particle ratios. 
Error bars are SEM (n = 3).  
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 Characterisation of porous PGS-M disk scaffolds by Raman spectroscopy 4.3.5
Raman spectroscopy was used to determine if any residual sucrose remained in the 
porous PGS-M scaffolds following leaching of the sucrose in dH2O. The spectra from 
the interiors of fully processed and porous PGS-M disk scaffolds were compared to 
those of equivalent scaffolds where the sucrose had not yet been washed out, along 
with the spectra from a sample of pure sucrose and a non-porous disk of pure PGS-M 
(Figure 53).   
The spectra from the pure sucrose and pure PGS-M appeared distinctly different. The 
spectra from the unwashed PGS-M scaffolds with included sucrose particles appeared 
to be very similar to the spectra from the pure sucrose. Peaks unique to the spectrum 
from the pure PGS-M, such as at 1730 cm-1, were absent from the spectrum from the 
unwashed scaffold, suggesting the sucrose signal dominated. The spectra from the 
washed PGS-M scaffolds appeared very similar to that of the pure PGS-M, although the 
peak intensities across the entire spectrum appeared to be reduced. No spectral 
signals associated with the sucrose could be determined.   
 
 
 
 
Figure 53. Raman spectra for PGS-M disk scaffolds with sucrose washed out (Washed PGS-M scaffold) or unwashed (PGS-M scaffold+sucrose). 
Spectra for PGS-M only (Pure PGS-M) and sucrose (Pure sucrose) are included for comparison. The spectrum generated by the washed PGS-M 
scaffold was similar to that of the pure PGS-M and did not contain recognisable elements from the sucrose spectrum. 
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  Culture of SMCs on porous PGS-M disk scaffolds 4.3.6
SMCs were seeded onto porous PGS-M disk scaffolds, produced from mixed sucrose 
particles at a PGS-M:sucrose particle ratio of 1:3.8, and cultured for 1 and 7 days. At 
the end of the culture periods, the viability of the cells on the scaffolds was measured 
using the RR assay. At the end of the assay, the scaffolds seeded with SMCs appeared 
to be stained strongly purple, whereas the unseeded scaffolds remained white (Figure 
54). The results of the assay are shown in Figure 55. Scaffolds seeded with SMCs 
produced significantly greater fluorescence compared to unseeded PGS-M scaffolds 
(negative controls) (P<0.001). Additionally, the fluorescence produced by the SMCs 
cultured on the PGS-M scaffolds increased over the duration of the study with the 
values being significantly different between day 1 and day 7 (P<0.05).   
The SMC seeded scaffolds were also fixed and stained with H&E for histological 
examination. The sections from both 1 day and 7 day cultures showed the presence of 
sporadic SMCs on the surface of the scaffolds and also penetrating into the interiors 
~500 µm (Figure 56). No significant differences could be discerned between the 
seeded scaffolds cultured for 1 day and 7 days, based on the visual examination of the 
stained sections. Unseeded scaffolds, also stained with H&E, did not show the 
presence of cells (Figure 57).   
Additionally, PGS-M scaffolds seeded with SMCs and cultured for 7 days were also 
fixed and examined using SEM. The seeded surface of the scaffolds appeared to be 
almost completely covered by SMCs and ECM (Figure 58).    
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Figure 54. Porous PGS-M disk scaffolds seeded with SMCs and cultured for 7 days, after 
RR assay (above). Unseeded scaffolds cultured and assayed in parallel (below). Scale 
bar is 1 cm.  
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Figure 55. RR assay for SMC viability on porous PGS-M disk scaffolds. Negative controls 
were unseeded PGS-M scaffolds. Error bars are SEM (n = 2).  
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Figure 56. Representative images of H&E stained sections of porous PGS-M disk 
scaffolds seeded with SMCs and cultured for 1 day (above) and 7 days (below) (n = 2). 
SMCs were present at the surface of the scaffolds and also penetrated into them. Scale 
bar is 200 µm. 
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Figure 57. Representative image of H&E stained sections of porous PGS-M disk 
scaffolds cultured for 1 day and 7 days without seeded SMCs (negative controls) (n = 2). 
No cells appeared to be present within the sections. Scale bar is 200 µm.  
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Figure 58. Representative SEM images of porous PGS-M disk scaffolds seeded with 
SMCs and cultured for 7 days (n = 3). The surface of the scaffolds was almost 
completely covered (above) by SMCs and ECM (below). 
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 Fabrication of porous tubular PGS-M scaffolds using porogen leaching 4.3.7
Several different methods were explored to manufacture porous tubular scaffolds 
from PGS-M using the porogen leaching technique. These scaffolds were designed with 
3 mm internal diameters and thin walls (<1.5 mm) for applications in producing 
small-diameter TEVGs. The quality of the scaffolds produced by each method was 
assessed using SEM. The results are summarised in Table 9. 
Method i was explored initially and utilised a steel rod and silicone mould to shape the 
PGS-M and sucrose mixture into a tube. This method was not compatible with the 
optimum ratios of PGS-M:sucrose particles that were identified in the porous disk 
scaffolds. PGS-M and sucrose mixtures at these ratios could not be shaped effectively 
using the steel rod and silicone mould and tended crack and break apart. Examination 
of the scaffolds that were produced, at sub-optimum PGS-M:sucrose particle ratios, 
revealed conserved geometries (Figure 59). The tubes were self-supporting and 
showed uniform wall thicknesses. Additional examination showed that, although the 
scaffold interiors appeared to be porous, the outer and luminal surfaces were partially 
covered by a skin of PGS-M, limiting their porosity,  
Method ii utilised a syringe and PVA rod to shape the PGS-M and sucrose mixture into 
a tube. Using mixed sucrose particles, at their optimum ratio of PGS-M:sucrose 
particles, the scaffolds produced were uniform, self-supporting tubes with consistent 
wall thicknesses across their length and around their circumference (Figure 59).  The 
scaffolds were porous across their outer surfaces and throughout their interiors. 
However, their luminal surfaces possessed reduced porosity due to the presence of a 
skin of PGS-M. This was less pronounced than observed in the scaffolds produced using 
method i, but still limited the surface porosity compared to the interior and outer 
surface.  
Method iii used a corer to remove the central portion from a compact of PGS-M and 
sucrose mixture, shaped in a syringe, to produce a tube. This method appeared to 
produce scaffolds with porous outer and luminal surfaces, as well as interiors (Figure 
59). However, the tubular geometry of the scaffolds appeared to be deformed. This 
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was a result of collapse of the tubular PGS-M and sucrose compacts when they were 
extruded from the syringes, prior to photocuring.  
Method iv was similar to method iii, but the compacts were photocured inside the 
syringes to avoid collapse on extrusion. The scaffolds produced possessed uniform 
tubular geometries and retained the porous luminal surfaces seen in method iii (Figure 
60). However, their outer surfaces showed large regions of skin formation which 
appeared to greatly reduce the surface porosity.   
Method v was again similar to method iii, except the central cavities of the cored 
PGS-M and sucrose compacts were filled with sucrose particles to prevent collapse on 
extrusion out of the syringes. These scaffolds were similar to those produced in 
method iii, but without the deformation associated with compact collapse (Figure 60). 
The scaffolds were self-supporting and demonstrated uniform tubular geometry with 
conserved wall thicknesses throughout. They also appeared to possess porous outer 
and luminal surfaces, along with porous interiors.  
Method vi utilised a drill to cut the central portion from a cylinder of photocured 
PGS-M and sucrose compact, to produce a tube. This method produced scaffolds with 
porous outer surfaces; however, the scaffold walls were non-uniform and varied in 
thickness across the length of the scaffolds (Figure 60). The luminal surfaces, although 
porous, also appeared disrupted and damaged in some regions.  
 
Table 9. Summary of the structures of the scaffolds produced using methods i to vi.  
Tubular scaffold 
fabrication method 
Outer surface Interior Luminal surface Additional comments 
i Skin layer present Porous Skin layer present Not compatible with optimum 
ratios of PGS-M:sucrose particles 
ii Porous Porous Skin layer present  
iii Porous Porous Porous Scaffolds deformed due to collapse 
of the compact during extrusion 
from the syringes 
iv Skin layer present Porous Porous   
v Porous Porous Porous  
vi Porous Porous Porous Scaffolds damaged by drill 
 
 
 
Figure 59. Representative SEM images of tubular PGS-M scaffolds produced using methods i, ii and iii.    
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Figure 60. Representative SEM images of tubular PGS-M scaffolds produced using methods iv, v and vi.  
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With the SEM analysis suggesting that method v produced the best quality tubular 
PGS-M scaffolds, these scaffolds were further examined for reproducibility. The 
scaffolds appeared reproducible. The internal and outer diameters displayed some 
small variation. Average values were 3.245 ± 0.136 mm and 4.346 ± 0.129 mm, 
respectively (mean average ± standard deviation). Greater variation was seen in the 
thickness of the scaffold walls, with the average value being 0.555 ± 0.111 mm. All 
scaffolds produced possessed suitable handling properties for use in the culture of the 
TEVGs. 
 
 Manufacture of porous PGS-M scaffolds using hybrid additive manufacturing 4.3.8
and porogen leaching method 
A hybrid additive manufacturing and porogen leaching method was developed to 
explore the possibility of producing porous PGS-M scaffolds in more complex and 
varied geometries then disks or tubes. This method was based on the selective 
photocuring of thin layers of PGS-M and sucrose compact to build up a 3D structure. 
As a proof-of-concept, a scaffold composed of a simple spiral of disks was produced. 
The manufacturing process appeared to be successful. Methanol washing dissolved the 
PGS-M which had not been photocured during the manufacturing process and 
released any surrounding sucrose particles with it. This revealed a construct composed 
of photocured PGS-M with included sucrose particles. The construct appeared to 
conform to the intended design and could be seen to consist of many similar sized 
disks stacked on top of each other and arranged in a spiral (Figure 61). Large regions of 
connectivity between the disks were visible, although some areas of separation were 
also present. Interestingly, the diameter of the disks appeared to exceed the diameter 
of the hole through which they were photocured. Disks appeared to be ~12 mm in 
diameter whereas the hole was only 8 mm in diameter. Dissolving the included sucrose 
particles appeared to produce a porous structure with similar handling properties to 
the disk and tubular scaffolds produced previously.   
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Figure 61. Proof-of-concept PGS-M scaffold produced using hybrid additive 
manufacturing and porogen leaching method. The scaffold design (left) was well 
produced using the manufacturing process (right). Scale bar is 1 cm.  
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 Discussion 4.4
Porous scaffolds were produced from PGS-M using a porogen leaching method with 
sucrose particles of different sizes. Initially, disk shaped scaffolds were produced and 
the optimum ratios of PGS-M:sucrose particles for producing these scaffolds were 
explored. The optimum ratio of PGS-M:sucrose particles was selected based on a 
number of factors. The handling characteristics of the PGS-M and sucrose mixtures 
were important in the production of the scaffolds. Mixtures were required that could 
be shaped, using moulds, without significant adherence to the tools or gloves used to 
handle them, but while also maintaining cohesion. Achieving the former required a 
minimum proportion of sucrose particles in the mixture and defined the upper limit for 
the ratios of PGS-M:sucrose particles that would be explored within each different 
sucrose particle size range (large, medium, mixed and small). Maintaining a cohesive 
mixture of PGS-M and sucrose particles contributed to defining the lower limit for the 
PGS-M:sucrose particle ratios that were explored. Increasing the fraction of sucrose 
particles in the PGS-M and sucrose particle mixtures, thereby reducing the ratio of 
PGS-M:sucrose particles, reduced the adhesiveness of the mixtures. This was because 
the adhesive quality of the mixture was only provided by the PGS-M prepolymer and 
not by the sucrose particles. In addition to the handling qualities of the PGS-M and 
sucrose particle mixtures, the structural properties of the ultimately derived scaffolds 
were also an important factor. Once the sucrose particles had been washed out, the 
PGS-M scaffolds were required to be self-supporting and not collapse under their own 
weight, when wet. This property would contribute to maintaining open pore structures 
within the scaffolds and also aid in manipulating them. The structural properties of the 
scaffolds contributed to defining the lower limits for the PGS-M:sucrose particle ratios 
that were explored. As the ratios reduced, the proportion of PGS-M in the mixtures, 
and therefore in the ultimately derived scaffolds, reduced. This reduction of material 
resulted in reduced structural integrity and eventually resulted in scaffold collapse.  
To determine the optimum ratio of PGS-M:sucrose particles for each sucrose particle 
size the upper limit ratio was first determined, based on the handling qualities and 
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adhesiveness of the PGS-M and sucrose mixtures. The ratio of PGS-M:sucrose particles 
was then reduced incrementally, until the lower limit ratio was reached, and the 
scaffolds generated were no longer self-supporting. The optimum ratios were defined 
as the lowest that produced a self-supporting scaffold. This definition maximised the 
sucrose content of the mixtures and, subsequently, the porosity of the scaffolds. 
Maximising scaffold porosity is well established as advantageous for tissue engineering, 
as this helps facilitate cell in growth, mass transport and nutrient exchange and, in the 
case of degradable scaffold materials, facilitates increased degradation rates due to 
greater surface area to volume ratios.338–341  
 
Comparing porous scaffolds produced using the different sizes of PGS-M particles 
showed that the lowest optimum ratio of PGS-M:sucrose particles was achieved using 
the mixed particles. These could be combined with PGS-M at a PGS-M:sucrose particle 
ratio of 1:3.8. When considering the large and medium sucrose particles, the optimum 
PGS-M:sucrose particle ratios determined appeared to correlate with particle size. 
Large sucrose particles produced the highest optimum ratio of PGS-M:sucrose particles, 
at 1:2.8, and the medium sucrose particles produced the second highest ratio, at 1:3. 
Although the optimum ratio of PGS-M:sucrose particles determined for the small 
sucrose particles was lower than those determined for both the large and medium 
sucrose particles, it was not lower than the optimum ratio for the mixed particles. The 
mixed sucrose particles were composed of medium and small particles. It appeared 
that this combination allowed the PGS-M and sucrose particle mixtures to retain 
acceptable handling properties, and the derived scaffolds to remain self-supporting, at 
lower PGS-M:sucrose particle ratios than when using either of the particle sizes alone. 
A partial explanation for this may come from the observation that the scaffolds 
produced using the small sucrose particles appeared to retain some residual 
adhesiveness, even after being washed in dH2O and methanol. This may have resulted 
in scaffolds that appeared to not be self-supporting, because of pores collapsing due to 
adhesion between their surfaces, not because of insufficient strength. It may be 
possible to produce porous PGS-M scaffolds using the small sucrose particles at a 
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lower ratio than the optimum that was determined if the residual adhesiveness of the 
scaffolds could be removed.   
   
PGS-M disk scaffolds, were examined using sectioning and SEM. This revealed the 
structures of the pores. The sizes of the pores present in the scaffolds appeared to 
correlate well with the sizes of the sucrose particles used to produce them. Average 
scaffold pore sizes reduced with decreasing sucrose particle size. In the scaffolds 
produced using the mixed sucrose particles, a range of pore sizes appeared to be 
present, reflecting the particle size range. The pore size distribution suggested that 
pores generated by both the medium and small sucrose particles appeared to be 
present in these scaffolds, although it is difficult to assess the influence of the small 
sucrose particles due to the random location of the cutting plane through each pore in 
the SEM images. The effect of porogen size on pore size has been well established in 
the literature when using porogen leaching to produce porous structures.93,94,336,340 
Indeed, allowing pore size modulation by selection of different sized porogen particles 
is a key advantage to the porogen leaching process, as pore size can affect cell 
phenotype and proliferation.340,342 The porous structures of the PGS-M disk scaffolds 
appeared comparable to those demonstrated in published works. Porous scaffolds for 
use in TEVGs were produced from thermally cured PGS using three different size 
ranges of NaCl: 75-90 µm, 45-53 µm, and 25-32 µm. These porous PGS scaffolds 
showed clear differences in pore size, in line with the sizes of the NaCl porogens used, 
and appeared similar to the scaffolds produced herein, with interconnected clearly 
defined pores.93 Porous disk scaffolds produced from PLLA using NaCl particles of 
between 38 µm and 150 µm also demonstrated similar pore structures.340 
The pore structures observed within the PGS-M disk scaffolds, using sectioning and 
SEM, also suggested additional evidence to explain the differences in the optimum 
PGS-M:sucrose particle ratios that were determined for the scaffolds produced using 
the different size sucrose particles. The optimum ratios of PGS-M:sucrose particles 
were higher when using large particle sizes. These ratios were determined based on 
the scaffolds being self-supporting and not collapsing when wet. Reducing the sizes of 
181 
 
the pores within the scaffolds, as a result of using smaller sucrose particles, may have 
resulted in an increase in triangulation within the scaffold structures. This increased 
the stiffness of the scaffolds and their abilities to spread and support mechanical loads 
without deformation, allowing them to remain self-supporting at lower ratios of 
PGS-M:sucrose particles.  
The ideal pore size required in a scaffold used for the production of a TEVG may 
depend on the scaffold material and the cell types involved. In the static culture of 
SMCs, pore sizes of between 38 µm and 200 µm have proven to produce similar results 
in PLLA and PLGA scaffolds.338,340 In the culture of TEVGs, under dynamic conditions, 
pore sizes of between 25 µm and 90 µm all produced favourable results, although 
there was some preference towards smaller pore sizes.93  The sizes of the pores 
present in the different PGS-M scaffolds, determined using the SEM images, were 
within these ranges and were therefore considered suitable for use in scaffolds 
intended for producing TEVGs. 
It was interesting to compare the sizes of the pores within the PGS-M scaffolds with 
the sizes of the sucrose particles used to produce them. The sucrose particles were 
divided into different size ranges using size exclusion. This was performed using sieves 
which were composed of regularly arranged wire grids with different sized square 
holes through which selected particles could pass based on their size. If the particles 
were assumed to be spherical then the sieves essentially selected particles based on 
their diameters. This allows a comparison to be made with average pore diameters 
that were determined from the SEM images of the porous PGS-M scaffolds. Making 
this comparison for the scaffolds produced using the different sizes (diameters) of 
sucrose particles shows that the pore diameters appeared to be below, or at the lower 
region of, the diameter range of the sucrose particles within each different size range 
(Table 10).  
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Table 10. Sucrose particle sizes (as diameters) compared to the average pore 
diameters generated in the PGS-M disk scaffolds.  
Sucrose particles Particle size (diameter) range       
(µm) 
Average scaffold pore 
diameter (µm) 
Large 100-200 106 ± 3 
Medium 50-100 49 ± 18 
Mixed 1:1 blend of 50-100 and 38-50 35 ± 16 
Small 38-50 26 ± 8 
 
 
This suggests that each of the sucrose particle size ranges produced by the sieving 
process may actually have contained a significant fraction of particles below the lower 
limit of the range. Alternatively, the scaffold pores may have experienced some 
shrinkage during the washes with dH2O and methanol, following photocuring, or in the 
freeze drying process prior to SEM examination. Similar effects have been reported in 
the literature, but these are not universal. The average pore sizes in thermally cured 
PGS scaffolds produced using NaCl porogens of three different size ranges appeared to 
be below the lower limits of the porogen size ranges in each case.93 Here, the average 
sizes of the pores in the scaffolds were measured using microcomputed tomography 
(micro-CT) which was likely more robust and accurate than the method employed in 
the present study. Conversely, when using similar sizes of NaCl porogens to produce 
porous PLLA scaffolds, the average pore sizes appeared to be larger than the NaCl 
porogens used to generate them.340 This study also assessed the scaffold pore sizes 
using micro-CT. It was suggested that the way in which the micro-CT data was 
processed may have accounted for the apparently enlarged pore sizes. Smaller 
interconnected pores, produced by the individual porogens, may have been measured 
as singular large pores. It is unclear how the processing of this micro-CT data compared 
to that performed in the study on the porous thermally cured PGS scaffolds, so only 
limited comparisons can be made. However, it is possible to conceive that the lower 
stiffness of PGS-M and thermally cured PGS compared to PLLA may have resulted in 
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increased pore deformation and shrinkage after the removal of the porogen particles 
from the scaffolds, thus accounting for the differences between porogen sizes and 
scaffold pore sizes observed in the these studies. Additionally, the shrinkage of 
photocurable polymers, functionalised by methacrylation, has been observed in other 
biomaterial applications, such as dental resins.343 Here, shrinkage of the photocured 
polymers was attributed to the reduction in the size of the methacrylate groups, as a 
result of the formation of crosslinks. A similar mechanism may also have affected the 
pores present in the porous PGS-M scaffolds.  
It is important to also acknowledge the limitations of the method used to assess the 
sizes of the pores present in the PGS-M scaffolds. This utilised measurements of a 
selection of pores from the SEM images coupled to a correction factor to account for 
the nonequatorial location of the cutting plane through each pore. Most notably, this 
method was dependent on the assumption that the pores were spherical. Examination 
of the SEM images shows that this assumption may only be partially valid. The pores 
present across the different PGS-M scaffolds show a variety of shapes and were largely 
not spherical. This reflects the variety in the sucrose porogens used to produce the 
pores, which were likely not spherical and instead possessed more angular 
morphologies as a result of the crystalline nature of the sucrose. It may therefore be 
more prudent to not rely on the specific values for the average pore sizes determined 
for the scaffolds, using the SEM images, and only to rely on the trends demonstrated 
between the different sizes of the porogen particles and the sizes of the resulting 
pores in the scaffolds.  
 
A semi-quantitative analysis of the wettability of the porous PGS-M disk scaffolds 
suggested that the scaffolds produced using the small sucrose particles were the most 
wettable. This may have been due to the smaller pores present in these scaffolds 
producing a larger surface area for contact with the PBS droplet, facilitating more rapid 
absorbance. It must be noted that there appeared to be little difference between the 
wettability of the different scaffold types with all appearing to be relatively 
hydrophobic. The PBS droplets formed tight beads, with surface contact angles 
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exceeding 90°, when initially placed on the surfaces of all of the scaffolds. Similar 
results have been observed in porous scaffolds produced from PLLA. These scaffolds 
showed large surface contact angles and little absorption over 1 hour.301 Interestingly, 
the addition of PGS to these PLLA scaffolds produced a large improvement in the 
wettability of the scaffolds, with absorption times reducing from >1 hour to 
<30 seconds. The hydrophilic nature of PGS has been well established and is attributed 
to the non-bonded hydroxyl groups on the PGS polymer backbone.301,344,345 It was 
therefore interesting that similar hydrophilicity was not seen in the PGS-M scaffolds, 
which possess the same polymer backbones with non-bonded hydroxyl groups. It may 
be that the addition of the methacrylate groups in the PGS-M is responsible for the 
hydrophobic nature of the material.  
The hydrophobic nature of the PGS-M scaffolds was countered during their use in cell 
culture by pre-treating the scaffolds in appropriate growth medium. This allowed the 
embedding and attachment of proteins to the scaffold surfaces which then aid cell 
attachment by providing binding sites for integrins.346 
The wetting behaviour of the different PGS-M scaffolds may also be a function of their 
permeability and the pore interconnectivity. However, it is difficult to distinguish the 
effects of these two factors. Both increased scaffold permeability and increased pore 
interconnectivity may facilitate the increased absorbance of the PBS droplets into the 
scaffolds.   
 
The porosity of the PGS-M disk scaffolds was quantified using helium pycnometry. The 
results showed that the lowest ratio of PGS-M:sucrose particles that was used to 
produce a scaffold (1:3.8 for mixed sucrose particles) produced the greatest scaffold 
porosity, at 82.9 ± 0.7%. This was significantly different from the porosities of all of the 
other scaffolds examined. Since the porosity of the scaffolds was a result of the 
removal of the sucrose porogen particles, it would be expected to be directly related 
to the proportion of porogen particles used to produce the scaffolds. Therefore, it is 
understandable that the scaffolds produced with the greatest proportion of sucrose 
particles (lowest PGS-M:sucrose particle ratio) contained the greatest porosity. 
185 
 
Interestingly, the porosity of the scaffolds produced using the different sucrose particle 
sizes did not appear to correlate with the ratios of PGS-M:sucrose particles. At their 
optimum PGS-M:sucrose particle ratios, the scaffolds produced using the medium 
sucrose particles demonstrated significantly greater porosity than the scaffolds 
produced using the small sucrose particles. This may have been a result of the residual 
adhesiveness that was observed in the scaffolds produced using the small sucrose 
particles. This may have caused the closure of some of the pores which manifested as 
a reduced measurement of the scaffold porosity.  
Also of note was that the only significant difference in porosity between the scaffolds 
produced using the same sucrose particle sizes at optimum and sub-optimum 
PGS-M:sucrose particle ratios was seen when using the mixed sucrose particles. Since 
the mixed sucrose particles were a mixture of medium and small particles, it may be 
possible that the small particles facilitated the formation of small pores which acted to 
connect the pores created by the medium particles. Indeed, examination of the SEM 
images of the different PGS-M scaffolds suggested this. Scaffolds produced using the 
mixed sucrose particles appeared to show small interconnecting pores that were not 
present in the scaffolds produced using the medium sucrose particles. Therefore, in 
the scaffolds produced using the mixed sucrose particles, the additional small particles 
present at the optimum ratio of PGS-M:sucrose particles compared to the 
sub-optimum ratio may have resulted in the formation of more small pore 
interconnections. This may have then resulted in a significant increase in scaffold 
porosity due to a reduction in non-connected pores.  
The porosities of all of the PGS-M scaffolds produced were within the ranges of those 
shown to be successful for tissue engineering applications in previous publications 
where a porogen leaching method was employed. These appeared to range from 
60% - 97%.93,338–340   
 
Raman spectroscopy was used to determine if any residual sucrose remained in the 
porous PGS-M scaffolds after repeated washing in dH2O. The spectra produced from 
the scaffolds that had been washed in dH2O appeared to be similar to the spectra 
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produced by a sample of pure PGS-M. No peaks associated with the sucrose appeared 
to be present in the spectra from the washed scaffolds. As it was the interiors of the 
porous scaffolds that were examined, the results suggested that the washing process 
had been sufficient to remove the sucrose.  
Although the peak positions in the spectra were comparable between the washed 
PGS-M scaffolds and the pure PGS-M sample, they showed different intensities, with 
those of the latter being higher. This was likely due to the difference between the 
surface geometries of the two samples. The pure PGS-M samples were disks and 
presented a flat surface as the target for the laser used during the Raman spectroscopy 
process. However, the porous nature of the PGS-M scaffolds, coupled to the laser spot 
size being within the size range of the pores (~50 µm), would have resulted in an 
uneven surface being presented as the target for the laser. The variation in the height 
of the surface examined in the porous scaffolds may have resulted in a spectrum with 
reduced intensity signals compared to that of a flat sample.  
It is interesting to note that, although porogen leaching has been a widely utilised 
method for producing porous structures for tissue engineering in the literature, 
examinations of the success of the porogen removal processes is usually omitted or 
neglected. Here it has been demonstrated that Raman spectroscopy offers a simple 
and non-destructive method for determining the complete removal of the porogen 
particles from scaffold structures.   
 
Cell viability and proliferation on the porous PGS-M scaffolds was examined using 
SMCs seeded onto the scaffolds and cultured for up to 7 days. Based on the 
examinations of the scaffolds produced using the different sizes of sucrose porogens, 
the scaffolds used for cell culture were produced using the mixed sucrose particles, at 
their optimum PGS-M:sucrose particle ratio. This particle size was selected because it 
resulted in the greatest scaffold porosity and this has been identified as advantageous 
in scaffolds for tissue engineering.338–341 SMCs appeared to remain viable when 
cultured on the porous PGS-M scaffolds for 7 days. Comparing the results of the RR 
assays performed on cultures after 1 day and 7 days showed a significant increase in 
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metabolism present on the scaffolds. However, this increase cannot be interpreted as 
evidence of an increased number of SMCs present on the scaffolds after 7 days, as a 
result of cell proliferation, as discussed previously (‎3.4). It should also be noted that 
the PGS-M scaffolds appeared to be stained strongly by the purple resorufin that was 
produced during the RR assay. This suggested that some of this compound may have 
been retained by the scaffolds. In the RR assay, resazurin sodium salt is reduced to 
resorufin when exposed to the reducing environment present in viable cells. The 
resorufin content is then assessed, using fluorescence detection, to provide a relative 
measurement of the metabolic activity present in a sample. Any retention of resorufin 
by the PGS-M scaffolds may therefore have resulted in an inaccurate assessment of 
the metabolic activity present in the scaffolds.     
Histological examination provided some insight into the level of cell proliferation on 
the SMC seeded scaffolds. Sections stained with H&E showed the presence of cells 
across the surfaces of the SMC seeded scaffolds and additional cells penetrating into 
the scaffold interiors. The cells did appear to be limited in numbers and no significant 
difference could be seen between the cultures after 1 day and 7 days. Given the 
growth rate the SMCs had demonstrated during 2D culture on TCP (population 
doubling time ~35 hours) it was expected that significant cell numbers would have 
been present after 7 days in culture on the PGS-M scaffolds.   
Similar results, in terms of both the RR assay and the histological examination of the 
scaffolds, have been observed in the literature. Canine vascular SMCs cultured on PLLA 
scaffolds showed little change in metabolism or evidence of cell proliferation over 4 
weeks.340 The distribution of the SMCs within the PLLA scaffolds was similar to that 
observed in the PGS-M scaffolds. SMCs were present at the surfaces of the scaffolds 
and also sporadically in the interiors. This study used a similar cell seeding density and 
scaffolds with similar porosities to those employed herein. Alternatively, the 
proliferation of SMCs has been observed in static cultures on porous scaffolds 
produced by porogen leaching. This was attributed to mass transport effects within the 
scaffolds. Using sucrose particles as porogens, porous scaffolds were produce from 
PLGA and seeded with SMCs.338 These scaffolds possessed mm scale villi structures 
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produced by shaping them in moulds. These villi were designed to increase the 
boundary surface area of the scaffolds and facilitate greater diffusion of oxygen and 
nutrients into the scaffolds. The results demonstrated proliferation of the SMCs 
seeded onto the scaffolds over 2 weeks with increased proliferation observed in the 
scaffolds with the smallest villi, and therefore the greatest boundary surface area. 
Limitations on mass transport into the scaffolds may have been responsible for the 
lack of SMC proliferation on the porous PGS-M scaffolds observed in the present study. 
To utilise the PGS-M scaffolds for producing TEVGs this limitation may be overcome by 
perfusion of the scaffolds in a dynamic culture system.  
Examination of the SMC seeded PGS-M scaffolds using SEM showed the presence of 
sheets of ECM covering the scaffolds’ porous surfaces. This was similar to the results 
observed in a previous study. Baboon SMCs were cultured on porous PGS scaffolds for 
15 days.189 At the end of the culture period the surfaces of the scaffolds appeared 
almost completely covered by a sheet of confluent cells and associated ECM. 
Trichrome staining suggested that this matrix was largely composed of collagen. It is 
possible that the matrix observed covering the PGS-M scaffolds seeded with SMCs also 
had a similar composition.   
 
Following the confirmation of cell viability on the porous PGS-M disk scaffolds, 
methods for producing porous tubular scaffolds were investigated. These scaffolds 
were intended for applications in TEVGs.  
The first method investigated, method i, appeared to be incompatible with the 
optimum ratios of PGS-M:sucrose particles that were identified for use in producing 
the porous scaffolds. This method shaped the PGS-M and sucrose mixture around a 
stainless steel rod and in a mould. This required the mixture to maintain a certain 
degree of cohesion and this could only be achieved at sub-optimum ratios of 
PGS-M:sucrose particles, due to the adhesive effect of the greater proportion of 
PGS-M present in the mixture. Examination of the scaffolds that were produced, using 
sub-optimum ratios of PGS-M:sucrose particles, suggested acceptable interior 
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porosities, but limited outer and luminal surface porosities due to the formation of 
skins of PGS-M polymer.    
To counter the reduced cohesion demonstrated by the PGS-M and sucrose mixtures at 
the optimum ratio of PGS-M:sucrose particles, the mixtures were constrained inside 
syringes forming compacts. This technique was employed in the subsequent tubular 
scaffold fabrication methods that were explored. Method ii coupled the use of the 
syringes with a PVA rod to produce the middle of the tubular scaffolds. The PGS-M and 
sucrose compact, packed around the PVA rod, was extruded out of the syringes for 
photocuring. This produced suitable outer surface and interior porosity, but the 
luminal porosity continued to be limited be skin formation. Method iii attempted to 
remove the PVA rod; however, the lack of this constraint resulted in partial scaffold 
collapse during the extrusion of the PGS-M and sucrose compact out of the syringes. A 
porous luminal surface was produced, so to avoid the compacts collapsing, in method 
iv the PGS-M and sucrose compacts were shaped as in method iii, but were 
photocured while still inside the syringes and then extruded out. This resulted in 
scaffolds with suitable internal and luminal surface porosity; however, the outer 
surface now appeared to show the formation of polymer skin.  
The results observed from using methods i-iv to produce porous tubular PGS-M 
scaffolds suggested that contact between the PGS-M and sucrose compact and a 
smooth surface during the photocuring process resulted in the formation of polymer 
skin layers that limited the porosity of the derived scaffolds. Contact between the 
stainless steel/PVA rods and the PGS-M and sucrose compact during photocuring 
resulted in polymer skin formation on the luminal surfaces of the scaffolds in methods 
i and ii. Contact between the syringe wall and the PGS-M and sucrose compact during 
photocuring resulted in polymer skin formation on the outer surface of the scaffolds in 
method iv. When the PGS-M and sucrose compacts were photocured without contact 
with a smooth surface, as in method iii, porous outer and luminal surfaces were 
produced. These results may have been due to some interaction between the PGS-M 
polymer and the smooth surfaces during the photocuring process. Alternatively, the 
extrusion of the PGS-M and sucrose compacts out of the syringes, prior to photocuring, 
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may have acted to remove PGS-M from the outer surface of the shaped compacts 
through shear. The formation of polymer skins during the production of porous 
scaffolds has been reported in the literature, but is usually attributed to solvation of 
the polymer materials used.340 No solvent was used in the production of the tubular 
PGS-M scaffolds so the cause of the skin layers remains unclear.  
Methods for fabricating the tubular PGS-M scaffolds were subsequently developed 
which avoided contact between the PGS-M and sucrose compacts and smooth 
surfaces during the photocuring process. Method v used sucrose particles packed into 
the middle of the PGS-M and sucrose compact tubes formed inside the syringes. This 
was intended to prevent the partial collapse of the compacts when they were extruded 
out of the syringes prior to photocuring, as was observed in method iii. The packed 
sucrose particles did not present a flat surface in contact with the PGS-M and sucrose 
compacts. The scaffolds produced using method v appeared to possess interior 
porosity and both outer and luminal surface porosity. Additionally, method vi explored 
photocuring the PGS-M and sucrose compacts as cylinders, and then removing the 
central cavities using a drill to produce tubes. The cylinders were formed inside 
syringes and extruded out for photocuring, as had proven successful in methods ii, iii 
and v. Although the drill appeared to produce porous luminal surfaces it caused 
damage to the scaffolds. This was likely a result of the interaction between the 
relatively soft photocured PGS-M and sucrose composite and the high rotation speed 
of the drill. It is possible that a lower cutting speed may produce improved results.  
Method v was therefore selected for the production of the tubular PGS-M scaffolds 
that were used to generate the TEVGs. This method produced suitable scaffold 
structures with porous surfaces and interiors. Further analysis of these scaffolds 
demonstrated they possessed relatively conserved internal and outer diameters, 
although with some variation in their wall thicknesses. This was likely a result of 
variation in the alignment of the corer relative to the syringe barrel used in the scaffold 
manufacturing process. Since the corer and syringe barrel dimensions were conserved, 
these resulted in the relatively conserved values for the scaffolds’ internal and outer 
diameters. Misalignment of the corer and syringe barrel resulted in differences in the 
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scaffold wall thicknesses. The dimensions of the scaffolds were within the range 
specified for use in the culture of the TEVGs (internal diameter ~3 mm, wall thickness 
<1.5 mm).     
  
In addition to the methods for fabricating tubular PGS-M scaffolds, a method was also 
developed to produce scaffolds of varied and complex shapes, using a combination of 
additive manufacturing and porogen leaching. This process built up the scaffold 
structure by selectively photocuring layers of PGS-M and sucrose mixture. The sucrose 
was then removed from the photocured composite to produce porosity. A single 
scaffold structure was produced as a proof-of-concept. This appeared to conform to 
the intended design, a spiral of stacked disks. The disks appeared to be slightly larger 
than the hole through which they were selectively photocured using UV light. This was 
likely a result of scattering of the incident light by the white PGS-M and sucrose 
mixture. The layers of photocured PGS-M were able to fuse together, although not 
completely with some gaps observed, and the scaffolds demonstrated similar handling 
properties to the previously produced disk and tubular scaffolds, after the removal of 
the sucrose.  
This method of scaffold fabrication requires further development. Investigations into 
using different sizes of the sucrose particles are required along with further 
characterisation of the scaffolds, particularly in relation to the interconnections 
created between the separately photocured PGS-M layers. It would also be desirable 
to enhance the selective photocuring mechanism by using image projection to define 
the geometry of each PGS-M layer. This, coupled to an automated method of 
delivering each additional layer of PGS-M and sucrose mixture into the build chamber, 
may produce a system capable of generating a wide range of predefined scaffold 
geometries.    
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 Conclusions 4.5
Porous scaffold structures, suitable for use in tissue engineering, were produced from 
PGS-M using a porogen leaching method with sucrose particles. Combining PGS-M 
with sucrose particles of different sizes, at different ratios, allowed variation of the 
scaffolds’ handling properties, pore sizes, porosities and wettability. SMCs seeded onto 
porous PGS-M scaffolds remained viable for 7 days in static culture and partially 
infiltrated the scaffold interiors.    
A method was developed to produce the porous scaffolds as tubes of suitable 
geometry and porosity for use in the generation of TEVGs. Additionally, a method for 
producing porous PGS-M scaffolds in a variety of geometries, using additive 
manufacturing, was also demonstrated as a proof-of-concept. This process requires 
further development.    
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Chapter 5 - Design of a dynamic culture 
bioreactor for TEVGs 
 Introduction 5.1
The production of TEVGs requires specialised equipment and protocols. Producing a 
complex 3D structure cannot be achieved using standard cell culture equipment based 
on in vitro cell culture on 2D surfaces under static conditions.  
Aside from a supporting scaffold, or some other means of directing the macroscopic 
shape of the vessel, a dynamic culture environment is also required to culture TEVGs. 
This usually takes the form of a bioreactor system. The use of bioreactors has been 
well established in the literature. In a number of studies, dynamic culture methods 
yielded superior results to static cultures when generating TEVGs and appear to be a 
prerequisite to generate TEVGs with sufficient mechanical strength to be employed in 
vivo.61,66,75,84,87,93,98,122,169,233,336,347,348 Indeed, the research groups at the forefront of 
producing TEVGs, in vitro, utilise dynamic culture bioreactors.  
Within the dynamic culture environment, the need to provide mechanical stimulation 
to developing TEVGs has also been well established. Niklason and Langer 
demonstrated this in their seminal work on producing TEVGs in vitro under pulsatile 
flow.61 It was shown that TEVGs based on PGA scaffolds seeded with SMCs developed 
increased ECM contents and subsequent increased strengths as a result of the 
mechanical stimulation applied by the pulsatile flow. These findings have been 
replicated in a number of studies, using a variety of TEVG designs.61,66,75,84,93,98,122,336 
In this chapter, the design of a dynamic culture bioreactor capable of supporting the 
culture of TEVGs in vitro is presented.   
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 Design brief 5.1.1
Produce a bioreactor cable of supporting the growth and development of a TEVG in 
vitro. The TEVG will be composed of a PGS-M porous scaffold seeded with cells. The 
bioreactor culture environment will be regulated by an incubator. The bioreactor must 
culture the TEVG under dynamic conditions and apply mechanical stimulation. 
 
 Materials and Methods 5.2
In the following methods, all chemical reagents were obtained from Sigma Aldrich, UK 
unless otherwise stated. These reagents were measured and utilised in inert vessels.  
 
 Identification of design objectives 5.2.1
A list of design of objectives which the bioreactor design had to satisfy was identified. 
These were then expanded and arranged into an objectives tree to visualise their 
relationships to each other.349–351 
 
 Functional analysis 5.2.2
Based on the design brief for the bioreactor, a functional analysis was performed to 
define the scope of the design process and the relevant inputs, sub-functions and 
outputs.349,351 The overall function of the bioreactor design was expressed as a simple 
conversion of inputs to outputs. The overall function was then broken down into 
sub-functions. These sub-functions would then be targeted during the process of 
generating initial ideas for design solutions.   
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 Performance specification  5.2.3
A performance specification for the bioreactor design was produced. This defined the 
precise limits within which the design solution would operate.349,351 Performance 
attributes were identified and targets and constraints quantified where possible.  
 
 Design solution generation and evaluation 5.2.4
Based on the functional analysis, described in (‎5.2.2), the bioreactor design was 
separated into sub-functions and solutions to these explored. A number of different 
initial design idea were proposed to achieve these sub-functions.  
The initial ideas were then evaluated using a weighted objective evaluation matrix. 
This process quantified the success of each design in accomplishing the design 
requirements.349,351 For each sub-function, several assessment criteria were proposed, 
guided by the design objectives and performance specification, described in (‎5.2.1) and 
(‎5.2.3). The assessment criteria were then ranked, using pairwise comparisons, and 
then weight factors assigned to them based on their relative importance towards 
achieving the overall design brief. The weight factors were assigned based on the 
distribution of a total score of 100 among the assessment criteria.   
The success of each initial design in relation to the assessment criteria was then 
evaluated and given a score out of 5. These scores were then multiplied by their 
associated weight factors and the total score for each design, across all the assessment 
criteria, calculated and compared. A final design was then proposed based on the 
combined results.   
 
 Manufacture of the bioreactor final design 5.2.5
The proposed final design for the bioreactor, designated Bioreactor design 1.1, was 
constructed from a combination of bespoke and pre-manufactured components. These 
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were sourced from reputable vendors. Where possible, certified or guaranteed 
components were selected.    
 
 Bioreactor leak testing 5.2.6
The bioreactor was fully assembled with analogues for the TEVGs, produced from 
Tygon tubing, inserted into the flow circuit. The culture chamber was then filled with 
600 ml of H2O using the growth medium exchange tank. This was 100 ml greater than 
the normal working volume to ensure the joint between the culture chamber and its 
lid was in contact with the fluid. The flow circuit outlet line was positioned in the 
peristaltic pump (Masterflex L/S variable-speed drive with Easy-Load PPS, SS rotor 
pump head) and, after priming, the pump applied at 60 rpm. The pressure regulator 
valve was set to produce a relative pressure of 200 mmHg in the flow circuit, measured 
using the pressure transducer (MTL844, ADInstruments, UK). To simulate the culture of 
TEVGs, while the pump was active, the culture chamber was periodically handled 
(raised, lowered and tilted) and the attached tubing flexed. After 24 hrs, the pump was 
deactivated and the H2O was removed from the culture chamber using the growth 
medium exchange tank. Throughout the testing period, the bioreactor was examined 
for leaks. Leak testing was conducted 3 times.  
 
 Bioreactor design 1.1 sterilisation by autoclave 5.2.7
The bioreactor was assembled with the lines which attached to the 0.22 µm air filters, 
fitted to the culture chamber lid and growth medium exchange tank, capped. The 
pressure transducer port was also removed and its inlet and outlet lines connected. 
The bioreactor was then sterilised by autoclave, at 121°C, for 30 minutes and then 
placed in a biological safety cabinet. Sterile air filters (Minisart®, Sartorius stedim 
biotech, Germany) were attached to the previously capped lines, and a sterile pressure 
transducer port attached to the corresponding inlet and outlet lines.  
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 Bioreactor design 1.1 sterility testing 5.2.8
The bioreactor was sterilised as described in (‎5.2.7). 500 ml of fibroblast growth 
medium, prepared as described in (‎3.2.3), was then added to the bioreactor culture 
chamber using the growth medium exchange tank, inside the biological safety cabinet. 
The bioreactor was placed inside an incubator (Sanyo MCO 175 CO2) with the flow 
circuit outlet line running through an access port and fitted to the peristaltic pump 
outside. The pump was applied at 60 rpm. Additionally, 20 ml of fibroblast growth 
medium was placed in a polypropylene container, sterilised by gamma irradiation 
(Fisher Scientific, UK), and incubated in parallel with the bioreactor, to act as a positive 
control. The medium was inspected daily for signs of infection. After 7 days, the 
medium was withdrawn, via the growth medium exchange bottle, and an RR assay 
performed on triplicate 1 ml samples. 0.0251 (w/v) resazurin sodium salt was dissolved 
in dH2O and the solution filter sterilised using a 0.22 µm filter. The resazurin solution 
was mixed 10% (v/v) with the samples of medium from the bioreactor, along with 
equivalent samples of positive control medium. These samples were then placed in the 
incubator. Additionally, equivalent samples of resazurin-containing fresh fibroblast 
growth medium were also incubated, in parallel, for use as a blank. After 4 hours, all 
samples were removed from the incubator and 200 µl of solution was extracted from 
each, in triplicate, and placed in the wells of a 96-well plate. This plate was then read 
using a fluorescence plate reader (Bio-tek instruments FLX800) at 540 nm excitation 
and 635 nm emission, with the reading from the blank subtracted.  
The process of inserting a seeded PGS-M scaffold into the bioreactor was then 
simulated. Inside a biological safety cabinet, the lid was removed from the bioreactor 
culture chamber and three PGS-M scaffold analogues (Tygon tubes sterilised by 
autoclave at 121°C for 30 minutes) inserted into the flow circuit using sterile forceps. 
The lid was then reattached to the culture chamber and the bioreactor filled with 
500 ml of fresh fibroblast growth medium. The bioreactor was returned to the 
incubator with the flow circuit outlet line running through an access port and fitted to 
the peristaltic pump, as previously. The pump was applied at 60 rpm and the pressure 
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regulator valve set to deliver a maximum relative intraluminal pressure of 200 mmHg 
(determined using the pressure transducer). As previously, 20 ml of fibroblast growth 
medium placed in a polypropylene container sterilised by gamma irradiation was also 
incubated in parallel with the bioreactor, to act as a positive control. The medium was 
inspected daily for signs of infection. After 7 days, the medium was withdrawn and an 
RR assay performed, as described previously, including the positive controls and blanks. 
The results were analysed using one-way ANOVA with Tukey multiple comparisons 
analysis. P<0.05 was considered significant (*), P<0.01 was considered very significant 
(**) and P<0.001 was considered extremely significant (***).  
 
 Bioreactor design 1.2 sterilisation by peracetic acid 5.2.9
The bioreactor was assembled with three PGS-M scaffolds, manufactured as described 
in (‎4.2.13) using method v, or scaffold analogues produced from Tygon tubing, 
connected to the TEVG channels of the flow circuit, inside the culture chamber. The 
cell seeding ports and the lines which attached to the 0.22 µm air filters, fitted to the 
culture chamber lid and growth medium exchange bottle, were capped. The bioreactor 
was sterilised in two steps: firstly the growth medium exchange bottle was sterilised 
followed by the bioreactor culture chamber and flow circuit. Working inside a 
biological safety cabinet, the growth medium exchange bottle was isolated from the 
rest of the bioreactor using the gate valve. 500 ml of a 0.5% peracetic acid solution in 
dH2O was then added to the bottle and the lid closed. After 1 hour, the bottle was 
placed horizontally to sterilize the lid and associated air filter line. A sterile syringe was 
used to draw the acid solution up the air filter line fitted to the growth medium 
exchange bottle. After 1 hour, the bottle was righted and a sterile air filter (Minisart®, 
Sartorius stedim biotech, Germany) attached to the air filter line.  
The gate valve was then opened and the bioreactor culture chamber filled with 
peracetic acid solution. An additional 100 ml of acid solution was added, making the 
total volume 600 ml (100 ml greater than the normal working volume). The peracetic 
acid was circulated through the bioreactor flow circuit using the peristaltic pump at 
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20 rpm. Sterile syringes (Terumo medical, USA) were used to draw the solution into 
the cell seeding ports and up the air filter lines in the culture chamber lid. After 1 hour, 
the acid was removed, through the growth medium exchange bottle, and the inside of 
the bioreactor rinsed with triplicate washes of 600 ml of sterile PBS.   
 
 Bioreactor design 1.2 sterility testing 5.2.10
The bioreactor was assembled with PGS-M scaffold analogues, produced from Tygon 
tubing, inserted into the flow circuit and was sterilised as described in (‎5.2.9). 500 ml 
of fibroblast growth medium, prepared as described in (‎3.2.3), was then added to the 
bioreactor culture chamber using the growth medium exchange bottle, inside the 
biological safety cabinet. The bioreactor was placed inside an incubator (Sanyo MCO 
175 CO2) with the flow circuit outlet line running through an access port and fitted to 
the peristaltic pump outside. The pump was applied at 60 rpm. Additionally, 20 ml of 
fibroblast growth medium was placed in a polypropylene container, sterilised by 
gamma irradiation (Fisher Scientific, UK), and incubated in parallel with the bioreactor, 
to act as a positive control. The medium was inspected daily for signs of infection. 
After 7 days, the medium was withdrawn, via the growth medium exchange bottle, 
and an RR assay performed on triplicate 1 ml samples. 0.0251 (w/v) resazurin sodium 
salt was dissolved in dH2O and the solution filter sterilised using a 0.22 µm filter. The 
resazurin solution was mixed 10% (v/v) with the samples of medium from the 
bioreactor, along with equivalent samples of positive control medium. Additionally, 
equivalent samples of resazurin-containing fresh fibroblast growth medium were also 
incubated, in parallel, for use as a blank. After 4 hours, all samples were removed from 
the incubator and 200 µl of solution was extracted from each, in triplicate, and placed 
in the wells of a 96-well plate. This plate was then read using a fluorescence plate 
reader (Bio-tek instruments FLX800) at 540 nm excitation and 635 nm emission, with 
the reading from the blank subtracted.  
The process of seeding cells onto the PGS-M scaffolds inside the bioreactor was then 
simulated. Inside a biological safety cabinet, the TEVG channels were isolated from the 
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flow circuit, using the three-way stopcocks, and the cell seeding ports opened. 100 µl 
of fresh fibroblast growth medium was then injected into each port, using a pipette. A 
sterile syringe was then attached to each port and depressed to move the 100 µl 
volume of growth medium down the TEVG channels and into the scaffold analogues. 
The seeding ports were then closed and the TEVG channels reconnected to the flow 
circuit. The bioreactor was then filled with 500 ml of fresh fibroblast growth medium 
and returned to the incubator with the flow circuit outlet line running through an 
access port and fitted to the peristaltic pump, as previously. The pump was applied at 
60 rpm and the pressure regulator valve set to deliver a maximum relative pressure of 
200 mmHg (determined using the pressure transducer). As previously, 20 ml of 
equivalent fibroblast growth medium, placed in a polypropylene container sterilised by 
gamma irradiation, was also incubated in parallel with the bioreactor, to act as a 
positive control. The medium was inspected daily for signs of infection. After 7 days, 
the medium was withdrawn and an RR assay performed, as described previously, 
including the positive controls and blanks. The results were analysed using one-way 
ANOVA with Tukey multiple comparisons analysis. P<0.05 was considered significant 
(*), P<0.01 was considered very significant (**) and P<0.001 was considered extremely 
significant (***).    
 
 Bioreactor design 1.2 flow rate measurement 5.2.11
To determine the flow rate within the different channels of the flow circuit the 
bioreactor was prepared as described in (‎5.2.6), accept with just 500 ml of H2O (normal 
working volume) added to the culture chamber. The pump was applied at 60 rpm for 
5 minutes to remove any air from the system and then the three TEVG channels and 
the pressure transducer channel disconnected, downstream of the culture chamber, 
before they converged into the return line. The pump was then reapplied at 6, 20 and 
60 rpm, for 1 minute, and the volume of dH2O produced from each channel measured, 
in triplicate.  
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The results were statistically analysed using two-way ANOVA with Tukey multiple 
comparisons analysis. P<0.05 was considered significant (*), P<0.01 was considered 
very significant (**) and P<0.001 was considered extremely significant (***). 
 
 Mechanical stimulation testing 5.2.12
A pulsatile flow, generated by the peristaltic pump, would be used to apply mechanical 
stimulation to the TEVGs during culture. The flow was examined using an in-line 
pressure transducer, calibrated using a pressure gauge, in accordance with the 
manufacturer’s instructions.  
The bioreactor culture chamber was filled with 500 ml of dH2O, as described (‎5.2.11). 
The pump was applied at 5, 20 and 60 rpm, with the pressure regulator valve fully 
open and then closed to produce a maximum relative pressure of 50 mmHg and 
200 mmHg.  
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 Results and Discussion 5.3
 Identification of design objectives 5.3.1
A list of design objectives which the bioreactor design had to satisfy was identified. 
These were broadly defined as:  
 Simple to manufacture 
 Reliable operation 
 High safety 
 Good operating characteristics 
 
These objectives were further expanded into more specific objectives and arranged 
into an objectives tree (Figure 62). This showed the relationships between the 
different objectives and demonstrated how achieving the specific objectives 
contributed to achieving the broader objectives. The identified design objectives were 
considered throughout the design process to inform decisions and evaluate competing 
solutions.  
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Figure 62. Design objectives tree for the design of the dynamic culture bioreactor for TEVGs. 
Dynamic culture 
bioreactor or 
TEVGs 
Simple to 
manufacture 
Simple component 
manufacture 
Low complexity of 
components 
Maximise bought 
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Use readily 
available materials 
and manufacturing 
methods 
Simple assembly Minimise number 
of components 
Use standard 
fasteners 
Reliable operation 
Reproducible 
dynamic 
environment 
Low wear of 
components 
Maximise 
guaranteed 
components 
Use sensors and 
monitoring 
Maintains sterility 
Components can 
be reliably 
sterilised 
Minimise infection 
routes 
Can be used in a 
biological safety 
cabinet 
Reproducible 
culture 
environment 
Fits inside 
incubator 
Allows gas and 
medium exchange 
High safety 
High mechanical 
safety 
Minimise/shield 
mechanical 
components 
Reduce traps and 
sharps 
High electrical 
safety 
Minimise powered 
components 
Use low voltage/ 
appropriate 
insulation 
Good operating 
characteristics 
Easy maintenance 
Maximise ability to 
disassemble  
Maximise 
maintenance free 
components 
Easy handling 
Minimise weight 
Minimise total 
volume 
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 Functional analysis 5.3.2
Based on the design brief, a functional analysis was performed to define the scope of 
the design process and the relevant inputs, sub-functions and outputs. Firstly, the 
overall function of the bioreactor design was expressed as a simple conversion of 
inputs (PGS-M scaffold + Cells) to outputs (TEVG). The overall function was then 
broken down into sub-functions. These included: sterilisation of the bioreactor before 
beginning the TEVG culture process, seeding the cells onto the PGS-M scaffold, 
culturing the seeded scaffold and applying mechanical stimulation (Figure 63). The 
design process now concentrated on generating solutions to these sub-functions.  
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Figure 63. Functional analysis of the dynamic culture bioreactor for TEVGs.  
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 Performance specification  5.3.3
A performance specification for the bioreactor design was produced (Table 11). This 
defined the precise limits within which the design solution would operate.  
Some design constraints were implicit at the outset of the design process. These 
included the cost of the final design and the maximum overall dimensions which were 
a function of the incubator (Sanyo MCO 175 CO2) and biological safety cabinet 
(Herasafe™, Heraeus, USA) the bioreactor would be operated in. The maximum mass 
of the final design was based on a single operator handling the bioreactor with one 
hand.  
It was decided that the bioreactor should be able to culture up to 3 TEVGs 
simultaneously. This would provide a suitable number of experimental replicates per 
bioreactor culture cycle, while minimizing the requirements for cells, growth medium 
and PGS-M scaffolds. The bioreactor should also be able to accommodate TEVGs of a 
maximum length of 80 mm and outer diameter of 5 mm. Grafts of this size would 
ultimately be suitable for a variety of characterisation procedures, such as burst 
pressure and compliance testing, along with implantation in a small animal model.352     
Modes of sterilisation were selected based on those available. A variety of methods 
were proposed, including liquid based disinfection and steam sterilisation by autoclave.   
A number of performance requirements were defined through the reviewing the 
literature. The minimum volume of growth medium the bioreactor could 
accommodate was selected based on the size of the culture chambers used in 
previously published bioreactors for TEVGs.95,98,122,226,336,353,354 These were considered 
to present better guidance than scaling up the medium requirements from in vitro cell 
culture methods on flat surfaces based on the number of cells estimated to populate 
the TEVGs.  
A number of studies on successfully generating TEVGs described using a cell seeding 
density of between 1 and 2 million cells per cm2 of scaffold surface. The bioreactor 
must therefore be able to accept this number of cells, for three scaffolds, in a single 
cycle of use.61,70,88,93 Additionally, in terms of mechanical stimulation, a cyclic radial 
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strain of 5-10% at a maximum of 180 Hz, applied to the TEVG was specified. This had 
proven to be a successful stimulation regime in a number of studies on TEVGs.61,70,84   
Performance attributes based on infection resistance, biocompatibility, material 
stability and safety were also defined.  
 
Table 11. Performance specification for the dynamic culture bioreactor for TEVGs. 
Attribute Specification 
Dimensions TEVG culture chamber <400 x 400 x 250 mm, to fit inside incubator and biological 
safety cabinet (reduced size preferred).  
Ancillaries <500 x 500 x 500 mm These may remain outside the incubator, connected to 
the TEVG culture chamber through its access ports.   
Mass Total system <8 kg (reduced weight preferred). 
Cost ≤£2,000 (reduced cost preferred). 
Disposable materials ≤ £30 per bioreactor culture. 
TEVG size Must be able to accommodate TEVGs of maximum 80 mm length and 5 mm diameter.  
Yield Must be able to culture up to 3 TEVGs per use cycle. 
Volume Must hold >300 ml of growth medium.  
Sterility Materials are resistant to 70% (v/v) ethanol in H2O, 0.5% (v/v) peracetic acid in H2O or 
autoclave at 121°C for 30 minutes for 1,000 sterilisation cycles.   
Disposable components must be purchased sterile and fitted in a biological safety 
cabinet.  
Cell seeding Seeding of cells permitted under sterile conditions or in a biological safety cabinet.  
Cell suspensions of 2 x 106 cells/cm2 of scaffold permitted.  
Seeding method distributes cells throughout the PGS-M scaffold.    
Mechanical stimulation Up to 5-10% cyclic radial strain applied to TEVG. 
Maximum frequency 180 Hz.  
Monitoring and measurement of stimulation regime permitted.  
Infection resistant  Growth medium contacting surfaces impermeable to water at 1 atm.  
Filters for gas exchange ≤ 0.22 µm pore size.  
Growth medium exchange permitted under sterile conditions or in a biological safety 
cabinet.  
Biocompatible Growth medium contacting surfaces are non-toxic. 
Stable/reusable  Materials are corrosion resistant and non-reactive with the growth medium. 
Materials will not alter significantly in terms of chemistry or mechanical strength at 
between 0 and 121°C. 
Disposable materials minimised.   
Safe No sharp edges.  
Electrical components fully insulated.  
Mechanical components shielded to prevent injury.  
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 Design solution generation and evaluation 5.3.4
Based on the functional analysis, the bioreactor design was separated into three 
sub-functions: cell seeding, TEVG culture and mechanical stimulation. While 
considering the design objectives and the performance specification, a number of 
initial design ideas were proposed to accomplish each sub-function (See Appendix). 
The success with which each of the initial designs would achieve the design 
requirements for the bioreactor was then quantified using a weighted objective 
evaluation matrix. The assessment criteria used for evaluating the initial designs for 
each sub-function of the bioreactor are shown in Table 12, Table 13 and Table 14.  
Weight factors for the assessment criteria and the scores for the initial design ideas are 
shown in Table 15,Table 16 and Table 17.  
 
Table 12. Assessment criteria for the initial design ideas for the bioreactor cell seeding 
sub-function.  
Assessment criteria Description 
Sterility Assessment of how successfully the design would maintain sterility 
during cell seeding.   
Cell viability Assessment of how successfully the design would maintain cell viability. 
Distribution on scaffold Assessment of how well the design would distribute cells on the PGS-M 
scaffold. 
Scaffold integrity Assessment of the potential for the scaffold to retain integrity during cell 
seeding.  
Operation Assessment of how easily the design may be used.  
Manufacture Assessment of how easily the design could be manufactured. 
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Table 13. Assessment criteria for the initial design ideas for the bioreactor TEVG 
culture sub-function.  
Assessment criteria Description 
Sterilisation Assessment of how easily the design could be successfully sterilised prior 
to beginning TEVG culture.  
Medium exchange Assessment of how easily growth medium could be removed and 
replaced without damaging the developing TEVGs and while maintaining 
sterility. 
Gas exchange Assessment of the potential for sufficient gaseous exchange during TEVG 
culture. 
TEVG harvest Assessment of how the design allows for the successful removal of the 
culture TEVG while retaining their viability and sterility.  
Handling and operation Assessment of how easily the design may be manipulated during use.  
Manufacture Assessment of how easily the design could be manufactured. 
 
 
Table 14. Assessment criteria for the initial design ideas for the bioreactor mechanical 
stimulation sub-function. 
Assessment criteria Description 
Accuracy Assessment of how accurately the mechanical stimulation could be 
applied.  
Repeatability Assessment of how successfully the mechanical stimulation regime could 
be repeated. 
Cell viability Assessment of how successfully the design would maintain cell viability. 
Scaffold integrity Assessment of the potential for the scaffold to retain integrity during 
stimulation. 
Operation Assessment of how easily the mechanical stimulation could be applied. 
Manufacture Assessment of how easily the design could be manufactured. 
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Table 15. Weighted objective evaluation matrix for the initial designs of the bioreactor 
cell seeding sub-function. 
 
The results of the weighted objective evaluation matrix for the initial designs for the 
cell seeding sub-function showed that design 2 appeared to be the most suitable 
solution. This design scored well due to its ease of manufacture and operation and its 
potential success in retaining cell viability and distributing cells evenly throughout the 
scaffold. The key aspect of this design was that cell seeding was proposed to be 
conducted outside of the bioreactor. This reduced the complexity of the seeding 
system by allowing standard cell culture equipment to be employed. Scaffolds would 
be seeded with cells intraluminally, using a pipette and forceps, in petri dishes. An 
even distribution of cells throughout the scaffold would be achieved simply by rotating 
the scaffolds manually during seeding. The seeded scaffolds would then be inserted 
into the bioreactor for further culture. This method of cell seeding did present the 
greatest potential for infection however, as any manipulation of the seeded scaffolds, 
even inside a biological safety cabinet, would increase the risk of acquiring infection. 
This risk was determined to be acceptable given the benefits in simplicity and 
operation that the design offered.  
 
Assessment criteria                               Initial designs 
 1 2 3 4 5 Weight factor 
Sterility 3 3 5 4 4 20 
Cell viability 5 5 3 5 4 20 
Distribution on scaffold 1 4 2 5 4 14 
Scaffold integrity 4 3 1 5 2 16 
Operation 4 4 5 4 3 12 
Manufacture 5 5 5 1 3 18 
Final score (weight 
factors applied) 
376 402 354 396 338  
Rank 3rd 1st 4th 2nd 5th  
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Table 16. Weighted objective evaluation matrix for the initial designs of the bioreactor 
TEVG culture sub-function.  
Assessment criteria                         Initial designs 
 1 2 3 4 Weight factor 
Sterilisation 5 4 3 5 22 
Medium exchange 3 3 5 1 20 
Gas exchange 4 5 5 4 14 
TEVG harvest 4 2 4 4 16 
Handling and operation 4 2 1 5 10 
Manufacture 4 1 2 5 18 
Final score (weight 
factors applied) 
346 274 318 320  
Rank 1st 4th 3rd 2nd  
 
The results of the weighted objective evaluation matrix for the initial designs of the 
bioreactor TEVG culture sub-function revealed that design 1 appeared to be the most 
suitable solution. This design was considered easy to successfully sterilise, with the 
potential to use ethanol, peracetic acid or autoclaving, and allowed for the TEVGs to be 
easily harvested at the completion of the culture period. Additionally, the design 
would be simple to manufacture and operate. Exchange of growth medium was 
permitted via an exchange bottle linked to the culture chamber. This represented the 
weakest area of the design. Although the bottle could be placed inside a biological 
safety cabinet for medium exchanges, this would increase the risk of infective agents 
entering the system. This risk was outweighed by the advantages in manufacturing and 
sterilisation that the design offered.  
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Table 17. Weighted objective evaluation matrix for the initial design ideas for the 
bioreactor mechanical stimulation sub-function. 
 
 The results of the weighted objective evaluation matrix for the initial designs of the 
bioreactor mechanical stimulation sub-function suggested that design 1 would be the 
most suitable solution. This design would be easy to operate and had the greatest 
potential for maintaining cell viability and scaffold integrity. The design applied a 
pulsatile flow of growth medium through each TEVG, producing cyclic radial strain and 
providing mechanical stimulation to the developing grafts. This was a proven method 
in the culture of TEVGs and represented a biomimetic solution where the natural 
environment of blood vessels was simulated.61,75,88,95,98,116,125,175 This would allow 
suitable parameters for flow rates and pressures to be suggested from the literature. 
The design would also be simple to manufacture, as the mechanical components to 
provide the pulsatile flow could be purchased as a single peristaltic pump unit 
designed for this purpose. An inline pressure transducer would allow the fluid pressure 
inside each TEVG to be measured without disrupting the culture. However, regular 
monitoring would be needed to ensure adjustments to the pressure could be made in 
order to maintain a constant level of mechanical stimulation.  
 
  
Assessment criteria Initial designs 
 1 2 3 4 5 Weight factor 
Accuracy 3 5 3 5 4 16 
Repeatability 3 5 3 5 4 16 
Cell viability 5 1 5 1 4 22 
Scaffold integrity 5 1 4 1 3 20 
Operation 5 3 5 2 1 12 
Manufacture 4 2 5 2 1 14 
Final score (weight 
factors applied) 
422 302 404 290 294  
Rank 1st 3rd 2nd 5th 4th  
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 Final design – Bioreactor design 1.1 5.3.5
The most suitable initial designs for the bioreactor sub-functions, identified using the 
weighted objective evaluation matrices, were integrated together into a final design 
for the bioreactor, Bioreactor design 1.1. A schematic drawing is shown in Figure 64.   
The design featured a single culture chamber capable of supporting up to 3 TEVGs at 
once, submerged in growth medium. PGS-M scaffolds would be seeded with cells and 
then connected to the bioreactor through on opening at the top of the culture 
chamber, covered by a lid. This would be performed in a biological safety cabinet to 
reduce the risk of infection. The reverse process would be used to harvest the TEVGs at 
the completion of the culture.  
The growth medium in the culture chamber would be exchanged through a bottle 
connected via a feed line. To fill the chamber, the medium exchange bottle would be 
placed inside a biological safety cabinet and filled with growth medium under sterile 
conditions. The medium would then be gravity fed into the culture chamber. The 
reverse of this process would be used to remove growth medium for exchange.  
Gaseous exchange between the bioreactor and the incubator would be achieved 
through sterile 0.22 µm filters attached to the culture chamber lid. These filters could 
be purchased sterile and attached to the bioreactor inside a biological safety cabinet. A 
filter was also fitted to the medium exchange tank to prevent air locks during the filling 
process.  
The culture chamber acted as the reservoir for the flow circuit that would provide 
mechanical stimulation to the TEVGs. The flow circuit ran from the chamber and 
passed through a peristaltic pump before branching into channels which connected to 
the TEVGs. Growth medium would be drawn from the culture chamber and pumped, 
as a pulsatile flow, through the lumens of the TEVGs before converging and returning 
to the culture chamber. A channel of the flow circuit also ran outside of the culture 
chamber, in parallel with the TEVGs, to allow the pressure transducer to be connected. 
A pressure control valve positioned downstream of the TEVGs would allow the 
intraluminal pressure to be modulated.   
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Figure 64. Schematic drawing of bioreactor design 1.1.  
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The performance requirements for the flow circuit in terms of pressure and flow rate 
were determined from the literature. A maximum pressure of 200 mmHg, a maximum 
flow rate of 15 ml/min and a maximum frequency of 3 Hz (180 beats per minute) were 
suggested.61,93,122 These values were within the physiological range of human blood 
flow.355 The assembled bioreactor could be sterilised by autoclave or by filling it with 
ethanol or peracetic acid and circulating these through the flow circuit.   
The bioreactor was assembled from a range of bespoke and pre-manufactured parts 
(Table 18). The use of pre-manufactured parts was maximised to reduce costs. In 
addition to this, certified or guaranteed components were selected, where possible, to 
improve the reliability of the bioreactor.    
The complete assembly of bioreactor design 1.1 is shown in Figure 65.  
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Table 18. Parts list for bioreactor design 1.1.   
Component Material/Product Manufactured/Purchased  Comments 
Culture chamber + lid Polycarbonate Manufactured Excellent strength, autoclavable, resistant 
to relevant chemicals (ethanol, peracetic 
acid, growth medium, H2O, PBS), easily 
machined, biocompatible, transparent.  
Tubing Pharmed BPT (flow circuit) 
Tygon ND 100-65 (TEVG 
channels and gaseous 
exchange lines) 
C-flex (flow circuit and 
feed line) 
 
Purchased (Cole-Parmer, UK) Autoclavable, chemically resistant to 
relevant chemicals (ethanol, peracetic 
acid, growth medium, H2O, PBS),  
biocompatible. 
Pharmed BPT – 10000 hour peristaltic 
pump life. 
Tygon ND 100-65 – highly flexible to aid 
seeded scaffold installation, transparent. 
C-Flex – highly flexible to aid pressure 
regulator valve action and medium 
exchange tank handling. 
Tubing fittings Nylon/Polypropylene Purchased (Cole-Parmer, UK) Autoclavable, available in a range of sizes. 
Growth medium 
exchange tank 
Borosilicate glass Manufactured  Autoclavable, transparent. 
Pressure regulator 
valve  
Polypropylene pinch valve Purchased (Cole-Parmer, UK) Autoclavable, screw action for precise 
control. 
Gate valve Polypropylene pinch valve Purchased (Cole-Parmer, UK) Autoclavable. 
Sterile filters Minisart®, Cellulose 
acetate filter 
Purchased (Sartorius stedim 
biotech, Germany) 
Pre-sterilised by gamma irradiation.  
Pump Masterflex L/S variable-
speed drive with Easy-
Load PPS, SS rotor pump 
head.  
Purchased (Cole-Parmer, UK) Variable speed control, compatible with 
various tubing sizes, 3-roller pump head 
utilised in published TEVG culture.61  
Pressure transducer MLT844 physiological 
pressure transducer  
Purchased (ADInstruments, 
UK) 
Pressure monitoring between -20 and 
300 mmHg. Measures pressure without 
contact with the flow (reduced infection 
risk).     
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Figure 65. Bioreactor design 1.1. (Above) components are labelled: TEVG culture 
chamber (a), flow circuit (b), TEVG channels (c), TEVGs (d), pressure transducer (e), air 
filters (f), pressure regulator valve (g), feed line (h), gate valve (i), growth medium 
exchange bottle (j). (Below) Bioreactor attached to the peristaltic pump. Scale bars are 
10 cm.  
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 Bioreactor leak testing 5.3.6
The fully assembled bioreactor was filled with H2O to examine it for leaks. Analogues 
for the PGS-M scaffolds, made from Tygon tubing, were inserted into the flow circuit 
and the peristaltic pump applied at 60 rpm, with the regulator valve set to produce a 
relative pressure of 200 mmHg within the flow circuit.  
In three consecutive tests over 24 hours, no leakage was detected between the 
bioreactor culture chamber and its lid or around the fittings which connected tubing 
within the flow circuit. On the initial test, some leakage was detected around the 
threaded fittings which were used to connect the various lines of tubing to the culture 
chamber. These fittings were subsequently reinforced using PTFE tape wrapped 
around their screw threads. No leakage was detected at these points in the following 
tests.  
The results demonstrated that the bioreactor was capable of functioning at the 
maximum operating pressure and flow pulse frequency designed for without leaking. 
The system was also robust and able to be manipulated and handled, in a similar 
fashion to during TEVG culture, without failure.  
 
 Bioreactor design sterility testing 5.3.7
The culture of TEVGs was simulated in the bioreactor to determine if a sterile 
environment could be maintained. The bioreactor was sterilised by autoclaving and 
then filled with fibroblast growth medium and incubated for 7 days. During this time 
no changes in the colour or clarity of the medium were observed. After 7 days, a 
sample of the medium was removed and a RR assay performed to determine if any 
metabolic activity was present. The results demonstrated no significant difference 
between the fluorescence produced by the samples of bioreactor medium and 
samples of medium cultured in parallel in a sterile container (positive control). This 
suggested that there was no metabolic activity present in the medium sample and that 
the bioreactor had remained sterile. The insertion of three PGS-M scaffolds was then 
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simulated, using analogues produced from sterile Tygon tubes (Figure 66). During the 
first repeat, after 3 days, the bioreactor appeared visibly infected with the growth 
medium pale and cloudy. An RR assay was not performed, in accordance with 
laboratory protocol. An RR assay was performed on the positive control sample, after 
7 days, and this had remained sterile (Figure 67). The experiment was repeated, this 
time with more stringent sterile conditions employed by using a surgical grade sterile 
gown and forceps. After 7 days of incubation, following the insertion of the scaffold 
analogues, the growth medium in the bioreactor appeared unchanged. However, the 
results of the RR assay suggested that an infection was present, with a significantly 
greater fluorescence value generated by the medium sample, compared to the 
controls (Figure 67). These results suggested that it was the insertion of the scaffold 
analogues that had compromised the sterility of the bioreactor. This process involved 
the culture chamber being opened for several minutes while the analogues were 
manipulated inside it. Although this was conducted in a biological safety cabinet, it was 
clear that infective agents were able to enter the bioreactor.  
 
Figure 66. Simulated insertion of PGS-M scaffolds into bioreactor design 1.1. Scale bar 
is 5 cm.  
 
 
 
Figure 67. RR assay for testing the sterility of bioreactor designs 1.1 and 1.2. In design 1.1, growth medium was incubated in the 
bioreactor for 7 days (n=2) or for 7 days following the simulated insertion of TEVGs (n=1). Controls were equivalent growth medium 
incubated in parallel in sterile conditions (n=2). In design 1.2, growth medium was incubated in the bioreactor for 7 days (n=3) or for 7 
days following simulated cell seeding (n=3). Controls were equivalent growth medium incubated in parallel in sterile conditions (n=3). 
Error bars are SEM.   
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In light of these results, the bioreactor design was modified to remove the need for 
PGS-M scaffolds seeded with cells to be inserted. This design had been selected 
because of the advantages that seeding the scaffolds outside of the bioreactor offered, 
allowing them to be manipulated more easily during seeding and also to be rotated 
easily to produce even cell coverage across their lumens. Based on a review of the 
initial designs for the cell seeding sub-function of the bioreactor and considering the 
current design, it was decided to add cell seeding ports to the TEVG flow channels. 
These ports could be opened to allow cell seeding onto PGS-M scaffolds already inside 
the sterile bioreactor. The bioreactor could also be placed on either side, following cell 
seeding, to encourage the attachment of cells to either side of the scaffold lumen to 
produce greater coverage. A schematic of the modified bioreactor, designated 
Bioreactor design 1.2, is shown in Figure 68. The cell seeding ports could be isolated 
from the flow circuit using 3-way stopcocks. This would ensure that during cell seeding, 
all of the suspended cells were directed towards the PGS-M scaffolds in the culture 
chamber.  
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Figure 68. Schematic drawing of bioreactor design 1.2. Cell seeding ports are in purple.  
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Additionally, it was noticed during the assembly of bioreactor design 1.2 that the 
polycarbonate culture chamber was displaying signs of stress cracking. These appeared 
to be focused around stress concentrations, such as the threaded holes which 
accepted fittings for the various tubing lines attaching to the culture chamber. It was 
determined that the most likely cause of these stress cracks was the autoclave 
sterilisation process which exerted high temperatures and pressures on the bioreactor. 
Although polycarbonate had been selected as the material for the culture chamber 
based on its ability to be autoclaved, it appeared that the design of the bioreactor had 
compromised this. As a result, an alternative sterilisation method using 0.5% peracetic 
acid was employed. This treatment had been shown to be biocidal, fungicidal and 
sporicidal and used successfully in a number of tissue engineering and biomaterial 
sterilisation processes.356–361 It had also been demonstrated that peracetic acid could 
be used to sterilise PGS-M structures without a significant effect on their mechanical 
properties. Therefore, using peracetic acid allowed the PGS-M scaffolds to be installed 
in the bioreactor culture chamber during the sterilisation process.  
The complete assembly of bioreactor design 1.2 is shown in Figure 69. 
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Figure 69. Bioreactor design 1.2. The modifications from the previous design are 
labelled: cell seeding ports (a) and 3-way stopcocks (b). Scale bar is 10 cm.  
 
Following successful leak testing of bioreactor design 1.2, sterility testing was 
performed. Tygon PGS-M scaffold analogues were inserted into the culture chamber 
and the bioreactor was sterilised using peracetic acid, before being filled with 
fibroblast growth medium and incubated for 7 days. As observed in bioreactor design 
1.1, no signs of infection were observed over this time period. Additionally, a RR assay 
performed on a sample of growth medium extracted from the bioreactor did not show 
any significant difference compared to the sterile control medium, cultured in parallel, 
both producing negligible fluorescence values (Figure 67). The process of seeding cells 
onto the PGS-M scaffolds, through the cell seeding ports, was then simulated. 
Following this the bioreactor was again filled with growth medium and incubated for 
7 days. Again, no signs of infection were observed over the incubation period. 
Additionally, unlike in the previous bioreactor design, the results of the RR assay also 
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suggested that the bioreactor had remained sterile, with only negligible fluorescence 
values generated, with no significant difference from the positive controls. The sterility 
tests were performed three times, with equivalent results. The modified design of the 
bioreactor, bioreactor design 1.2, could be successfully sterilised using, peracetic acid, 
and maintain sterility during simulated operation.      
 
 Bioreactor design 1.2 flow rate measurement 5.3.8
The flow rates in the different bioreactor channels were measured at 6, 20 and 60 rpm. 
The results are shown in Figure 70. The flow rates appeared to increase linearly with 
increasing pump rpm. No significant differences were seen between the flow rates in 
any of the channels at 6 and 20 rpm. At 60 rpm, the flow rates in all three TEVG 
channels were statistically significantly different from the pressure transducer channel 
(P<0.001, in all comparisons), but not significantly different from each other. The flow 
rate in the pressure transducer channel appeared to be significantly greater than in 
any of the TEVG channels.  
 
0 1 0 2 0 3 0 4 0 5 0 6 0 7 0
0
1 0
2 0
3 0
4 0
5 0
6 0
P e r is ta lt ic  p u m p  s p e e d  (rp m )
F
lo
w
 r
a
te
 (
m
l/
m
in
)
T E V G  c h a n n e l 1
T E V G  c h a n n e l 2
T E V G  c h a n n e l 3
P re s s u re  tra n s d u c e r
 
Figure 70. Bioreactor channel flow rates at 6, 20 and 60 rpm. Error bars are SEM (n = 3).   
*** 
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The maximum flow rate required in each channel was specified as 15 ml/min. This was 
achieved at ~20 rpm in all of the channels.  
The difference in flow rates may have been due to the differences between the 
designs of the channels. The three TEVG channels were all of equal length and 
composition (tubing material, fittings and TEVG analogue). The pressure transducer 
channel was different to the TEVG channels. It did not feature the same fittings, as it 
did not have cell seeding ports, it was not required to pass through the bioreactor 
culture chamber, and had a port for the attachment of the pressure transducer, 
instead of a TEVG analogue. The differences between the designs of the pressure 
transducer channel and the TEVG channels may have had an effect on the pressure 
losses experienced within the flow passing through them. The greater number of 
fittings may have caused greater pressure losses in the TEVG channels compared to 
the pressure transducer channel. All of the fittings had a smaller internal diameter 
than the tubing attached to them. This change in diameter, and thus flow cross-section, 
would have likely resulted in some disturbance of the flow, in the form of turbulence, 
and therefore resulted in pressure losses across the TEVG channels. With fewer fittings, 
the pressure transducer channel experienced a lower pressure drop. The effect of 
pressure losses on flow rate is demonstrated by considering  ernoulli’s principle 
(Equation 1).  
 
1
2
𝜌(𝐶2
2 − 𝐶1
2) + 𝜌𝑔(𝑧2 − 𝑧1) + 𝑃2 − 𝑃1 + 𝑃𝐿𝑜𝑠𝑠 = 0 
 
Equation 1.  ernoulli’s principle for steady flow with losses. Fluid density (ρ), fluid 
pressure (P), fluid velocity (C), elevation (z), acceleration due to gravity (g).  
 
All of the bioreactor channels were supplied by the same peristaltic pump and during 
the measurement of their flow rates they exhausted into the atmosphere, therefore 
the difference in pressure between the flow inlet and outlet (P2 – P1) was the same for 
all of the channels. Additionally, all of the channels were horizontal and at equal 
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heights during the flow rate measurements, therefore any difference in elevation 
could be discounted. Subsequently, any change in fluid velocity (flow rate) is a result of 
pressure losses only, with increased pressure losses resulting in a reduced fluid velocity. 
The equation assumes that the fluid is incompressible, which is a robust assumption 
for dH2O at atmospheric pressure and temperature. The equation also assumes that 
the flow is steady. The peristaltic pump did not produce a completely steady flow. 
Instead, a pulsatile flow was generated due to the action of the rollers which moved 
the fluid. However, it was assumed that the flow within each fluid pulse was steady 
and therefore the assumption was valid.  
The difference between the flow rates observed in the TEVG channels and the 
pressure transducer channel were acceptable within the parameters of the bioreactor 
design. Critically, the flow rates within the TEVG channels were not significantly 
different. This would insure that during culture of TEVGs each graft would be subjected 
to comparable flows and therefore would be comparable to each other when analysed. 
The pressure transducer channel was designed to allow the pressure inside the TEVG 
channels, and therefore inside the TEVGs, to be measured. The reduced pressure 
losses generated by this channel may result in an overestimate of the pressure in the 
TEVG channels. This could be accounted for during the bioreactor culture and could 
also be considered to provide a degree of safety against over-pressurising the TEVGs 
during culture.     
The design of the bioreactor could have been improved by adding in-line flow rate and 
pressure monitoring (non-invasive) to each individual TEVG channel. This could be 
accompanied by valves to allow adjustments to be made to the flow in each channel. 
This would have added complexity to the design, but would likely result in a more 
uniform flow regime within the TEVGs. 
 
 Mechanical stimulation 5.3.9
Modulation of the pulsatile flow, generated by the peristaltic pump, was examined to 
determine if the system was suitable for applying mechanical stimulation to the TEVGs 
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during culture. Using the pressure transducer, the pulsatile flow was measured at 6, 20 
and 60 rpm with the relative intraluminal pressure set at 0, 50 and 200 mmHg using 
the pressure regulator valve.  
It was shown that the pressure pulse could be modulated between the rpm and 
pressure range examined (Figure 71). At a given rpm, the intraluminal pressure could 
be accurately altered using the pressure regulator valve. With the regulator valve fully 
open, only a small fluctuation in pressure was observed in the flow at 6 and 20 rpm 
(~-2-3 and ~-4-7 mmHg, respectively), however, at 60 rpm, the pulse ranged from 
~-10-45 mmHg. With the regulator valve set to deliver a maximum pressure of 
50 mmHg, a similar pressure variation was seen across all three pump speeds, 
although at 20 and 60 rpm, a small period of negative pressure was generated at the 
end of each pulse (~-7 and ~-10 mmHg, respectively). Finally, when the regulator value 
was set to deliver a maximum pressure of 200 mmHg, the pressure pulse remained 
positive throughout. The pressure range covered in a single pulse increased with 
increasing rpm, from amplitudes of ~120 mmHg to ~140 mmHg at 6 and 60 rpm, 
respectively.  
As the speed of the peristaltic pump increased, the time between each roller acting on 
the fluid decreased, resulting in shorter periods when the pump was not applying 
pressure. Therefore each pressure pulse was unable to subside and return to a 
near-zero pressure value before the following pulse began.        
The results demonstrated that a pressure pulse ranging from 0-200 mmHg could not 
be generated in the bioreactor flow circuit at between 6 and 60 rpm. The maximum 
range possible was from ~60-200 mmHg at 60 rpm. A maximum flow pressure of 
200 mmHg was specified as a design target for the bioreactor, based on similar designs 
in the literature. However, the pressure pulse amplitude was not considered. 
Engbers-Buijtenhuijs et al. did report using a pressure wave form ranging from 61 to 
124 mmHg in the culture of TEVGs based on collagen and elastin scaffolds. This range 
had been selected based on the physiological blood pressure range in humans. 
Considering the biomimetic nature of the bioreactor herein, it was suggested that its 
performance would generate a suitable pressure range for applying mechanical 
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stimulation to TEVGs during culture. The maximum healthy blood pressure range 
within adult humans is 120 mmHg systolic to 60 mmHg diastolic and the average heart 
rate is 50-80 beats per minute. In adolescence, blood pressure is at its highest, ranging 
from 140 mmHg systolic to 60 mmHg diastolic at 60-105 beats per minute. In 
newborns, blood pressure is lower, at 100 mmHg systolic to 50 mmHg diastolic, but 
heart rate is at its fastest, at 100-160 beats per minute.355 Considering these values 
and converting the pump rpm to beats per minute by multiplying by 3, due to the 3 
rollers in the pump head, all of these pressure and frequency ranges could be 
produced by the bioreactor. The design, therefore, represented a suitable system for 
applying biomimetic mechanical stimulation to TEVGs.  
It may be possible that TEVG development may actually be enhanced by mechanical 
stimulation operating outside of the normal human blood pressure and flow ranges. 
This may be examined to some degree using the current design of the bioreactor, as 
both the pressure and flowrate could be increased beyond the physiological values.  
 
It was also noted that the pressure wave forms generated by the peristaltic pump 
appeared to be noisy. This was most apparent at 6 and 20 rpm, with smoother profiles 
generated at 60 rpm. This was likely a result of friction between the rollers of the 
peristaltic pump head and the flow circuit tubing. This friction was overcome as the 
rpm increased, resulting in a smoother application of pressure to the circulating fluid 
and a smoother pressure wave profile. Given the erratic pressure waveforms that 
natural blood vessels, in vivo, are subjected to as a result of the cardiac cycle, this was 
not considered to be potentially detrimental to the culture of the TEVGs.355     
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Figure 71. Bioreactor flow circuit relative pressure at pump speeds of 6, 20 and 60 rpm. 
The maximum relative pressure was modulated using the regulator valve and set to 
deliver 0 (fully open), 50 and 200 mmHg.  
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 Conclusions 5.4
The design brief proposed at the beginning of this chapter was to produce a bioreactor 
cable of supporting the growth and development of TEVGs in vitro. The TEVGs would 
be composed of porous PGS-M scaffolds seeded with cells. The bioreactor culture 
environment would be regulated by an incubator and the bioreactor had to culture the 
TEVGs under dynamic conditions and apply mechanical stimulation. 
 
The design process reported yielded a bioreactor that satisfied the design brief. It was 
demonstrated that bioreactor design 1.2 could be successfully sterilised and 
maintained a sterile environment throughout the simulated culture of a TEVG. The 
bioreactor was also capable of providing mechanical stimulation to the developing 
TEVGs, through a pulsatile flow. This flow could be modulated to produce pressures 
and flow rates within the range of physiological blood flow which were appropriate for 
the culture of TEVGs.  
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Chapter 6 - Bioreactor culture of TEVGs 
 Introduction 6.1
In the previous chapters, tubular scaffolds suitable for supporting the growth of TEVGs 
in vitro were fabricated from 30% Low Mw PGS-M. Additionally, a bioreactor capable of 
supporting the culture of TEVGs under dynamic conditions, through the application of 
mechanical stimulation, was designed and manufactured.     
In this chapter, the technologies described previously are combined to produce TEVGs 
in vitro. Tubular PGS-M scaffolds were seeded with SMCs and cultured under dynamic 
and static conditions, for 7 days, as TEVGs. These grafts were then examined for cell 
proliferation, phenotype and ECM content to determine the effect of the different 
culture methods.    
 
 
 Materials and Methods 6.2
In the following methods, all chemical reagents were obtained from Sigma Aldrich, UK 
unless otherwise stated. These reagents were measured and utilised in inert vessels.  
 
 Sterilisation of tubular PGS-M scaffolds 6.2.1
Tubular scaffolds, 30 mm in length, were produced from 30% Low Mw PGS-M 
combined 1:3.8 with sucrose porogens (mixed size, 1:1 blend of 50-100 µm and 38-
50 µm), using method v as described in (‎4.2.13).  
Three different methods of sterilising the scaffolds were examined. In the first method, 
the PGS-M scaffolds were swelled by immersion in a 70% ethanol in dH2O solution for 
24 hours. The barbed ends of female luer x 1/8” hose barb nylon fittings (Cole-Parmer, 
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UK) were then inserted into each end of the swollen scaffolds. The scaffolds, with 
attached fittings, were then immersed in dH2O. This caused them to contract and 
shrink around the fittings. This prevented the fittings from being pulled out of the 
scaffolds during handling. The scaffolds remained in dH2O for 72 hours, with the dH2O 
refreshed every 24 hours. After this time, the scaffolds were sealed in autoclave bags 
and sterilised by autoclave at 121°C for 30 minutes.  
In the second sterilisation method, the PGS-M scaffolds were again placed in the 
ethanol solution; however, this was refreshed every 24 hours, three times, under 
sterile conditions inside a biological safety cabinet. After the third ethanol wash, 
female luer x 1/8” hose barb nylon fittings which had been sterilised by autoclave, at 
121°C for 30 minutes, were inserted, using the barbed end, into each end of the 
scaffolds using forceps. The scaffolds were then soaked in sterile dH2O for 24 hours, 
three times.  
In the final sterilisation method, the scaffolds were prepared as described in the first 
method, except instead of autoclave bags, the scaffolds were placed in 50 ml of dH2O 
inside borosilicate glass bottles and autoclaved, while submerged, at 121°C for 
30 minutes. These scaffolds were subsequently incubated in SMC growth medium, 
prepared as described in (‎3.2.3) for 24 hours, with parallel samples of control medium 
also incubated.   
 
 Sectioning of PGS-M scaffolds/TEVGs 6.2.2
Fixed scaffolds/TEVGs were immersed in OCT compound (Tissue-Tek, Sakura, Japan) 
and frozen at -20°C. Frozen samples were mounted on stubs and cryosectioned (Lieca 
CM1860 UV), at -25°C, across their cross-sections, at a thickness of 5 µm. Sections 
were mounted on glass slides (Superfrost® Plus, Menzel-Gläser, Germany) and, after 
24 hours, rinsed in dH2O to remove the OCT compound.      
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 H&E staining of sections of PGS-M scaffolds/TEVGs 6.2.3
Sections of PGS-M scaffolds/TEVGs, prepared and affixed to glass slides as described in 
(‎6.2.2), were immersed in Modified Harris haematoxylin solution for 90 seconds and 
then rinsed in H2O for 4 minutes. They were then immersed in eosin Y solution for 
5 minutes before being rinsed with H2O, twice, followed by 70%  IMS (Fisher Scientific, 
UK) solution in H2O, then IMS and then Xylene. Samples were then coated with DPX 
mountant, covered with glass coverslips and allowed to dry for 12 hours. The sections 
were imaged using light microscopy (Zeiss Stemi 305 for low magnification, Motic B5 
professional series for higher magnification). Staining was conducted on quadruplicate 
sections taken from each scaffold/TEVG sample.  
Sections of human umbilical cord, prepared as described in (‎3.2.10), were also stained 
for use as positive controls.  
 
 RR assay on used SMC growth medium 6.2.4
Samples of used SMC growth medium, taken from the PGS-M scaffold sterilisation 
experiments or the bioreactor cultures, were examined for metabolic activity using the 
RR assay. Associated samples of control growth medium which had been incubated in 
parallel to the scaffold sterilisation experiments and bioreactor cultures were also 
examined. 0.0251 (w/v) resazurin sodium salt was dissolved in dH2O and the solution 
filter sterilised using a 0.22 µm filter. The resazurin solution was mixed 10% (v/v) with 
triplicate samples of used SMC growth medium, and associated control medium, and 
placed in an incubator. Additionally, equivalent samples of resazurin-containing fresh 
SMC growth medium were also incubated, in parallel, for use as a blank. After 4 hours, 
all samples were removed from the incubator and 200 µl of solution was extracted 
from each, in triplicate, and placed in the wells of a 96-well plate. This plate was then 
read using a fluorescence plate reader (Bio-tek instruments FLX800) at 540 nm 
excitation and 635 nm emission, with the reading from the blank subtracted. 
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Results were analysed using two way ANOVA with Tukey multiple comparisons analysis. 
P<0.05 was considered significant (*), P<0.01 was considered very significant (**) and 
P<0.001 was considered extremely significant (***).  
 
 Seeding of SMCs onto tubular PGS-M scaffolds 6.2.5
Triplicate PGS-M scaffolds were sterilised by autoclave while immersed in dH2O, as 
described in (‎6.2.1). They were then placed, individually, in petri dishes (100 x 25 mm, 
Fisher Scientific, UK) containing 60 ml of SMC growth medium and incubated at 37°C 
and 5% CO2 for 24 hours, in preparation for cell seeding.  
Human coronary artery SMCs (Promocell, Germany) were expanded on TCP in flasks, 
as described in (‎3.2.5). SMCs between passage 9 and 10 were harvested using trypsin 
(0.025%)/EDTA (0.01%) solution at 0.067 ml/cm2 of culture area. This was quenched 
after 5 minutes with an equal volume of trypsin inhibitor (PromoCell, Germany) and 
the cell suspension centrifuged at 1200 rpm for 4 minutes (Hettich Zentrifugen Rotofix 
32A with 131 mm rotor radius) before being resuspended in SMC growth medium at 
13.6 x 106 cells/ml.   
Using a pipette and forceps, the suspended SMCs were seeded intraluminally onto the 
PGS-M scaffolds in their petri dishes, following the removal of the growth medium. 
110 µl of the cell suspension was applied to the lumen of each scaffold, this would 
result in a seeding density of 2 x 106 cells/cm2 of lumen surface area.70,88,93 The 
scaffolds in petri dishes were returned to the incubator for 6 hours, to allow for cell 
attachment. After this time, 60 ml of SMC growth medium was applied to each petri 
dish before being returned to the incubator again. After 12 hours, the growth medium 
was removed from the petri dishes and the scaffolds rotated axially 180°. Cell seeding 
was then repeated, as previously, and the scaffolds incubated for 6 hours again, before 
being immersed in 60 ml of growth medium, in their petri dishes, and incubated for a 
further 12 hours. Finally, all scaffolds were rinsed with PBS, three times, and then fixed 
with 3.7 % formaldehyde (methanol free) for 24 hours. After this, they were rinsed 
with PBS, three times, and stored in PBS until analysed.      
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Unseeded scaffolds acted as negative controls. These were incubated, rotated and 
fixed in an equivalent manner to the cell seeded scaffolds, except with cell-free SMC 
growth medium applied to their lumens. Experiments were performed in duplicate.  
 
 Bioreactor culture of TEVGs under dynamic and static conditions. 6.2.6
Bioreactor design 1.2, as described in (‎5.3.7), was assembled with triplicate, 30 mm 
long, tubular PGS-M scaffolds inserted into the TEVG channels of the flow circuit. The 
scaffolds were sterilised by autoclave while immersed in dH2O, as described in (‎6.2.1), 
prior to insertion into the bioreactor. The bioreactor was then sterilised using 0.5% 
peracetic acid, as described in (‎5.2.9). Following this, the bioreactor was filled with 500 
ml of SMC growth medium, using the growth medium exchange bottle, and placed in 
an incubator at 37°C and 5% CO2 for 24 hours.  
SMCs were then seeded onto the PGS-M scaffolds inside the bioreactor culture 
chamber. Working inside a biological safety cabinet, the growth medium was 
withdrawn from the bioreactor culture chamber into the exchange bottle and held 
there by closing the gate valve. The TEVG channels were isolated from the flow circuit, 
using the three-way stopcocks, and the cell seeding ports opened. SMCs, between 
passage 9 and 10, were cultured and suspended in SMC growth medium as described 
in (‎6.2.5). 110 µl of the cell suspension was then injected into each of the cell seeding 
ports, using a pipette. A sterile syringe was then attached to each port and depressed 
to move the 110 µl volume of growth medium down the TEVG channels and into the 
PGS-M scaffolds. The seeding ports were then closed and the TEVG channels reopened 
to the flow circuit. The bioreactor was then returned to the incubator with the culture 
chamber placed down on one of the sides that was parallel with the scaffolds axis of 
rotation. After 6 hours, the gate valve was opened and the SMC growth medium 
returned to the culture chamber. After a further 12 hours, the growth medium was 
once again withdrawn into the exchange bottle and the cell seeding process repeated. 
This time, the bioreactor culture chamber as placed down in the incubator on the 
opposite side to the previous occasion. Again, after 6 hours, the growth medium was 
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released back into the culture chamber. After a further 12 hours, the flow circuit outlet 
line was run through an access port in the incubator door and fitted to the peristaltic 
pump. For dynamic culture, where mechanical stimulation was applied to the TEVGs by 
a pulsatile flow, the peristaltic pump was then activated at 6 rpm with the pressure 
regulator valve set to deliver a relative pressure of 10 mmHg inside the TEVG channels, 
measured using the pressure transducer. Over the next 7 days, the pump and pressure 
were altered as described in Table 19. After 7 days, the pump was deactivated and the 
growth medium withdrawn from the culture chamber into the exchange bottle. 
Working inside a biological safety cabinet, the culture chamber was opened and the 
scaffolds, now considered TEVGs, were removed using forceps and rinsed with PBS, 
three times, before being fixed with 3.7 % formaldehyde (methanol free) for 24 hours. 
After this, they were rinsed with PBS, three times, and then cut into three equal 
lengths and stored in PBS until analysed.  
TEVGs were also cultured under static conditions. In this case, the bioreactor was 
assembled and seeded with cells as described above, however the pump was only 
activated for 1 minute, to fill the flow circuit with growth medium. The pump remained 
off for the remaining 7 days of the culture.  
Additionally, unseeded PGS-M scaffolds were also cultured to act as negative controls. 
These were cultured as described for the seeded scaffolds under dynamic conditions, 
however, without cells seeded onto them. Instead, 110 µl of fresh SMC growth 
medium was injected into each of the cell seeding ports.  
TEVGs cultured under static conditions and unseeded negative controls were fixed and 
cut into three equal lengths as described for the TEVGs cultured under dynamic 
conditions. 
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Table 19. Pump speed and pressure regime for TEVGs under dynamic culture.  
Day Peristaltic pump speed (rpm) Relative pressure in TEVG 
channels (mmHg) 
1 6 10 
2 6 12 
3 7 15 
4 7 18 
5 8 21 
6 9 24 
7 10 27 
 
 
 Staining of TEVGs for collagen 6.2.7
Sections of TEVGs were prepared as described in (‎6.2.2). Staining was performed with 
Sirius red. Direct red 80 was dissolved at 1 mg/ml in saturated aqueous picric acid to 
produce the stain. The stain was applied to dry sections and left for 18 hours at room 
temperature. The sections were then rinsed with H2O, twice, followed by 70% IMS 
(Fisher Scientific, UK) solution in H2O, then IMS and then Xylene. Samples were then 
coated with DPX mountant, covered with glass coverslips and allowed to dry for 12 
hours. The sections were imaged using light microscopy as described in (‎4.2.11). 
Staining was conducted on quadruplicate sections taken from each TEVG sample.  
Sections of human umbilical cord, prepared as described in (‎3.2.10), were also stained 
for use as positive controls.  
 
 Collagen visualisation and quantification using second harmonic generation 6.2.8
Sections of TEVGs cultured under dynamic and static conditions for 7 days in the 
bioreactor were prepared as described in (‎6.2.2) and dried at room temperature. The 
sections were examined for the presence of collagen by examining second harmonic 
generation (SHG) using a laser-scanning confocal microscope (Zeiss LSM 510 Meta) 
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attached to a tuneable (700–1060 nm) Chameleon Ti:sapphire multiphoton laser 
(Coherent, USA). The multiphoton illumination wavelength was set at 50% 950 nm. 
SHG emissions were collected in a 10 nm bandpass filter centred around 474 nm. All 
imaging was performed using a 40x 1.3 NA oil immersion objective with the pinhole set 
to 1000 µm. SHG was collected in the backward direction after filtration through a 
primary dichroic (HFT KP650). Transmitted light DIC images were collected in tandem 
to assist subsequent image analysis. Imaging parameters were optimised and 
maintained for all samples. 
Three images were taken from triplicate sections from each of the three lengths that 
the TEVGs were divided into following fixation, unless otherwise stated. Imaging was 
focused on areas of the TEVGs which showed the presence of cells. Additionally, the 
unseeded TEVGs cultured for 7 days in the bioreactor under dynamic conditions, as 
negative controls, were also examined to determine the SHG signal produced by the 
PGS-M scaffold alone.  
 
Collagen content was quantified using image analysis software (ImageJ, version 1.45s) 
to determine the SHG signal strength. Firstly the background signal strength was 
determined by selecting 50 random sections from the background of the SHG images 
and averaging their signal intensities. Sections were selected using the transmitted 
light DIC counterpart images for guidance (Figure 72a). Next, the signal strength 
generated from the PGS-M scaffold was determined by selecting 50 random sections 
from the scaffold in the SHG images and averaging their signal intensities (Figure 72b). 
Finally, the signal strength generated from the regions of cells present in the TEVGs 
was determined by selecting 50 random sections from these regions in the SHG images 
and averaging their signal intensities (Figure 72c) The average background signal was 
then subtracted from the average signals calculated for the scaffold and the cellular 
regions. 
The results were statistically analysed using two-way ANOVA with Tukey multiple 
comparisons analysis. P<0.05 was considered significant (*), P<0.01 was considered 
very significant (**) and P<0.001 was considered extremely significant (***).   
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Figure 72. TEVG collagen quantification using transmitted light DIC (left) and SHG (right) 
images. (a) Background areas selected, (b) PGS-M scaffold selected, (c) Regions of cells 
selected. All images were processed using equal display settings. Scale bars are 50 µm. 
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 Staining of TEVGs for elastin 6.2.9
Sections of TEVGs were prepared as described in (‎6.2.2). For staining, the sections 
were first rinsed in dH2O, twice, followed by rinsing in a 95% solution of IMS in dH2O, 
twice. The sections were then stained with Miller’s Elastin stain (VWR, UK) for 
1.5 hours, before being rinsed again in a 95% IMS solution, twice, followed by dH2O, 
twice, to remove excess stain. The sections were then rinsed in 70% IMS (Fisher 
Scientific, UK) solution in H2O, then IMS and then Xylene. Finally, the sections were 
coated with DPX mountant and coverslips applied over them. They were examined by 
light microscopy, as described in (‎4.2.11).   
Sections of human umbilical cord, prepared as described in (‎3.2.10), were also stained 
for use as positive controls.  
 
 Immunofluorescence staining of TEVGs for α-SMA 6.2.10
Sections of TEVGs were prepared as described in (‎6.2.2) and dried at room 
temperature. The staining process then began by permeablising the samples with 
100 µl of a 0.5% (v/v) solution of Triton X 100 (Fisher Scientific, UK) in PBS. After 1 hour 
of permeablisation, the Triton X 100 solution was removed and the samples washed 
with PBS, three times, before being blocked with 100 µl of a 5% (w/v) solution of BSA 
in PBS. After 1 hour, the BSA solution was removed and 100 µl of a 0.2% (v/v) 
anti α-SMA mouse monoclonal antibody conjugated with Cy3™ and 5% (w/v)  SA in 
PBS solution was added to each sample. After incubation at room temperature, in the 
absence of light, for 2 hours the antibody solution was removed and the sections again 
washed with PBS, three times, followed by once with dH2O, to remove any remaining 
salts. The sections were then imaged, using a fluorescence microscope (Olympus IX73) 
with 550-570 nm excitation and 600-660 nm emission.  
Various controls were also produced and imaged. TEVG sections, containing SMCs, that 
were fixed, permeablised and blocked, but not treated with antibody were used to 
establish the effect of any background fluorescence. Additionally, fixed unseeded 
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TEVGs were stained and left unstained to act as negative controls. Staining was 
conducted on quadruplicate sections taken from each of the three lengths that the 
TEVGs were divided into following fixation, unless otherwise stated.  
Sections of human umbilical cord, prepared as described in (‎3.2.10), were also stained 
for use as positive controls.  
 
 Immunofluorescence staining of TEVGs for calponin 6.2.11
Sections of TEVGs were prepared, permeablised and blocked as described in (‎6.2.10). 
Following the removal of the BSA blocking solution, 100 µl of a 0.4% (v/v) 
anti calponin 1 rabbit polyclonal antibody conjugated with FITC (Insight Biotechnology, 
UK) and 5% (w/v) BSA in PBS solution was added to each sample. After incubation at 
room temperature, in the absence of light, for 2 hours the antibody solution was 
removed and the sections again washed with PBS, three times, followed by once with 
dH2O, to remove any remaining salts. The sections were then imaged, using a 
fluorescence microscope (Olympus IX73) with 480-500 nm excitation and 510-550 nm 
emission.  
Controls were also produced as described in (‎6.2.10). Staining was conducted on 
quadruplicate sections taken from each of the three lengths that the TEVGs were 
divided into following fixation, unless otherwise stated.  
Sections of human umbilical cord, prepared as described in (‎3.2.10), were also stained 
for use as positive controls.  
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 Results 6.3
 Sterilisation of tubular PGS-M scaffolds 6.3.1
The PGS-M scaffolds required sterilisation prior to cell seeding. Initially, this was 
conducted using autoclaving, with the scaffolds in autoclave bags. Although this 
method had proven successful in the sterilisation of porous PGS-M disks, as described 
in (‎4.2.9), the tubular scaffolds suffered deformation as a result of the process. The 
scaffolds appeared to shrivel and were no longer able to retain a tubular shape (Figure 
73). They had also become damaged and torn around the ends which were fitted over 
the nylon fittings.  
As a result, an alternative sterilisation method was sought. Scaffolds were 
subsequently sterilised using triplicate washes in a 70% ethanol solution in dH2O. This 
process did not appear to compromise the integrity of the scaffolds. However, after 
attempts at seeding cells onto them, an examination of the sectioned scaffolds 
suggested that they carried an infection. H&E staining revealed cellular bodies around 
the exterior of the scaffolds. These stained strongly purple and appeared to possess 
filamentous structures, possibly suggesting a fungal organism (Figure 74). This 
infection presented in two separate seeding experiments. 
To avoid repeated infections, sterilisation by autoclave was reemployed; however, the 
scaffolds were now immersed in dH2O throughout the process. This prevented them 
from deforming and becoming damaged as had been observed previously. Subsequent 
sectioning of the scaffolds sterilised in this manner did not show any signs of infection 
(Figure 75). Additionally, SMC growth medium incubated in the presence of these 
scaffolds for 24 hours did not show any significant difference compared to control 
growth medium, incubated in parallel without contact with the scaffolds, when 
examined using the RR assay. The results of the RR assay showed both medium 
samples generated negligible fluorescence values, suggesting that no metabolic 
activity was present in the medium (Figure 76).   
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Figure 73. Representative image of a tubular PGS-M scaffold sterilised by autoclave in 
an autoclave bag. The scaffold deformed and shrivelled resulting in damage and 
tearing around the interface with the nylon fittings (arrowed). Scale bar is 1 cm.  
244 
 
 
Figure 74. Representative H&E stained images of tubular PGS-M scaffolds sterilised by 
70% ethanol treatment and seeded with SMCs (n = 2). (Above) Scaffold cross-sections 
showed cellular bodies present around the exterior of the scaffolds. No cells appeared 
to be present on the luminal surface. Scale bar is 1 mm. (Below) Cellular bodies 
appeared to possess filamentous structures. Scale bar is 250 µm.  
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Figure 75. Representative H&E stained image of a tubular PGS-M scaffold sterilised by 
autoclave while immersed in dH2O (n = 3). No evidence of infection was present 
throughout the scaffold after incubation in SMC growth medium for 24 hours. Scale 
bar is 1 mm.  
 
Figure 76. RR assay for metabolic activity in SMC growth medium incubated in the 
presence or absence (control) of tubular PGS-M scaffolds sterilised by autoclave while 
immersed in dH2O. Error bars are SEM (n = 3).  
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 Seeding of SMCs onto tubular PGS-M scaffolds 6.3.2
The seeding of SMCs onto the luminal surfaces of tubular PGS-M scaffolds was 
conducted in petri dishes, before it was attempted in the bioreactor (Figure 77). 
Scaffolds were seeded with SMCs, at a density of 2 x 106 cells/cm2 of lumen. This was 
conducted twice with the scaffolds rotated 180° about their axis of rotation between 
seeding procedures.  
 
Figure 77. Tubular PGS-M scaffolds with attached nylon fittings seeded with SMCs and 
cultured in petri dishes. Scale bar is 1 cm.  
 
The seeded scaffolds demonstrated the presence of attached SMCs. Sections stained 
with H&E showed cell masses clearly visible in all seeded scaffolds (Figure 78). Cells 
covered a large proportion of the luminal surface, but were concentrated at opposing 
sides. Cell invasion into the interior of the scaffold wall was also present in some areas. 
Unseeded negative control scaffolds, cultured in parallel in equivalent conditions, did 
not show any evidence of SMCs (Figure 79).  
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Figure 78. Representative images of sections of tubular PGS-M scaffolds seeded with 
SMCs (n = 2). (Above) SMCs attached around the luminal surface and were 
concentrated at opposing sides. Scale bar is 1 mm. (Below) SMCs invaded into the 
scaffold wall in some areas. Scale bar is 200 µm. 
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Figure 79. Representative image of unseeded tubular PGS-M scaffolds (negative 
controls) (n = 2). No evidence of SMCs was present. Scale bar is 1 mm.  
 
 Bioreactor culture under dynamic and static conditions. 6.3.3
Tubular PGS-M scaffolds were positioned inside bioreactor design 1.2 and seeded with 
SMCs, via the cell seeding ports. Seeding was conducted twice, at a cell density of 
2 x 106 cells/cm2 of lumen, with the bioreactor rotated 180° about the rotational axis 
of the scaffolds between seeding procedures. The seeded scaffolds, now referred to as 
TEVGs, were cultured for 7 days in the bioreactor under dynamic conditions with a 
pulsatile flow of incrementally increasing pressure and flow rate (Figure 80). The TEVGs 
maintained structural integrity throughout the culture. They could be seen to visibly 
deform and pulsate as a reaction to the flow moving through them. After 7 days the 
scaffolds were fixed and divided into three equal lengths for analysis. No evidence of 
infection was seen throughout the bioreactor culture, with the medium retaining its 
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clarity and colour. Additionally, a sample of the used SMC growth medium was taken 
from the bioreactor and tested for the presence of metabolic activity using the RR 
assay. This was compared to a sample of SMC growth medium cultured in parallel to 
the bioreactor. The results of the RR assay showed no significant difference between 
the two samples of medium. Both samples generated negligible fluorescence values, 
suggesting that no metabolic activity was present in the medium (Figure 81).  
 
 
 
Figure 80. Bioreactor culture of TEVGs under pulsatile flow. Scale bar is 2 cm.  
  
 
The three replicate TEVGs cultured under pulsatile flow in the bioreactor showed 
differing results (Figure 82). The TEVG attached to TEVG channel 1 of the bioreactor 
did not show any evidence of cells. 5 µm sections, stained for H&E, taken from each of 
the three lengths of the TEVG did not show any evidence of cells. The TEVG attached 
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to TEVG channel 2 of the bioreactor did not show any evidence of cells in the first two 
lengths, most proximal to the peristaltic pump. However, there were some small 
regions of cells attached to the scaffold lumen visible in H&E stained sections taken 
from the third length of the graft, most distal to the peristaltic pump. Finally, the TEVG 
attached to TEVG channel 3 of the bioreactor did not show any evidence of cells in first 
two lengths, most proximal to the peristaltic pump. However, there was considerable 
evidence of cells present in H&E stained sections taken from the third length of the 
graft (Figure 83). The cells appeared isolated to a single quadrant of the luminal 
surface and formed a densely packed cell sheet of ~200 µm thick. This thickness was 
constant across the sheet, tapering down smoothly to the luminal surface at the ends. 
The cells appeared confined to the lumen, with no evidence of invasion into the 
scaffold wall. Compared to sections of human umbilical artery, also stained with H&E, 
the cells attached to the luminal surface displayed a similar structure to the SMCs 
present in the tunica media of the artery (Figure 84).  
 
TEVGs were also cultured in the bioreactor under static conditions. After 7 days, the 
TEVGs were removed and fixed and, as in the dynamic bioreactor culture, a sample of 
the used SMC growth medium was taken from the bioreactor and tested for the 
presence of metabolic activity using the RR assay. This was compared to a sample of 
SMC growth medium cultured in parallel to the bioreactor. The results of the RR assay 
showed no significant difference between the two samples of medium. Both samples 
generated negligible fluorescence values, suggesting that no metabolic activity was 
present in the medium (Figure 81). 
Examination of all three TEVG replicates showed evidence of cells. H&E stained 
sections taken from all three lengths of all three replicate grafts showed the presence 
of cells attached to the luminal surface (Figure 85). Similar to the results from the cell 
seeding experiments, these cells appeared to be concentrated on opposing areas of 
the luminal surface. However, the cells appeared to be present over more of the 
lumen than in the cell seeding experiments, covering almost the entire surface. No 
significant differences were observed down the lengths of each TEVG, based on 
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comparisons of sections taken form the three lengths of each graft. All graft sections 
appeared to show some detachment of the cells from the scaffold lumen.  
 
PGS-M scaffolds without seeded SMCs were also cultured in the bioreactor, under 
dynamic conditions, as negative controls. No evidence of cells was seen in any of the 
sections taken from the lengths of these scaffolds (Figure 85). Additionally, a sample of 
the used SMC growth medium, taken from the bioreactor, tested for the presence of 
metabolic activity using the RR assay showed no significant difference compared to a 
control sample of SMC growth medium cultured in parallel. Both medium samples 
generated negligible fluorescence values, suggesting that no metabolic activity was 
present in the medium (Figure 81). 
 
 
 
 
Figure 81. RR assay for metabolic activity in SMC growth medium used in the dynamic, 
static and unseeded bioreactor cultures for 7 days. Control medium was cultured in 
parallel to the bioreactor in equivalent conditions. Error bars are SEM (n = 1). 
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Figure 82. Representative H&E stained sections from TEVGs cultured under dynamic conditions (pulsatile flow) in the bioreactor for 
7 days (n = 1). No cells were present in the TEVG connected to channel 1 in the bioreactor. Some small regions of cells were present in 
length 3 from the TEVG connected to channel 2 in the bioreactor (arrowed). A thick cell sheet was present around part of the lumen in 
length 3 from the TEVG connected to channel 3 in the bioreactor. Scale bars are 1 mm.  
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Figure 83. Representative H&E stained section from length 3 of the TEVG connected to 
channel 3 in the bioreactor and cultured under dynamic conditions (n = 1). (Above) The 
cell sheet was isolated to a single quadrant of the lumen. Scale bar is 1 mm. (Below) 
The cell sheet was ~200 µm thick. Scale bar is 100 µm.  
254 
 
 
Figure 84. Representative H&E stained section of human umbilical artery (n = 1). 
(Above) Vessel cross-section. Scale bar is 200 µm. (Below) Enhanced view of the tunica 
media showing the arrangement of the SMCs. Scale bar is 100 µm.  
 
 
 
 
Figure 85. Representative H&E stained sections from TEVGs cultured under static conditions and unseeded control grafts cultured 
under dynamic conditions in the bioreactor for 7 days (n = 1). Cells were present throughout all sections of the TEVGs cultured under 
static conditions. The cells appeared concentrated on opposing regions of the luminal surface. Unseeded TEVGs cultured under 
dynamic conditions did not show any evidence of cells. Scale bars are 1 mm.  
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 Staining of TEVGs for collagen 6.3.4
Sections from TEVGs cultured in the bioreactor were stained for the presence of 
collagen (Figure 86). In the TEVGs cultured under dynamic conditions, collagen only 
appeared present in the third length cut from the graft connected to TEVG channel 3 in 
the bioreactor. Collagen fibres stained orange/yellow. Collagen was located 
throughout the small cell sheet attached to the graft lumen in this area of the TEVG, 
although this only stained faintly, compared to the positive control (human umbilical 
artery) suggesting a lower quantity. 
Collagen was also present in the TEVGs cultured under static conditions in the 
bioreactor. The collagen was present throughout the regions of cells attached to the 
graft lumens. Again, the staining strength was weaker than observed in the positive 
control, suggesting a smaller quantity of collagen was present. No significant 
difference could be determined, by observation, between the collagen present in the 
TEVGs cultured under dynamic conditions, compared to those cultured under static 
conditions.   
No collagen was observed in the unseeded TEVGs cultured under dynamic conditions 
in the bioreactor.  
 
 
 
Figure 86. Representative collagen stained sections from TEVGs cultured under dynamic and static conditions in the bioreactor for 7 
days (n = 1). Collagen was present throughout regions of attached cells on the grafts luminal surfaces. Human umbilical arteries 
(positive control) stained strongly for collagen. Unseeded TEVGs cultured under dynamic conditions in the bioreactor (negative 
controls) did not show any evidence of collagen. Scale bars are 200 µm. 
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 Collagen visualisation and quantification using second harmonic generation 6.3.5
The collagen content of the TEVGs cultured in the bioreactor for 7 days under dynamic 
and static conditions was assessed using confocal microscopy to detect SHG (Figure 87). 
Images were then analysed to determine the signal intensities associated with the 
PGS-M scaffold and the regions of cells attached to the luminal surfaces of the TEVGs. 
In the examination of TEVGs cultured under dynamic conditions, only sections from 
the third length cut from the TEVG connected to channel 3 of the bioreactor were 
examined for SHG. All TEVGs cultured under static conditions in the bioreactor were 
examined. 
The results are shown in Figure 88. The signal intensity generated by the regions of 
cells was significantly greater than the signal intensity generated by the PGS-M scaffold 
in TEVGs cultured under dynamic and static conditions (P<0.001 and 0.01, respectively). 
This suggested that collagen was present in the regions containing cells. There was no 
significant difference between the signal intensities generated by the regions of cells 
present in the TEVGs cultured under dynamic conditions and those cultured under 
static conditions. Additionally, the signal intensities generated by the PGS-M scaffolds 
in TEVGs cultured under dynamic and static conditions were not significantly different 
from the signal generated by unseeded TEVG scaffolds alone. This suggested that the 
presence of seeded cells during the bioreactor culture did not alter the scaffolds 
inherent fluorescence.  
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Figure 87. Example of a cell containing region of a TEVG imaged using SHG for collagen. 
Scale bar is 50 µm.   
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Figure 88. SHG signal intensities in images of TEVGs cultured under dynamic and static 
conditions for 7 days in the bioreactor (n = 1). Signals were analysed from regions of 
the TEVG images containing attached cells (Cell region) and regions only containing 
PGS-M scaffold (Scaffold). Signal intensities from images of unseeded TEVG scaffolds 
acted as controls.  
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 Staining of TEVGs for elastin 6.3.6
Sections from TEVGs cultured in the bioreactor were stained for the presence of 
elastin (Figure 89). In the TEVGs cultured under dynamic conditions, elastin only 
appeared present in the third length cut from the graft connected to TEVG channel 3 in 
the bioreactor. Elastin fibres stained grey/black. The elastin was located throughout 
the small cell sheet attached to the graft lumen in this area of the TEVG, although this 
only stained faintly, compared to the positive control (human umbilical artery) 
suggesting a lower quantity. 
Elastin was also present in the TEVGs cultured under static conditions in the bioreactor. 
The elastin was present throughout the regions of cells attached to the graft lumens. 
Again, the staining strength was weaker than observed in the positive control, 
suggesting a smaller quantity of elastin was present. No significant difference could be 
determined, by observation, between the elastin present in the TEVGs cultured under 
dynamic conditions, compared to those cultured under static conditions.   
No elastin was observed in the unseeded TEVGs cultured under dynamic conditions in 
the bioreactor.  
 
 
 
 
 
Figure 89. Representative elastin stained sections from TEVGs cultured under dynamic and static conditions in the bioreactor for 7 days 
(n = 1). Elastin was present throughout regions of attached cells on the grafts luminal surfaces. Human umbilical arteries (positive control) 
stained strongly for elastin. Unseeded TEVGs cultured under dynamic conditions in the bioreactor (negative controls) did not show any 
evidence of elastin. Scale bars are 200 µm.  
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 Immunofluorescence staining of TEVGs for α-SMA 6.3.7
Sections from the TEVGs cultured under dynamic conditions were examined using 
immunohistochemistry to assess the expression of α-SMA in the SMCs seeded onto 
them in the bioreactor. α-SMA is a strong marker for contractile phenotype in SMCs. 
Only sections taken from the third length cut from the TEVG connected to channel 3 in 
the bioreactor were examined for α-SMA. This was the only region of the TEVGs 
cultured under dynamic conditions for 7 days which displayed significant cell 
attachment.  The cells present in these sections did not appear to stain positive for 
α-SMA (Figure 90). No significant fluorescence signal could be detected above the 
background fluorescence.  
Additionally, sections taken from the TEVGs cultured under static conditions for 7 days 
in the bioreactor were also examined. As in the TEVG cultured under dynamic 
conditions, the cells attached to these TEVGs did not stain positive for α-SMA, with no 
significant fluorescence signal above the background.  
Sections of human umbilical artery were used as positive controls and did stain 
positive for the presence of α-SMA. Negative controls were blocked, but unstained, 
sections of TEVGs seeded with SMCs and cultured in the bioreactor; unseeded and 
stained TEVGs cultured in the bioreactor and unseeded and unstained TEVGs cultured 
in the bioreactor. All of the negative controls did not stain positive for α-SMA.  
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Figure 90. Representative sections from TEVGs cultured in the bioreactor, for 7 days, 
under dynamic and static conditions stained for α-SMA using immunohistochemistry 
(n = 1). TEVGs cultured under dynamic and static conditions did not stain positive for α-
SMA (Dynamic culture + antibody and Static culture + antibody, respectively). Human 
umbilical cord arteries were used as positive controls and stained positive for α-SMA 
(Umbilical cord + antibody). Negative controls (Blocked, Unseeded + antibody and 
Unseeded only) did not stain positive for α-SMA. All images were captured and 
processed using equal exposure and display settings. Scale bars are 200 µm.  
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 Immunofluorescence staining of TEVGs for calponin 6.3.8
Sections from the TEVGs cultured under dynamic conditions were also examined for 
the presence of calponin in the SMCs seeded onto them in the bioreactor, using 
immunohistochemistry. Similar to α-SMA, calponin is also a strong marker for 
contractile phenotype in SMCs. As in the examination of α-SMA, only sections taken 
from the third length cut from the TEVG connected to channel 3 in the bioreactor were 
examined for calponin. This was the only region of the TEVGs cultured under dynamic 
conditions for 7 days which displayed significant cell attachment. The results were 
similar to those observed for α-SMA. The cells present in these sections did not appear 
to stain positive for calponin (Figure 91). No significant fluorescence signal could be 
detected above that of the background.  
Additionally, sections taken from the TEVGs cultured under static conditions for 7 days 
in the bioreactor were also examined for the presence of calponin. As in the TEVG 
cultured under dynamic conditions, the cells in these TEVGs did not stain positive for 
calponin, with no significant fluorescence signal detected.  
Sections of human umbilical artery, used as positive controls, stained positive for the 
presence of Calponin. Negative controls were blocked, but unstained, sections of 
TEVGs seeded with SMCs and cultured in the bioreactor; unseeded and stained TEVGs 
cultured in the bioreactor and unseeded and unstained TEVGs cultured in the 
bioreactor. All of the negative controls did not stain positive for calponin.  
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Figure 91. Representative sections from TEVGs cultured in the bioreactor, for 7 days, 
under dynamic and static conditions stained for calponin using immunohistochemistry 
(n = 1). TEVGs cultured under dynamic and static conditions did not stain positive for 
calponin (Dynamic culture + antibody and Static culture + antibody, respectively). 
Human umbilical cord arteries were used as positive controls and stained positive for 
calponin (Umbilical cord + antibody). Negative controls (Blocked, Unseeded + antibody 
and Unseeded only) did not stain positive for calponin. All images were captured and 
processed using equal exposure and display settings. Scale bars are 200 µm.  
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 Discussion 6.4
Tubular PGS-M scaffolds seeded with SMCs were cultured for 7 days under dynamic 
and static conditions in bioreactor design 1.2 as TEVGs.  
The PGS-M scaffolds required sterilisation prior to cell seeding. Sterilisation by 
autoclaving in autoclave bags resulted in severe deformation of the scaffolds. This may 
have been due to the pores in the scaffolds collapsing during the autoclave process. 
Subsequently, sterilisation using ethanol was employed. Although not appearing to 
damage the scaffolds structure, this resulted in infections appearing in the scaffolds 
during culture. Given that the sterilisation process had been undertaken using aseptic 
technique inside a biological safety cabinet and that the infection occurred on two 
separate occasions, it was possible that the infective agent was already present in the 
scaffolds. The infection appeared fungal, based on the appearance of filamentous 
structures in the scaffold sections examined using histology. It is possible that fungal 
spores were present in the sucrose porogens used to produce the scaffolds. Indeed, 
the dry environment required to store the porogens may have promoted fungal spore 
senescence. Fungal spores are highly resistant and may have survived the various 
solvent treatments involved in the scaffold manufacturing process along with the 
sterilisation with ethanol, which is not considered to be sporicidal.361–363 Germination 
of the spores may then have been triggered during the incubation of the scaffolds in 
SMC growth medium.  
Autoclaving the scaffolds while they were immersed in dH2O ultimately rendered them 
sterile. The scaffolds retained their tubular shape. This may have been due to the 
surrounding fluid preventing the pores from collapsing during the autoclave process. 
Autoclaving is considered to have sporicidal action and therefore eliminated any 
infective spores that may have been present in the scaffolds. No evidence of infection 
was seen in the histological examination of the scaffolds sterilised by autoclaving while 
immersed in dH2O. Additionally, the RR assay results for samples of the growth 
medium the scaffolds were incubated in were not significantly different from those of 
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the control growth medium. Both produced negligible fluorescence values suggesting 
that no metabolic activity, as a result of infection, was present in the medium.  
Scaffold sterilisation by autoclaving while immersed in dH2O was therefore employed 
prior to inserting the scaffolds into the bioreactor. The assembled bioreactor, 
containing the scaffolds was then sterilised by peracetic acid. This had previously been 
determined as a suitable method of sterilising the bioreactor. Although this treatment 
may also have been suitable to sterilise the scaffolds, the bioreactor represented a 
“high risk” environment for cell culture given the potential culture lengths that may 
ultimately be used (weeks/months). Using multiple sterilisation/disinfection processes 
is recommended as good practice in manufacturing and, therefore, both sterilisation 
methods were employed to treat the scaffolds. Autoclaving and peracetic acid 
treatment had been shown previously not to have a deleterious effect on the 
mechanical properties of the PGS-M scaffolds (‎2.3.7).   
 
To validate the cell seeding process, the tubular PGS-M scaffolds were seeded in petri 
dishes, prior to any seeding attempts in the bioreactor. The scaffolds were seeded 
intraluminally with 2 x 106 cells/cm2 of luminal surface area. This seeding density had 
been used in a number of previously published reports on producing TEVGs.70,88,93 It 
was suggested that such a high seeding density is required to encourage the cells to 
quickly form a monolayer over the luminal surface, which is enlarged due to the 
presence of the pores. The cell-to-cell contact within the monolayer then promotes 
ECM formation.93 Cell seeding was conducted twice with the scaffolds rotated about 
180° in between. After 24 hours, histological examination of the seeded scaffolds 
showed the attachment of SMCs. These cells appeared be concentrated on the luminal 
surface on opposing sides. This likely reflected the seeding process with the areas of 
the lumen that were lowest during seeding receiving the greatest complement of cells 
due to them settling under gravity. Rotating the scaffold 180° between seeding 
processes thus resulted in the cells appearing to be concentrated on opposite sides of 
the lumen.  
269 
 
Proliferation of the cells attached to the luminal surface was likely limited by the short 
culture time (24 hours post seeding) prior to fixation and examination and therefore 
complete luminal coverage was not achieved.  
A number of studies have demonstrated the positive effects of scaffold rotation during 
cell seeding. This process can be used to achieve greater and more uniform cell 
coverage of the scaffold and ultimately produce superior TEVGs. Seeding of scaffolds 
under rotation has be employed for both SMCs88,93,116,122 and ECs65,103,147 in vascular 
graft tissue engineering. Published methods appear to perform scaffold rotation about, 
180°-360°, over a period of hours to allow for cell attachment across the luminal 
surface. A greater degree of rotation may be required to improve the luminal surface 
coverage the PGS-M scaffolds herein.   
24 hours after cell seeding, limited cell invasion into the scaffold walls was observed. 
This was isolated to small regions and appeared sporadic. This suggested that the 
luminal surface porosity may be non-uniform and more limiting to cell invasion in 
some regions. This was similar to the observations of the PGS-M disks seeded with 
SMCs and cultured for 24 hours and 7 days (‎4.3.6). These results suggest that the 
surface of the porous PGS-M scaffolds may be a limiting factor to cell proliferation into 
the scaffold interiors.  
 
Following validation of the cell seeding method, tubular PGS-M scaffolds were seeded 
with SMCs and cultured under dynamic conditions with pulsatile flow for 7 days in the 
bioreactor. Samples of the medium extracted from the bioreactor after completion of 
the culture did not show any significant metabolic activity when examined using the RR 
assay. The medium from the bioreactor culture produced fluorescence values that 
were not significantly different from a sample of control medium. This suggested that 
the bioreactor had remained free of infection throughout the dynamic culture. This 
result was replicated in the subsequent culture of TEVGs under static conditions and 
unseeded TEVGs under dynamic conditions, suggesting the bioreactor had also 
remained free of infection throughout these experiments.  
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Examination of the TEVGs seeded with SMCs and cultured under dynamic conditions 
showed high variability between the three replicates. SMCs were only present in the 
TEVGs connected to channels 2 and 3 of the bioreactor, and these were very limited in 
the former. In both cases, the cells were only present in the third length of the TEVGs, 
distal to the pump. These results suggested that the flow through the grafts may have 
had a detrimental effect on the seeded cells. When examining the TEVGs cultured 
under static conditions in the bioreactor, again for 7 days, SMCs were seen to be 
distributed throughout the graft lengths and appeared similar between replicates. This 
suggests that the seeding method was able to evenly distribute the cells across the 
lumen and adds further to the possibility of the flow being responsible for the 
variability observed between the TEVGs cultured under dynamic conditions. It is 
possible that the flow rate applied to the TEVGs was too high resulting in the removal 
of cells from the grafts or causing their movement down the luminal surfaces towards 
the distal end. The flow regime was selected based on a previously published 
successful method for culturing TEVGs in a bioreactor under pulsatile flow.88,93 This 
work, by Wang and colleagues, utilised a similar scaffold design to that employed 
herein (a porous tubular PGS scaffold produced by porogen leaching with a 4 mm 
internal diameter, a 1 mm thick wall and ~70-80% porosity). Their scaffold was seeded 
with a different cell type to that used in this study, however (baboon carotid artery 
smooth muscle cells). Comparing the work by Wang and colleagues with the present 
study, it is possible that cell attachment and retention in the scaffolds may have varied 
due to subtle differences between the scaffold materials, porosity or surface 
topography, along with the cell type used. This could have produced the differences in 
the results observed.   
Interestingly, flow rate measurements demonstrated that the flow rates across the 
three TEVG channels in the bioreactor were comparable between pump speeds of 6 
and 60 rpm and relative pressures of 0 to 200 mmHg (‎5.3.8). In addition to this, the 
TEVGs cultured under static controls demonstrated that the cell seeding method used 
produced uniform cell coverage across the three TEVG replicates. The causes of the 
variability observed between the three TEVG replicates cultured under dynamic 
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conditions are therefore unclear. It must be noted, however, that the limited number 
of replicates makes drawing conclusions difficult. In the singular bioreactor culture 
conducted under dynamic conditions, it is possible that ineffective cell seeding may 
have affected the TEVG connected to channel 1 resulting in no cells being visible at 
day 7.  
 
Although only small traces of SMCs could be seen in the TEVG connected to channel 2 
in the bioreactor and cultured under dynamic conditions, in the TEVG connected to 
channel 3 the cell content was significant. Interestingly, the cells appeared to have 
formed a thick cell sheet across about one quarter of the luminal surface. This cell 
sheet appeared strongly attached to the scaffold, with no separation observed in any 
of the sections, as was common in sections from the TEVGs cultured under static 
conditions. The cell sheet appeared to be ~200 µm thick. It was unlikely that this was 
an artefact of the sectioning process or that a thinner layer of cells had become 
detached from the luminal surface and compacted to give the appearance of a thick 
sheet. This was because the structure of the cell sheet appeared conserved throughout 
the various sections cut and the ends of the sheet appeared to taper gradually down to 
reach the scaffold’s luminal surface, suggesting some degree of order. Although cells 
were present throughout the TEVGs cultured under static conditions, none of these 
showed the formation of a cell sheet of equivalent structure or thickness to that seen 
in the TEVG cultured under dynamic conditions. This result suggests that the pulsatile 
flow applied during the dynamic culture may be the reason for the formation of this 
thick cell sheet. The flow may have improved the supply of nutrients to the cells 
attached to the scaffold or the mechanical stimulation resulting from the pressure 
pulses may have encouraged proliferation causing cell sheet thickening.    
Wang and colleagues observed a similar behaviour in their TEVGs cultured under 
pulsatile flow. The group found that TEVG formation was improved by using scaffolds 
with smaller pore sizes.93 They examined scaffolds produced from porogens of 
75-90 µm, 45-53 µm and 25-35 µm. In the scaffolds with the smaller pores, cell 
infiltration was less than in those with larger pores; however, ECM deposition was 
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greater. The seeded SMCs formed a thick cell sheet of ~200 µm, similar to that 
observed in the present study (Figure 92). It was suggested that the limited infiltration 
of the SMCs into the scaffold, caused by the smaller pore sizes, produced greater 
cell-to-cell contact and aided self-assembly and organisation of the SMCs into a cell 
sheet. A similar effect may have occurred in the present study, with the luminal 
surface of the PGS-M scaffolds limiting cell penetration into the scaffold interior and 
promoting self-assembly and organisation into a cell sheet.  
 
 
Figure 92. H&E stained sections from TEVGs produced by Wang and colleagues.93 
Porous PGS scaffolds were seeded with baboon carotid artery SMCs and cultured in a 
pulsatile flow bioreactor for 21 days. Scaffolds were produced from Large (75-90 µm), 
Medium (45-53 µm) and Small (25-35 µm) porogens to generate different pore size 
ranges. A baboon carotid artery was sectioned and stained to act as a control. (A) TEVG 
cross-sections, (B) boxed regions highlighted in A magnified. Cell sheets composed of 
SMCs were seen across the luminal surface of all of the seeded scaffolds. Limited cell 
invasion into the PGS scaffolds was observed with this being most pronounced in the 
Small pore scaffolds. Scale bars are 500 µm in A and 50 µm in B. L denotes the TEVG 
lumen. Figure reproduced with permission.      
 
 
A 
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Comparing the structure of the cell sheet in the dynamic cultured TEVG with the 
human umbilical artery showed similar structures. H&E stained sections showed 
connective tissues with similar organisation. This suggests that the cell sheet was 
organised in a similar way to natural blood vessels. Comparing the sections taken from 
the TEVGs cultured under dynamic conditions with those cultured under static 
conditions suggested some difference in the organisation of the SMCs. All of the 
sections from TEVGs cultured under static conditions showed some detachment of the 
cells from the lumen. This was likely a result of the sectioning process; however, this 
also suggests that the attachment of the cells to the scaffold was weaker than in the 
TEVG cultured under dynamic conditions, where no detachment was observed. It may 
be possible that the relative pressure acting on the cells inside the lumen in the TEVGs 
in dynamic culture facilitated greater contact between the cells and the scaffold, 
resulting in greater adhesion between the two. Alternatively, the mechanical 
stimulation provided by the pulsatile flow may have resulted in gene expression 
changes which may have altered the cells binding to the PGS-M scaffold and improved 
cell attachment. Indeed,  the expression of integrins, which are key proteins for the 
binding of cells to substrata, has been shown to be upregulated by mechanical 
stimulation in vascular cells.364  
 
The SMCs present in the TEVGs cultured under dynamic and static conditions both 
appeared to generate collagen. Histological staining showed that collagen was present 
throughout the cellular regions of both types of TEVGs. No significant differences in 
quantity were suggested by the staining alone, although both appeared to stain 
weaker than in the positive control (human umbilical artery), suggesting a lesser 
quantity than in this. The organisation of the collagen appeared similar to that of the 
umbilical artery, also.  
Subsequent analysis and quantification of the collagen content of the TEVGs using SHG 
supported the presence of collagen. The SHG signal intensity associated with collagen 
was higher than that generated by the PGS-M scaffold or background alone. No 
significant difference in collagen quantity could be found between the TEVGs cultured 
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under dynamic and static conditions. It should be noted, however, that the sample 
number used for this analysis was quite limited, as only the TEVG cultured under 
dynamic conditions connected to channel 3 of the bioreactor contained a significant 
area of cells for analysis. Although the effect of mechanical stimulation in dynamic 
culture on collagen deposition in TEVGs is well established, with dynamic cultures 
resulting in increased collagen deposition,61,75,84,122,336 strong conclusions about the 
collagen contents of the TEVGs produced in dynamic and static cultures in this study 
cannot be drawn without a greater sample size.      
 
Elastin also appeared to be present in the TEVGs cultured under dynamic and static 
conditions. Similar to the observations of collagen, no significant difference between 
the two culture regimes was observable from the staining alone. Both TEVGs stained 
less strongly than the umbilical artery, suggesting reduced elastin content compared to 
this. The organisation of the elastin also appeared similar to the umbilical artery. 
No quantification of the elastin content was made. Given the very small sample size it 
was not possible to draw conclusions about the differences in elastin deposition based 
on dynamic and static cultures in this study. The presence of elastin in both types of 
TEVG is all that can be confirmed.  
In the literature, generating elastin in TEVGs based on synthetic polymer scaffolds has 
proven challenging. Elastin deposition has been linked to a number of factors including 
scaffold stiffness, topography and degradation rate, along with application of 
mechanical stimulation and the cell source used.82,84,86,88,93,101,103,235,240–243 In studies 
where dynamic and static cultures have been compared, it has been shown that 
dynamic culture appears to increases elastin deposition, although this may be as a 
result of a synergistic effect between mechanical stimulation and the scaffold material.  
The organisation and maturity of the elastin deposited in TEVGs must also be 
considered. Although elastin may be detected in a TEVG, its assembly into microfibrils 
and mature fibres is required to achieve its native function.230 Assessing elastin 
maturity is difficult using visual inspection alone and, therefore, it is not possible to 
meaningfully assess the maturity of the elastin fibres observed in the TEVGs produced 
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herein, in both dynamic and static cultures. Measuring the desmosine content of 
TEVGs allows a method of quantifying mature elastin content, as this is a cross-linker 
unique to mature elastin.93,365 This could be employed to determine if any difference in 
the organisation and maturity of the elastin fibres is present between TEVGs produced 
using PGS-M scaffolds and dynamic and static cultures.   
 
Examination using immunohistochemistry revealed that the SMCs present on the 
TEVGs cultured under dynamic and static conditions in the bioreactor did not appear 
to possess α-SMA or Calponin. α-SMA and calponin are considered as stronger markers 
for the mature contractile SMC phenotype, along with smooth muscle myosin heavy 
chains, SM22α and smoothelin.328 These proteins may be expressed individually and 
transiently in other cell types and therefore it is considered that a multitude of them 
must be detected in order to confidently determine the SMC phenotype.  
Mature SMCs are not terminally differentiated cells and possess considerable plasticity. 
This plasticity is required for blood vessel formation during embryogenesis and 
vascular remodelling and repair. SMC plasticity appears to be dependent on 
environmental and extracellular matrix signals sensed by the cells.366–368 Control of the 
SMC phenotype appears to be highly complex and variable and is not fully understood. 
It has been demonstrated that switching from a mature contractile SMC phenotype to 
a synthetic proliferative SMC phenotype is associated with a marked decrease in 
SMC-selective marker gene expression and increased proliferation and migration.328 
Some studies have demonstrated that the use of mechanical stimulation through cyclic 
strain applied to SMCs allows retention of the mature SMC phenotypic markers while 
also encouraging proliferation,369 although other works appear to contradict this.94,370 
SMCs have also been shown to change phenotype, from contractile to synthetic, in 
response to ECM interactions. Collagen I and fibronectin have both been shown to 
enhance SMC proliferation and ECM production while reducing the contractile 
phenotype markers.371,372  
In the present study the cause of the reduction in α-SMA and calponin expression, to 
levels undetectable using immunohistochemistry, is unclear. Given that this result was 
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seen in TEVGs cultured using both dynamic and static conditions suggests that the 
cause may not be associated with the different culture regimes. Interaction between 
the SMCs and PGS-M scaffold may have been the cause, as this was a common 
element in the two different bioreactor cultures. Although SMCs of a similar age to 
those used in the bioreactor cultures had been previously shown to retain the 
expression of α-SMA and calponin when cultured on PGS-M (‎3.3.4 and ‎3.3.5), these 
experiments were performed using 2D PGS-M surfaces. It is possible that an 
interaction between the SMCs and the 3D porous PGS-M scaffold may have caused the 
change in phenotype marker expression. Interestingly, Niklason and colleagues 
suggested that the degradation products generated by the hydrolysis of a PGA scaffold 
were the cause of the dedifferentiation of SMCs in the bioreactor culture of a TEVG.67 
A similar effect had been previously observed in the interaction of SMCs with polyester 
based vascular prosthetics.373 The mechanism behind this was unclear. A local 
decrease in pH due to glycolic acid components or effects of phagocytosed polymer 
particles, released by the degradation of the scaffold, were suggested as possible 
causes. A similar effect could have occurred in the present study. Indeed, the greater 
surface area of the PGS-M scaffolds compared to the 2D PGS-M surfaces would likely 
have enhanced degradation and this could explain the differences in α-SMA and 
calponin expression in the SMCs grown on these substrata.   
Further investigation is required to understand the change in the expression of the 
contractile SMC phenotypic markers observed in the TEVGs cultured under dynamic 
and static conditions in the present study. This may benefit from employing a method 
of quantitative examination of the expression of the contractile SMC phenotypic 
markers.  
 
Additionally, an interesting consideration is whether the apparent loss of the 
contractile SMC phenotype from the TEVGs cultured under dynamic and static 
conditions in the bioreactor is actually detrimental. The production of the TEVGs in 
vitro, using PGS-M scaffolds and the bioreactor requires the proliferation of SMCs, to 
populate the scaffold, and also requires the production of significant amounts of ECM, 
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to provide the graft with the required mechanical properties. SMC proliferation and 
ECM deposition are both typically associated with the dedifferentiated synthetic SMC 
phenotype and, therefore, this may be considered advantageous for TEVG generation. 
Historically, developers of TEVGs have attempted to avoid the synthetic SMC 
phenotype due to the issues this can cause in vivo. An underlying process in the 
formation of intimal hyperplasia and atherosclerosis is SMC phenotype switching, from 
contractile to proliferative.328 Therefore, the retention of the contractile phenotype 
has been favoured in TEVGs designed for direct implantation into patients, following in 
vitro culture. However, new techniques in TEVG manufacturing, such as the 
decellularisation of in vitro derived vessels, decouple the cells used to produce the 
TEVGs in culture from the intended patient. If these methods were incorporated into 
the production of a TEVG, loss of the contractile SMC phenotype may not be 
problematic.      
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 Conclusions 6.5
Human coronary artery SMCs were successfully seeded onto tubular PGS-M scaffolds 
and cultured for 7 days under dynamic and static conditions in a previously designed 
bioreactor. TEVGs cultured under dynamic conditions, with mechanical stimulation 
produced by a pulsatile flow, displayed highly variable results, but demonstrated the 
partial formation of blood vessel-like tissue in a small instance. TEVGs cultured under 
static conditions produced repeatable results, but demonstrated reduced vascular 
tissue formation compared to the grafts cultured under dynamic conditions. Both 
culture regimes produced TEVGs containing collagen and elastin and both also 
appeared to cause a change in the phenotype of the attached SMCs, from contractile 
to proliferative.  
Further work is required to optimise the production of TEVGs using PGS-M scaffolds 
and bioreactor culture. A combination of static and dynamic culture regimes may be 
employed in achieving this. Greater repeatability between the grafts cultured under 
dynamic conditions and the generation of suitable cellularity and ECM deposition are 
required to produce TEVGs with the potential for clinical use. 
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Chapter 7 - Future work 
In the previous chapters, the initial development of a TEVG based on a PGS-M polymer 
scaffold has been described. The original aim of this research was to produce a TEVG 
with mechanical properties more closely matching those of the gold standard 
autograft vessels (saphenous vein and internal thoracic artery) currently used in 
vascular surgery. To this end a synthetic polymer scaffold based approach to tissue 
engineering was employed. PGS-M was selected as the scaffold material because of its 
mechanical properties, degradation rate, biocompatibility and processing capabilities. 
Porous tubular scaffolds were fabricated from PGS-M, seeded with SMCs, and cultured 
inside a bespoke dynamic culture bioreactor. However, the bioreactor culture period 
was limited to only 7 days and only a small amount of vascular tissue was generated. 
Therefore, the original aim of this research has not yet been achieved. Future work 
may explore the further development of the PGS-M scaffold based TEVG, in an effort 
to achieve the originally defined aim.  
 
Future work should begin with an optimisation of the bioreactor culture of the PGS-M 
scaffold based TEVGs. Bioreactor cultures were conducted under both static and 
dynamic conditions, with the former producing consistent results, across three TEVG 
replicates, and the latter producing the best tissue formation, although inconsistently 
and only in a very limited quantity. Since it was the application of pulsatile flow, and 
therefore mechanical stimulation, to the TEVGs that was the difference between the 
dynamic and static cultures, improving the consistency of the TEVGs cultured under 
dynamic conditions may begin with altering the flow parameters. A combination of the 
static and dynamic culture regimes may be explored. An initial period of bioreactor 
culture under static conditions, to permit initial cell attachment and proliferation, 
followed by the application of a dynamic culture regime, to enhance tissue formation 
and ECM deposition, may produce improved results.    
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Once the bioreactor is able to produce consistent results, for both static and dynamic 
culture conditions, the culture lengths may be extended to increase tissue formation. 
The resulting TEVGs may then be analysed on a cellular and structural level. Cellular 
analysis in vitro may be challenging due to the bioreactor environment, however, a 
number of assays compatible with fixed tissue may offer insight into the health and 
phenotype of the cells within the TEVGs. Calcein AM and TUNEL assays are both 
compatible with fixed tissues and can be used to determine cell health by measuring 
apoptosis.374–376 Markers for mitosis; such as MPM-2, phospho-histone H3, 
proliferating cell nuclear antigen, topoisomerase II and Ki-67; can be detected using 
immunohistochemistry, offering information on the extent of cell proliferation within 
the TEVGs.374,377–379 Immunohistochemistry may also be used to examine the SMC 
phenotype. The markers α-SMA and calponin may be examined, as previously, along 
with myosin heavy chains and smoothelin which are also associated with this 
phenotype.328,329 Additionally, inflammation may be detected using assays for pro-
inflammatory cytokines or markers such as RelA or C-reactive protein (Cuhlmann 2011, 
Amsen 2009 and Venugopal 2002).380–382 The ECM composition of the TEVGs and their 
mechanical properties, including burst pressure, suture retention strength and 
compliance may also be examined. This would allow a comparison between the 
different culture regimes and also a comparison with the gold standard autograft 
vessels currently used in vascular grafting. These comparisons would then guide future 
developments of the TEVG culture protocol. Variation of the seeded cell type, flow 
parameters, culture length and medium supplementation may all be examined in an 
effort to generate a TEVG that demonstrates similar properties to the gold standard 
vessels.    
 
It may also be interesting to explore the addition of vascular ECs to the TEVG culture. 
These cells line the luminal surfaces of natural blood vessels and have important 
anti-thrombogenic properties. Additionally, vascular ECs are able to sense shear 
stresses associated with blood flow and act as mechanotransducers. The detected 
shear stresses generate signals which are transduced to the SMCs beyond the ECs 
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basement membrane and result in blood vessel remodelling. High shear stresses have 
been shown to be detected by ECs and result in changes in the structure of arteries, 
including increasing vessel diameters and ECM deposition.383,384  
Vascular ECs could be added to the TEVG culture without any modifications to the 
bioreactor. Following SMC seeding onto the PGS-M scaffolds, ECs could be seeded on 
top of the SMCs using the cell seeding ports. It is possible that adding ECs to the TEVG 
bioreactor culture may have a similar effect to that observed in the native vessels, with 
the mechanical stimulation provided by the bioreactor flow detected by the ECs and 
transduced to the underlying SMCs, resulting in improved ECM deposition. The 
bioreactor flow could be further modified to amplify this by generating higher flow 
rates. Utilising ECs in this way may offer a substitute to expensive media 
supplementation as a method of encouraging the SMCs to generate the required ECM 
proteins. The complexity added by the co-culture of the SMCs and ECs would have to 
be weighed against this gain, however.    
 
In addition to modifications to the bioreactor culture protocol, the PGS-M scaffold may 
also be altered to improve vascular tissue formation. The results demonstrated in this 
research suggested that little cell invasion into the porous PGS-M scaffolds occurred 
during bioreactor culture. This may be improved be altering the scaffold porosity. It 
was demonstrated that utilising different sized sucrose particle porogens produced 
variations in scaffold porosity. Tubular scaffolds produced from different sized 
porogens may be explored to examine their effect on TEVG development.  
 
With the exploration of longer bioreactor culture lengths, the degradation of the 
PGS-M scaffolds will become an important factor and warrant in depth investigation. 
PGS-M was selected for the scaffold material because of the rapid degradation rate the 
material exhibited during in vitro studies, although these results were not considered 
directly translatable to the TEVG culture environment. How the scaffold degrades and 
the effect that this has on the developing TEVGs must be explored. It may be 
interesting to explore the degradation of the scaffold using some of the spectroscopy 
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approaches used to characterise the PGS-M material. In particular, Raman 
spectroscopy may allow examination of the developing TEVG during culture, as Raman 
spectroscopy is compatible with live tissue samples.385 This would represent an 
interesting study in the field of TEVGs.    
 
Adding additional functionality to the bioreactor may also be considered. It may be 
valuable to add systems that allow for live monitoring of the developing TEVGs. 
Non-destructive methods such as optical coherence tomography and electrical 
impedance spectroscopy could be used. These techniques would be able to provide 
detail on the composition of the TEVGs, along with the migration and proliferation of 
the cells within them, without interfering with the culture process.386–389  
 
During the development of the bioreactor, maintaining sterility was challenging. 
Various sterilisation methods and scaffold seeding procedures were explored in an 
effort to avoid infection of the developing TEVGs. Although a sterilisation protocol, 
using peracetic acid, and scaffold seeding method were developed that successfully 
maintained sterility, limited examination of the infections that were experienced 
previously was performed. As bioreactor culture lengths are increased and more 
advanced culture protocols are explored, using SMC and EC co-cultures for example, it 
may be wise to examine any future infections, should they occur, in more detail. 
Microbiological analysis could be used to identify the infective agents and this 
information then used to suggest the source of the infection and determine the best 
possible countermeasures.   
It may also be useful to explore alternative sterilisation methods for the bioreactor. 
The peracetic acid sterilisation method employed previously is laborious and 
alternatives such as gamma irradiation or ethylene oxide treatment may be more 
efficient. It will be important to examine the effect that these methods have on the 
bioreactor and the porous PGS-M scaffolds, as different sterilisation methods have 
been shown to affect the mechanical properties of materials.390–392   
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Looking beyond the original aim of this research, should the PGS-M scaffold based 
TEVGs eventually display mechanical properties comparable to those of the current 
gold standards used in vascular grafting, research work should move towards potential 
clinical translation. To this end, it would be interesting to explore the possibility of 
decellularising the TEVGs following bioreactor culture. This process has proven 
successful in TEVGs currently undergoing the final stages of clinical trials and 
represents a potentially safer and more economical route to clinical application.70,72 A 
decellularisation protocol would require developing specifically for the PGS-M based 
TEVGs. This protocol would need to achieve suitable removal of the antigenic 
components of the grafts, while retaining their mechanical properties.     
 
Implantation in vivo should also be considered to assess the grafts under true 
physiological conditions. This should be performed for a short period in a small animal 
model first, with rabbit suggested as the most suitable, before examination in a larger 
host for a longer period.352 Efficacy must be established in animal models before the 
first human implantations can be considered.     
 
Additionally, it was also an aim of this research to produce a synthetic polymer scaffold 
for culturing TEVGs which could be made in any shape. This technology was 
demonstrated as a proof-of-concept and requires further development. The hybrid 
additive manufacturing and porogen leaching method may be further investigated. 
Producing scaffolds with varied porosities, by using different porogens, and in different 
geometries should be explored. This may be aided by some automation of the 
manufacturing process. Image projection may be used to selectively photocure the 
PGS-M prepolymer and sucrose layers and a mechanised deposition system added to 
apply these. Once different shaped porous PGS-M scaffolds have been produced they 
could then be seeded with cells and cultured in the bioreactor to produce TEVGs. This 
would likely require further investigations to develop culture protocols to produce the 
different shaped TEVGs. Ultimately, this technology may allow the production of 
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TEVGs with more complex geometries than simple tubes which has the potential to 
improve their performance and extend the possible clinical applications.  
 
Finally, the PGS-M material has possible applications in other areas of tissue 
engineering. It was demonstrated that this material has a wide range of tuneable 
mechanical properties. This would make it a suitable candidate for use in both hard 
and soft tissue engineering applications.  
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